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The spliceosome is a highly dynamic, multi-MDa eukaryotic RNA-protein (RNP) 
machinery that catalyzes precursor messenger RNA (pre-mRNA) splicing. Pre-mRNA 
splicing entails the excision of non-coding introns and the joining of the neighboring coding 
exons via two consecutive transesterification reactions. For each catalytic cycle, a 
spliceosome is assembled on a substrate pre-mRNA by the stepwise recruitment of five small 
nuclear (sn) ribonucleoproteins (RNPs) and numerous non-snRNP factors. In contrast to 
ribosomal subunits, for example, none of the snRNPs or non-snRNP complexes contain a pre-
formed catalytic center for the splicing catalysis. Instead, the active center of the spliceosome 
is formed anew during each spliceosome assembly cycle. 
Spliceosome assembly occurs stepwise via several discrete intermediates that have been 
experimentally defined. During the transition from one assembly stage to the next, the 
spliceosome undergoes profound compositional and conformational remodeling. These 
remodeling events are driven and controlled by eight highly conserved Superfamily (SF) 2 
RNP remodeling enzymes. In particular, an initial assembly containing all snRNPs (the so-
called B complex) is still catalytically inactive and requires major rearrangements of its RNA-
RNA, RNA-protein and protein-protein interaction networks in order to produce a 
catalytically competent spliceosome. Spliceosome catalytic activation requires a 650 kDa sub-
complex that is part of the U5 snRNP and is composed of a large scaffolding protein, Prp8, a 
G-protein, Snu114, and a Ski-2 RNA helicase, Brr2. The molecular mechanisms underlying 
spliceosome catalytic activation are poorly understood. To elucidate the architecture of the 
complex formed by Prp8, Snu114 and Brr2 we aimed at recombinant reconstitution of this 
micro-machinery. We managed to successfully co-express human (h) Prp8, hSnu114 and 
hBrr2 in insect cells. However, we were not able to co-purify all the components. Only hBrr2 
could be efficiently purified, indicating that under these working conditions, hBrr2 did not 
stably interact with hPrp8 and hSnu114. Using an ortholog screening approach, we tried to 
co-express the yeast (y) Prp8-ySnu114 sub-complex. Although yPrp8 was poorly expressed, 
we were able to co-purify small amounts of yPrp8 with ySnu114. Although these two proteins 
form a stable complex that can be purified, size exclusion chromatography revealed that the 
complex was possibly aggregated and unsuitable for further structural analysis since it 





While our initial strategy of co-expressing Prp8, Snu114 and Brr2 as a complex failed, we 
have succeeded in isolating human Brr2. Brr2 is an essential RNA helicase needed for U4/U6 
di-snRNP disruption during spliceosome catalytic activation. Brr2 is also the only 
spliceosomal helicase that is permanently associated with the spliceosome and thus requires 
faithful regulation. Concomitantly, Brr2 represents a unique subclass of SF2 nucleic acid 
helicases, containing tandem helicase cassettes. Presently, the mechanistic and regulatory 
consequences of this unconventional architecture are unknown. Henceforth, we then aimed at 
producing highly purified and homogeneous human and yeast Brr2 for further structural and 
functional investigations.  
Full length human and yeast Brr2 could be expressed and purified to near homogeneity. 
Both enzymes were active in ATP-dependent U4/U6 duplex unwinding but failed to 
crystallize. In order to remove putatively flexible regions that may hinder crystallization, we 
treated hBrr2 and yBrr2 with proteases, several of which gave rise to a protease-resistant ca. 
200 kDa fragment encompassing the two helicase cassettes. One of the six truncated hBrr2 
proteins, whose borders were designed based on the proteolysis experiments, crystallized 
readily and the crystals diffracted to 2.65 Å resolution. Elucidation of the crystal structure and 
biochemical analyses showed that in hBrr2 two ring-like helicase cassettes intimately interact 
and functionally cooperate. Only the N-terminal cassette harbored ATPase and helicase 
activities in isolation. Structural comparisons and mutational analyses suggested that the N-
terminal cassette of hBrr2 threads single-stranded RNA through a central tunnel and across a 
helix-loop-helix domain during duplex unwinding. While the C-terminal cassette did not seem 
to engage RNA in this fashion, it bound ATP and it strongly stimulated the N-terminal 
helicase. Stimulation depended on two inter-cassette communication lines, disruption of 
which affected ATPase and helicase activities in diverse ways. Additionally, mutations at the 
C-terminal ATP pocket affected the crosstalk between the two cassettes, suggesting that ATP 
binding may induce a specific C-terminal cassette conformation that solidifies important inter-
cassette contacts. Using pre-steady state kinetics, we also probed the nucleotide binding 
preferences and worked out possible nucleotide binding mechanisms of either cassette, 
confirming that the C-terminal cassette strongly binds ATP in solution. Taken together, our 
results revealed the structural and functional interplay between two helicase cassettes in a 
tandem SF2 enzyme and suggested how Brr2 interactors may exploit the C-terminal cassette 






1.1 pre-mRNA splicing 
The entirety of an organism's hereditary information is contained in the genome. 
Functionally, the genome can be split into repetitive, regulatory and gene sequences. A gene 
is a sequence of deoxyribonucleic acid (DNA) that encodes for a ribonucleic acid (RNA). In 
protein-coding genes, the RNA instructs production of protein. 
The process by which a gene gives rise to a protein is called gene expression. For most 
bacterial genes, gene expression consists of two steps. The first step is called transcription, 
when RNA, which is a copy of one strand of the DNA, is produced. These RNA molecules 
can play regulatory roles and can also carry the information into the next step. The latter RNA 
molecules are called messenger RNAs (mRNAs). In the second step, proteins are synthesized 
by ribosomes, using mRNA molecules as templates. The sequence of an mRNA is read in 
triplets (codons) to provide the series of amino acids that make the corresponding protein. 
An mRNA includes a sequence of nucleotides (nt) that corresponds to the sequence of 
amino acids in the protein. This part of the mRNA is called the coding region. Furthermore, 
the mRNA includes additional sequences on either end. The 5' untranslated region (UTR) is 
called the leader and the 3' UTR region is called the trailer. UTRs usually contain regulatory 
sequences controlling stability and translational activity of the transcripts.  
Considering that prokaryotic organisms possess only a single compartment, transcription 
and translation occur in the same place and are tightly coupled. In eukaryotes, however, 
mRNA molecules are first transcribed as primary transcripts in the nucleus and must be 
transported to the cytoplasm in order to be translated.  
Typically, eukaryotic RNA transcripts undergo several steps of processing before a 
mature mRNA is exported from the nucleus and is suitable for translation (Fig. 1.1). The 
maturation of a nuclear mRNAs starts with co-transcriptional capping of its 5' end. A 7-
methylguanosine is linked by an unusual 5'-5' triphosphate bond to the ribose at the 5' end of 
the transcript (Shatkin, 1976; Shatkin and Manley, 2000). This m7G cap (m7GpppN) is 
involved in mRNA export from the nucleus, initiation of protein synthesis and stabilization of 
mRNA (McCracken et al., 1997). Additionally, the 3' end of the mRNA is modified by a 





and a polyadenine (poly(A)) tail (100-200 adenine nt) is added by a poly(A) polymerase 
(Colgan and Manley, 1997).  
Furthermore, most genes in higher Eukarya (and few genes in Bacteria and Archaea) 
contain additional sequences that lie within the coding region that do not code for protein. 
These intervening, non-coding, sequences of the genes are called introns and the coding 
regions are called exons. The initial transcripts of such genes are called precursor mRNAs 
(pre-mRNAs) and require special processing in which the introns are removed from the 
nascent transcript and the adjacent exons are joined to obtain an mRNA that has a continuous 
open reading frame (ORF). 
 
Figure 1.1: Gene expression in eukaryotes. Following transcription, the pre-mRNA, containing exons (boxes) 
and introns (lines), is subjected to processing events such as capping, polyadenylation and splicing before it is 
exported to the cytoplasm, where translation takes place. 
There are four major classes of introns that are recognized based on their splicing 
mechanism: 
(I) Group I self-splicing introns are widespread in protist nuclear rDNA, fungal 
mitochondria, some bacteria and bacteriophages. These group I intron RNAs self-splice 
utilizing a distinctive two-step pathway that relies on an external guanosine nucleotide as a 
cofactor. Within group I introns, open reading frames are often found encoding homing 
endonucleases that promote intron mobility at the DNA level into intronless cognate sites 





(II) Group II self-splicing introns are phylogenetically unrelated to group I introns and are 
found in some bacteria and organellar genomes of plants, fungi, protists and some animals. 
Most group II intron RNAs consist of two basic components, a self-splicing ribozyme and an 
ORF for expression of a multifunctional protein (maturase) that facilitates splicing. These 
maturases contain endonuclease and reverse transcriptase domains that play crucial roles in 
homing and retrotransposition. Group II introns self-splice through a mechanism that is 
different from group I introns but similar to nuclear pre-mRNA splicing using the 2'-OH of an 
adenosine nucleotide within the intron as a nucleophile (Chan et al., 2012; Toor et al., 2008a). 
(III) The transfer RNA (tRNA) introns are found in eukaryotic nuclei and in Archaea and 
are enzymatically removed by a cut-and-rejoin mechanism that requires adenosine 
triphosphate (ATP) and an endonuclease (Abelson et al., 1998).  
(IV) Since this thesis deals with nuclear pre-mRNA splicing, the fourth class of introns 
present in nuclear pre-mRNAs will be described in more detail in the following sections. 
The process of nuclear pre-mRNA splicing is highly conserved from yeast to humans and 
is carried out by the spliceosome. Whereas nearly all human genes contain introns, they are 
present in only 3.8% of all genes of the yeast Saccharomyces cerevisiae (Lopez and Séraphin, 
1999; Barrass and Beggs, 2003). Furthermore, the small percentage of intron-containing 
genes in yeast generally harbors only one intron of relatively short size (approximately 100-
400 nt). In contrast, human pre-mRNAs contain on average of 7.8 introns varying from 100 to 
500.000 nucleotides (Ast, 2004; Rowen et al., 2002). The exons, however, have a rather fixed 
length of only approximately 120 nucleotides.  
Interestingly, the human genome consists of 20,000 – 25,000 genes although the number 
of translated products is much larger (80,000 – 120,000 different proteins) (Liang et al., 2000; 
Yura et al., 2006; Nilsen and Graveley, 2010). Possibly, this discrepancy can be explained by 
alternative splicing, which is thought to occur in up to 90% of all human genes (Wang et al., 
2008; Luco et al., 2011). Alternative splicing is a mechanism that generates variable forms of 
mRNA from a single pre-mRNA species due to differential incorporation of exons or 
retention of introns into the final transcript (Black, 2003). This finally leads to protein 
isoforms that differ in their amino acid sequence and, therefore, in their chemical and 
biological properties. Many alternative splicing events are regulated at the early phases of 
splicing by positive and negative regulators. These regulators bind to cis-acting sequences 
(exonic or intronic splicing enhancers – ESEs or ISEs; or inhibitors – ESIs or ISIs) and, 





Mutations affecting splicing are usually deleterious. The majority of these mutations are 
single base substitutions at the junctions between introns and exons. They may cause an exon 
to be left out of the product, cause an intron to be included or make splicing occur at an 
aberrant site. The most common outcome is to introduce a termination codon that results in 
truncation of the protein sequence. Anomalously processed or mutated mRNAs are eliminated 
via survey mechanisms, like nonsense-mediated decay, No-Go decay, non-stop decay or 
ribosome extension decay (Doma and Parker, 2006; Frischmeyer et al., 2002; Inada and Aiba, 
2005; Isken and Maquat, 2007; Kong and Liebhaber, 2007; Maquat et al., 2001; van Hoof et 
al., 2002). 
Once the mRNA is in the cytoplasm, translation takes place. Translation is accomplished 
by a complex apparatus that includes protein and RNA components, the ribosome. The 
process of recognizing which amino acid corresponds to a particular nucleotide triplet 
requires an intermediate tRNA. There is at least one tRNA species for every amino acid.  
1.1.1 The mechanism of nuclear pre-mRNA splicing  
Nuclear pre-mRNA splicing requires a large number of trans-acting factors that aid proper 
splice site selection as well as pre-mRNA folding, bringing together the sites at which ligation 
of exons will occur. These factors are brought together in a stepwise manner to form a 
dynamic macromolecular machine called the spliceosome.  
The spliceosome assembles from 5 small uridine-rich nuclear RNAs (U1, U2, U4, U5 and 
U6 snRNAs) organized in ribonucleoprotein complexes (snRNPs) and a plethora of non-
snRNP proteins (Will and Lührmann, 2006; Shatkin, 1976; Shatkin and Manley, 2000; Jurica 
and Moore, 2003). In metazoans, about 1% of all introns (called U12-type introns in contrast 
to U2-type introns of the major spliceosome) are spliced by a distinct spliceosome, called the 
minor spliceosome or U12-dependent spliceosome, comprising U11, U12, U4atac, U6atac 
snRNPs, which are functional analogs of U1, U2, U4, U6 snRNPS of the major spliceosome, 
respectively (Patel and Steitz, 2003; Will and Lührmann, 2005). The U5 snRNP is shared by 
both spliceosomes. The spliceosome assembles de novo on each intron of the pre-mRNA and 
catalyzes two transesterification reactions which are required for excision of introns and 
ligation of exons. 
Chemically, the splicing process seems very simple. It involves a two step reaction which 
produces an excised intron and ligated exons. However, the sites at which the mRNA is 
cleaved to splice out the intron(s) must be precisely selected since an error of one nucleotide 





site (SS) selection is a major challenge to the splicing machinery, especially in higher 
eukaryotes, considering that introns have variable sequences and lengths as well as low 
information content defining exon-intron boundaries. Nevertheless, a set of specific sequences 
required for splicing can, in most cases, be identified in introns and at the intron/exon 
boundaries (Fig. 1.2) (Stephens and Schneider, 1992). The 5' SS defines the 5' end of the 
intron and, in yeast, it is composed of 5'-R|GUAUGU-3' (Lopez and Séraphin, 1999) ('|' 
defines the exon-intron boundary, 'R' is a purine base and nucleotides in bold indicate at least 
90% conservation among yeast introns). In higher eukaryotes, the 5' SS is characterized by the 
consensus sequence 5'-AG|GURAGU-3' (bold letters indicate invariable nucleotides). The 
highly conserved yeast branch point (BP) sequence 5'-UACUAAC-3' contains a conserved 
adenosine (underlined) which is essential for catalysis of the first step of nuclear pre-mRNA 
splicing. The BP adenosine is located 10 to 155 nucleotides upstream of the yeast 3' SS 
(Spingola et al., 1999). In human, the BP sequence is normally located 18-40 nucleotides 
upstream of the 3' SS and comprises a degenerate sequence 5'-YNCURAC-3' ('Y' is a 
pyrimidine base, 'N' is any nucleotide) (Reed, 1989; Wahl et al., 2009; Zhang, 1998). A 10-15 
nucleotide long pyrimidine rich sequence, the polypyrimidine tract (PPT), can often be found 
in higher Eukarya introns one to five nucleotide upstream of the 3' SS. The PPT is essential 
for splicing in humans possibly due to the less conserved BP sequence in human introns. The 
3' SS follows the sequence 5'-YAG|-3' in most of the introns in vertebrates. The invariant AG 
dinucleotide defines the end of the intron (Reed, 1989). In addition, splicing is modulated by 
ESEs/ISEs and ESSs/ISSs, which are short sequences within the pre-mRNA recruiting 
regulatory proteins that either repress or stimulate spliceosome assembly. These sequences are 
not only important for constitutive splicing but also play a crucial role in alternative splicing 
as mentioned above (Black, 2003; Matlin et al., 2005). 
 
Figure 1.2: Conserved sequence elements found in introns from metazoans and budding yeast (S. cerevisiae). 
The 5' and 3' exons are shown as boxes. The branch point adenosine is underlined. "Y" – pyrimidine and "R" – 
purine. The polypyrimidine tract is indicated by "Y(n)".  
In metazoans and plants, a separate, less abundant class of introns exists harboring 
different consensus sequences (Jackson, 1991). In these U12-type introns, the sequences 5'-





respectively. Additionally, the U12-type introns lack the PPT and show a higher level of 
conservation of the 5' SS and BP sequence. The first identified introns of this class had 5' AT 
(AU for RNA) and 3' AC di-nucleotides instead of the highly conserved GT-AG (GU-AG) 
present at the 5' and 3' ends of U2-type introns. Consequently, they were originally called 
'ATAC'-introns. As previously mentioned, these introns are removed by the minor 
spliceosome (Burge et al., 1999).  
Regardless of the spliceosome type, introns are removed by a conserved mechanism 
involving two sequential SN2-type transesterification reactions (Fig. 1.3) (Query et al., 1994; 
Will and Lührmann, 2006). First, the oxygen of the 2' OH group of the BP adenosine makes a 
nucleophilic attack at the phosphodiester bond of the 5' SS exon-intron boundary. This leads 
to the formation of a free 3' OH group at the 3' terminal nucleotide of the 5' exon and the 
formation of 5'-2' phosphodiester bond between the 5' SS guanosine and the BP adenosine. 
The result is a free 5' exon and a lariat intermediate containing the intron and the downstream 
exon. In the second step, the 3' OH group of the 5' exon attacks the phosphodiester bond at the 
3' SS, thereby joining 5' and 3' exons and excising the intron as a lariat. Subsequently, the 
lariat intron is debranched and typically degraded, but can also be a source of regulatory 
RNAs (Carthew and Sontheimer, 2009; Voinnet, 2009), whereas the mRNA is exported from 
the nucleus into the cytoplasm (Brow, 2002). 
 
Figure 1.3: Schematic representation of the two-step mechanism of pre-mRNA splicing. Boxes and solid lines 
represent the exons and the intron, respectively. The branch site adenosine is indicated by the letter "A" and the 
phosphate groups by the letters "p" at the 5' and 3' splice sites. The red arrows indicate the nucleophilic attacks at 





1.1.2 Components of the spliceosome 
The major building blocks of both major and minor spliceosomes are snRNPs. Each 
snRNP is comprised of one (or two in case of U4/U6 snRNP) U snRNA molecule, seven 
common Sm or Sm-like (LSm) proteins, the latter in case of U6 and U6atac, and a variable 
number of snRNP-specific proteins (Will and Lührmann, 2006). The four major snRNPs (U1, 
U2, U5, U4/U6) are highly conserved in eukaryotes.  
The five U snRNAs are numbered according to the order of their discovery: U1, U2, U4, 
U5 and U6 snRNA (remark: U3 is involved in ribosomal RNA processing). U4 and U6 
snRNAs possess a large region of sequence complementarity and base pair via stem I and 
stem II through 22 Watson-Crick base pair interactions and, therefore, are usually found as a 
U4/U6 di-snRNP (Guthrie and Patterson, 1988). The major and minor spliceosomal snRNPs 
differ either with respect to their snRNAs and their specific proteins (U1 and U2 in 
comparison to U11/U12 snRNPs) or only with respect to their snRNAs (U4/U6 in comparison 
to U4atac/U6atac snRNPs). 
All U snRNAs, except U6 and U6atac, are transcribed by RNA polymerase II, receive a 7-
methyl-guanylate cap and are exported from the nucleus (Patel and Bellini, 2008). In the 
cytoplasm, a set of seven Sm proteins (namely B/B', D1, D2, D3, E, F and G) form a ring like 
structure (Sm ring) on a conserved uridine rich patch on the U snRNA, called the Sm-site 
(Achsel et al., 1999; Kambach et al., 1999; Kiss, 2004; Pomeranz Krummel et al., 2009; 
Weber et al., 2010; Leung et al., 2011). The Sm core assembly is mediated by two 
coordinated multifactorial assembly machineries: the protein arginine methyltransferase 5 
(PRMT5) complex and the survival of motor neurons (SMN) complex (Battle et al., 2006; 
Fischer et al,. 2011). After assembly of the Sm core RNPs, the snRNA m7GpppN caps are 
hypermethylated by a methyltransferase (Girard et al., 2008) and converted to a 2,2,7-
trimethylguanosine (m3
2,2,7
GpppN) cap, and the premature particles are returned to the 
nucleus. Constituting a unique feature of U snRNAs, the m3
2,2,7
G cap has been successfully 
employed for immunoaffinity-based purification of snRNPs (Bringmann et al., 1983). Final 
stages of snRNP assembly take place in the nuclear Cajal bodies, where the particle-specific 
proteins are thought to be added (Schaffert et al., 2004; Stanek and Neugebauer, 2006). 
Before association with the particle-specific proteins, many nucleotides of each U snRNA are 
modified by pseudouridylation and 2’-O-methylation (Jády and Kiss, 2001; Kiss, 2004). 
Unlike other U snRNAs, the U6 and U6atac snRNA are transcribed by RNA polymerase 





U6atac lack a Sm site and, instead, associate with a set of seven Sm-like proteins (LSm2-8) 
which bind to the 3’ end of U6/U6atac snRNAs, before they interact with the U4/U4atac 
snRNP to form the di-snRNP (Achsel et al., 1999; Séraphin, 1995).  
As mentioned above, every snRNP contains its own specific set of proteins (Fig. 1.4). 
Considering that all of the identified yeast splicing factors are conserved in metazoans, we 
mainly refer to the human nomenclature henceforth. The 12S U1 snRNP contains only three 
additional factors, U1-70K, U1-A and U1-C (Will and Lührmann, 2006). The 17S U2 snRNP 
consists of U2-A', U2-B" and the heteromeric complexes SF3a (consisting of the proteins 
SF3a120, 66 and 60, named according to their apparent molecular weight) and SF3b 
(SF3b155, 145, 130, 49, p14a/p14, 14b and 10). Additionally, several factors (i.e., U2AF65, 
U2AF35, SPF31, PUF60, CHERP, hPrp5, hPrp43, SPF30, SPF45 and SR140) have been 
identified in purified 17S U2 snRNPs, but seem to be loosely bound since they dissociate at 
salt concentrations higher than 250 mM (Will et al., 2002).   
The 13S U4/U6 di-snRNP contains a set of five specific proteins: hPrp3, hPrp31, hPrp4, 
CypH and 15.5K (hSnu13) (Behrens and Lührmann, 1991; Lauber et al., 1997). The 20S U5 
snRNP consists of eight additional factors: hPrp8, hBrr2, hSnu114, hPrp6, hPrp28, 52K 
(hLin1), 40K and hDib1, (Bach et al., 1989).  
Under physiological conditions, the 13S U4/U6 di-snRNP and the 20S U5 snRNP 
assemble a U4/U6-U5 tri-snRNP in the Cajal bodies (Schaffert et al., 2004) before 
incorporation into spliceosomesl. This 25S U4/U6.U5 tri-snRNP recruits three additional 
proteins: hSnu66, hSad1 and 27K (Behrens and Lührmann, 1991). The U5-52K protein is 
absent in this complex, but is supposed to play a role during assembly of the U4/U6.U5 tri-
snRNP (Laggerbauer et al., 2005). 
In yeast, a cytoplasmic precursor of U5 snRNP – containing only the U5 snRNA, the Sm 
proteins, and the U5-specific proteins Prp8p and Snu114p – has been characterized. Pre-U5 
snRNP lacks the Brr2 helicase and instead includes the Aar2 protein (Gottschalk et al., 2001; 
Boon et al., 2007). Recent studies have shown that Aar2 and Brr2 bind, respectively, to an 
RNase H-like domain and a Jab1/MPN-like (Jab1) domain that lie next to each other in the C-
terminal region of the Prp8 protein. Moreover, binding of Aar2 to the Prp8 RNase H-like 
domain sequestered the Jab1 domain by packaging the two Prp8 domains in a manner 
incompatible with Brr2 binding (Weber et al., 2011). Furthermore, Aar2 was shown to be 
phosphorylated at five sites in vivo and a phospho-mimetic mutation of Aar2 (S253E) 
diminished binding to the RNase H-like domain in vitro and abolished Aar2-Prp8 interaction 







Figure 1.4: Protein composition and snRNA secondary structures of the human major spliceosomal snRNPs. 
The seven Sm (B/B', D3, D2, D1, E, F and G) or LSm (LSm 2-8) proteins are indicated by "Sm" or "LSm" in a 
gray box. The colored boxes list the specific proteins associated with each snRNP. The tri-snRNP contains two 
sets of Sm proteins and one set of LSm proteins. 
Important bridging factors between U4/U6 di-snRNP and the U5 snRNP are U4/U6-
specific hPrp31 and U5-specific hPrp6 and depletion of one of these two factors abolishes 
U4/U6.U5 tri-snRNP formation (Makarova et al., 2002; Schaffert et al., 2004). hPrp31 is 
known to further interact via its NOP domain with 15.5K and the 5' stem loop of U4 snRNA 
(Liu et al., 2007). The other bridging protein hPrp6 has been shown to associate with the U5 
snRNP components hPrp8, hBrr2 and hSnu114, but not with the U5 snRNA (Liu et al., 2006; 
Makarov et al., 2000). 
A considerable number of factors are not stably attached to any U snRNA and are 
recruited to the spliceosome either individually or as part of a pre-assembled complex. These 
proteins or complexes are referred to as non-snRNP splicing factors and will be described 
briefly. 
Many spliceosomal SF2 helicases are thought to play an essential role in each step of 
spliceosome assembly by rearranging inter- and intra-molecular RNA structures or by 
dissociating RNA-protein complexes using energy from ATP hydrolysis (reviewed in Rocak 
and Linder, 2004). RNA helicases such as UAP56, hPrp5, hPrp2, hPrp16, hPrp22 and hPrp43, 





hBrr2 and hPrp28 helicases which are integral components of the U5 snRNP and U4/U6.U5 
tri-snRNP.  
SR (serine-arginine) proteins are known to act as activators of constitutive splicing and 
modulators of alternative splicing (reviewed in Graveley, 2000). SR proteins are typically 
characterized by the presence of one or more amino-terminal RNA recognition motifs (RRM) 
and an arginine/serine rich (RS) carboxy-terminal domain (Long and Caceres, 2009). The 
RRMs are involved in binding to ESEs, whereas the RS domain is engaged in protein-protein 
as well as protein-RNA interactions, which facilitate the recruitment of spliceosomal factors 
(Wu and Maniatis, 1993).  
The human Prp19/CDC5L complex (NineTeen Complex or NTC – in yeast) is recruited to 
the spliceosome prior to the first step of splicing and plays an important role during 
spliceosome activation apparently after U4/U6.U5 tri-snRNP association (Wahl et al., 2009; 
Makarov et al., 2002; Makarova et al., 2004). The hPrp19/CDC5L complex acts subsequent 
to the U4 dissociation, stabilizing the association of U5 and U6 with the activated 
spliceosome and specifying the proper interaction of U5 and U6 with the pre-mRNA prior to 
step 1 (Chan and Cheng, 2005; Chan et al., 2003).  
The RES (pre-mRNA REtention and Splicing) complex, which consists of three factors 
well characterized in yeast, Snu17, Bud13 and Pml1, was shown to influence the efficiency of 
the splicing process. This non-snRNP complex proved to be essential in yeast for the retention 
of unspliced pre-mRNAs in the nucleus (Dziembowski et al., 2004). 
It is noteworthy that in contrast to, for example, ribosomal subunits, none of the snRNPs 
as well as non-snRNP complexes contain a pre-formed catalytic center for the splicing 
transesterification reactions. Actually, the active center of the spliceosome is formed anew 
during each spliceosome assembly cycle. 
1.1.3 Stepwise assembly of the spliceosome 
In order to splice out the introns and ligate the adjacent exons, the 5' SS, BP and 3' SS 
have to be brought into close proximity. Self-splicing group II introns spontaneously adopt a 
three-dimensional fold that provides an active site where the reactive groups of the introns are 
juxtaposed (Toor et al., 2008b; Chan et al., 2012). In contrast, considering the limited 
information contained in the nuclear introns and the fact that the consensus sequences 
defining the 5' SS, BP and 3' SS are highly degenerated in metazoans, nuclear introns do not 
contain sufficient secondary and tertiary structure information to assemble in a productive 





manner conductive to splicing depends on many trans-acting factors that are brought together 
with the pre-mRNA to form the spliceosome. For each round of splicing, the spliceosome is 
assembled de novo and undergoes several rearrangements of its components generating well 
defined intermediate complexes that can be isolated in vitro (reviewed in Will and Lührmann, 
2011; Wahl et al., 2009).  
When introns do not exceed 200-250 nt, the spliceosome assembles across the intron (Fig. 
1.5) (Fox-Walsh et al., 2005). In major (U2-dependent) spliceosomes, the assembly starts 
with the ATP-independent recognition of the 5' splice site by U1 snRNP with the 5' end of the 
U1 snRNA base-pairing with the 5' splice site of the intron (Ruby and Abelson, 1988; 
Seraphin and Rosbash, 1989). Also, in the early assembly phase of the spliceosome, SF1/BBP 
protein and the 65 kDa subunit of the U2 auxiliary factor (U2AF) bind to the BPS and to the 
PPT, respectively (Berglund et al., 1998). Additionally, the 35 kDa subunit of U2AF binds to 
the AG dinucleotide of the 3' SS and, together, all these interactions yield the spliceosomal E 
complex (Hong et al., 1997; Das et al., 2000).  
Subsequent to E complex formation, U2 snRNA engages in base-pairing interactions with 
the BPS in an ATP-dependent manner, assisted by UAP56 and hPrp5 helicases (Xu et al., 
1996; Zhang, 2001; Fleckner et al., 1997). In the short U2-BPS duplex, the branch site 
adenosine is bulged out offering its 2'-OH as a nucleophile for the first catalytic step (Query et 
al., 1994). This base-pairing is stabilized by SF3a and SF3b protein complexes from U2 
snRNP and by the RS domain of U2AF. Association of U2 snRNP leads to the dissociation of 
SF1/BBP from the BPS and results in A complex formation (Lim and Hertel, 2004).  
In the next step, the pre-formed U4/U6.U5 tri-snRNP particle is recruited to the 
spliceosome, forming the B complex (Cheng and Abelson, 1987). Although it contains all 
snRNPs, the B complex is catalytically inactive and requires major compositional and 
conformational rearrangements. During spliceosome activation, U1 and U4 snRNPs dissociate 
from the spliceosome, giving rise to the activated spliceosome (B
act
 complex). hPrp28 and 
hBrr2 helicases are involved in disrupting the base-pair interactions of U1 and the 5' SS and 
of U4/U6 di-snRNA, respectively (Staley and Guthrie, 1999; Laggerbauer et al., 1998; 
Raghunathan and Guthrie, 1998). Concomitantly, the 5' end of U6 snRNA substitutes U1 and 
base pairs with the 5' SS. Extensive base-pairing network is formed between U2 and U6, 
bringing together the 5' SS and the BP sequence for the first step of splicing. Additionally, a 
central region of U6 snRNA forms an intramolecular stem-loop structure (U6-ISL) that seems 






Figure 1.5: Cross-intron assembly and disassembly of the major spliceosome. Only the stepwise interactions of 
the spliceosomal snRNPs (colored circles) but not those of the non-snRNP factors are shown. The spliceosomal 
complexes are named according to the metazoan nomenclature. Exons and introns are represented by boxes and 
lines, respectively. The stages at which remodeling takes place driven by SF2 RNA helicases and the GTPase 
Snu114 are indicated.   
At this stage, Prp2 plays a role in reorganizing the spliceosome, generating the B* 
complex (a catalytically activated spliceosome), which catalyses the first step of splicing 
(Kim and Lin, 1993; Warkocki et al., 2009). This yields the C complex. Prior to the second 
catalytic step, the spliceosome is remodeled again by the Prp16 helicase possibly to reposition 
the splicing intermediates (Schwer and Guthrie, 1992). Also before step 2, U5 contacts exon 
nucleotides downstream of the 3' SS and aligns 5' and 3' exons for the second catalytic step. 
All these events lead to the catalysis of step 2 (reviewed by Umen and Guthrie, 1995; Smith et 
al., 2008). Finally, the exon junction complex (EJC) is deposited 20 to 25 nt upstream of the 
exon-exon junction (Le Hir et al., 2000; Bono et al., 2006). The mRNA is then released in the 
form of an mRNP and transported out of the nucleus (Le Hir et al., 2000; Bono and Gehring, 
2011). At the same time, the post-spliceosomal complex (Makarov et al., 2002) is 
disassembled and the snRNPs are recycled to take part in subsequent splicing events. The 
released lariat intron (Martin et al., 2002) is debranched by Dbr1 and typically degraded 





Alternative spliceosome assembly pathways exist in metazoans, whose mRNAs contain 
multiple extremely large introns, from several hundred to several thousand nt (Deutsch and 
Long, 1999) and rather short exons. When intron length exceeds 250 nt, spliceosomal 
components assemble across an exon, a process called exon definition (Berget, 1995). During 
exon definition, U1 snRNP binds to the 5' SS downstream of an exon and stimulates the 
association of U2AF with the PPT and the 3' SS upstream of the same exon. Then, U2 snRNP 
is recruited to the BPS also upstream of the exon and ESEs recruit proteins of the SR family 
which stabilize the exon-defined complex (Hoffman and Grabowski, 1992; Reed, 2000). In a 
subsequent step, these cross-exon interactions must be substituted by cross-intron interactions. 
However, this process is poorly understood. It is suggested that exon exclusion and skipping 
during alternative splicing events occurs during the transition from a cross-exon to a cross-
intron complex (Sharma et al., 2008).  
1.1.4 Rearrangements of the RNA-RNA network during the splicing cycle 
An extensive RNA-RNA network is formed and significantly restructured during 
spliceosome assembly and activation (Fig. 1.6) (reviewed by Will and Lührmann, 2011; 
Nilsen, 1998). 
In the pre-catalytic B spliceosome, the U1 snRNA base pairs with the 5' SS of the pre-
mRNA (Zhuang and Weiner, 1986; Siliciano et al., 1991; Heinrichs et al., 1990) and U2 
snRNA base pairs with the BPS (Wu and Manley, 1989; Parker et al., 1987; Gozani et al., 
1998). In the latter duplex, the BP adenosine, that performs the nucleophilic attack in the first 
catalytic step, is bulged out. Furthermore, the U2 snRNA forms an internal stem-loop (SL I), 
while its 5' end base-pairs with the 3' region of the U6 snRNA forming the so-called helix II 
(Madhani and Guthrie, 1992). Simultaneously, nucleotides of U6 snRNA that are essential 
components of the spliceosome active site are extensively base-paired with the U4 snRNA 
forming stem I and stem II (Rinke et al., 1985). Finally, the conserved U5 snRNA loop 1 has 
been shown to be in the direct vicinity of exon 1 by cross-linking experiments (Newman et 
al., 1995; Wyatt et al., 1992). 
During the activation of the spliceosome, a dramatic remodeling of the RNA-RNA 
network positions the reactive groups of the pre-mRNA (i.e. the 5' SS and the BP adenosine) 
in a proper spatial organization for the first step of splicing (Fig. 1.6). The initial U1 snRNA 
base-pairing to the pre-mRNA is disrupted by Prp28 (Staley and Guthrie, 1999) and replaced 
by base-pairing between the pre-mRNA and the conserved ACAGA-box sequence in the 5' 





Additionally, the extensive and thermodynamically stable U4/U6 base-pairing is unwound by 
Brr2 (Laggerbauer et al., 1998; Raghunathan and Guthrie, 1998; Staley and Guthrie, 1999). 
Once the U4 snRNP has dissociated, short U2/U6 duplexes are formed and U6 snRNA 
rearranges from an inert to a catalytically active conformation, forming, in particular, the 
conserved internal stem-loop (ISL) structure which is involved in metal ion binding (Wolff 
and Bindereif, 1993; McManus et al., 2007; Yean et al., 2000). The initial delivery of U6 in 
an inactive conformation prevents the splicing cycle to proceed until the reactive groups of 
the pre-mRNA are properly positioned. 
 
Figure 1.6: Dynamic network of RNA-RNA interactions in the spliceosome. Exons are indicated as boxes and 
intron sequences by a black line. snRNAs are shown schematically (secondary structure as observed in 
mammals) in gray, with regions engaging in base paring interactions highlighted in color. 
The RNA-RNA network established by U2 and U6 snRNAs plays a crucial role in 
catalysis. Intriguingly, there are many similarities between the spliceosome and self-splicing 





splicing reaction requires divalent cations (Yean et al., 2000; Sontheimer, 2001). In addition, 
there are significant similarities in the sequence and secondary structure of snRNAs and some 
domains of group II introns. The catalytically critical Domain V of group II introns resembles 
the ISL in U6 snRNA. The structures of Domain V and U6-ISL contain a bulge, known to 
bind a divalent metal ion (Yean et al., 2000; Seetharaman et al., 2006), and a conserved 
catalytic triad, AGC, at their 5' ends. Besides, Domain VI of group II introns contains an 
equivalent of the structure formed between U2 snRNA and the BPS, with the adenosine 
nucleotide, which carries the nucleophile of the first step, bulged out. Additionally, three 
sequences in Domain I of group II introns bind exonic sequences in a manner similar to U5 
snRNA and another subdomain of Domain I recognizes the 5' SS and is considered a 
functional counterpart of U1 snRNA. Such parallels lead to the hypothesis that snRNAs might 
be evolutionary descendants of group II introns and, therefore, have a catalytic role during 
splicing (reviewed in Valadkhan, 2010).  
In agreement with the proposal of an RNA-based catalysis, U6 and U2 snRNAs can 
catalyze a two-step reaction with short RNA substrates that remotely resemble the one 
catalyzed by the spliceosome (Valadkhan et al., 2007, 2009). Additionally, structural studies 
of self-splicing group II introns place the elements equivalent to the U6-ISL and ACAGA-box 
as key active site components (Toor et al., 2008a; Chan et al., 2012). However, most 
similarities between group II introns and the spliceosome are related to the chemistry of 
splicing and the RNA components. Considering that the spliceosome is a protein-rich RNP, it 
is difficult to decide if the parallels between group II introns and the spliceosome truly reflect 
a common ancestry or if they are just a result of convergent evolution impelled by the need to 
catalyze the same reaction. However, recent studies have shown that Prp8, the largest and 
most conserved protein in the spliceosome, shares similarities to group II intron maturases 
(Dlakić and Mushegian, 2011). As mentioned above in section 1.1, maturases promote 
splicing by inducing and stabilizing the catalytically active RNA structure. The self-splicing 
process is very inefficient in the absence of maturases as is the splicing-like reaction catalyzed 
by a protein-free RNA duplex similar to U2/U6. The Prp8 protein interacts with all the 
reactive groups in the intron, 3' SS, 5' SS and BPS, and with U5 and U6 snRNAs, thus 
constituting a major scaffold and regulator of the RNA-RNA network in the spliceosome 
(reviewed in Grainger and Beggs, 2005). Therefore, Prp8 and maturases seem to play similar 
roles in their corresponding systems, providing additional evidence for a common 





1.1.5 Compositional changes within the spliceosome  
Despite the indications that pre-mRNA splicing catalysis is at least partially RNA-based, 
the spliceosome, unlike group II introns, requires a plethora of protein factors to assemble the 
introns and the snRNAs in a catalytic structure. These proteins play crucial roles in SS 
recognition; facilitate dynamics of RNA-RNA and RNA-protein interactions and ensure the 
proper arrangement of the catalytic centers of the spliceosome. 
The protein composition of affinity purified spliceosomal complexes stalled at certain 
assembly stages has been determined by mass spectrometry. These studies demonstrated that 
the composition of the spliceosome is highly dynamic with remarkable exchanges of proteins 
from the assembly stage, throughout activation and disassembly (Makarov et al., 2002; 
Makarova et al., 2004; Behzadnia et al., 2007; Bessonov et al., 2008, 2010; Deckert et al., 
2006).  
Besides the human and D. melanogaster spliceosomes, the protein composition of affinity 
purified, in vitro assembled S. cerevisiae spliceosomal complexes have been recently 
determined (Fabrizio et al., 2009). It can be noted that the yeast splicing machinery contains 
the evolutionary conserved core of spliceosomal proteins required for constitutive splicing. 
Additional proteins found in higher Eukarya spliceosomes are mainly implicated in alternative 
splicing, a process mostly absent in yeast. 
A dramatic exchange of proteins occurs during spliceosome assembly and activation. 
Interestingly, the proteins involved in dissociation/recruitment during B complex to C 
complex transitions are homologous in yeast and metazoans indicating that not only the 
proteins but also the compositional dynamics of the splicing machinery are evolutionarily 
conserved (Fabrizio et al., 2009; Bessonov et al., 2008, 2010).  
Proteomic analysis of human spliceosomal A complex revealed that it consists of ten A 
complex-specific proteins besides U1 and U2 snRNPs (Behzadnia et al., 2007). These non-
snRNPs leave the spliceosome during A to B complex transition while ~60 other proteins are 
recruited. Thus, the B complex contains U1 and U2 snRNPs, the U4/U6.U5 tri-snRNP plus 35 
non-snRNP proteins, including the hPrp19/CDC5L and RES complexes and a group of B 
complex-specific proteins (Deckert et al., 2006). In the conversion from B to B
act
 complex, all 
U1 and U4/U6 proteins are lost. In contrast, several proteins are recruited to or become more 
stably associated with the spliceosome. All hPrp19/CDC5L complex proteins as well as 
related proteins are more abundant in B
act
. The presence of hPrp2 in the purified B
act
 





is known to dissociate from the spliceosome after catalyzing the remodeling step that yields a 
catalytically active B* complex (Kim and Lin, 1996). In the transition from B
act
 to C complex, 
the new additions to the spliceosome mainly consist of C-complex specific proteins and the 
so-called step II factors, which are proteins known to function prior to or during the second 
transesterification reaction. Additionally, SF2 helicases and peptidyl-prolyl isomerases 
(PPIases) are recruited to the C complex, potentially playing a role in RNP remodeling at this 
stage of splicing. Furthermore, SF3a and SF3b proteins are specifically destabilized from the 
human spliceosome during B
act
 to C complex transition. Finally, members of the exon 
junction complex (EJC), which are important for mRNA translation, are recruited at this stage 
(Bessonov et al., 2008, 2010). 
In yeast, drastic rearrangements occur in the transition from B to B
act
 complex (Fig. 1.7), 
the latter representing the spliceosome prior to the final catalytic activation mediated by Prp2. 
U1 snRNP is released as well as the U4 snRNA and all the U4/U6 associated proteins. At this 
stage, 12 B
act
 proteins are recruited that may be either involved in establishing/stabilizing 
U2/U6 base-pairing (such as Ecm2 and Cwc2) or promoting step 1 (Prp2, Spp2 and Yju2). 
Comparison of B
act
 with C complexes (Fig. 1.7) shows that key proteins that are required at 
later stages of splicing are recruited during this transition. At least nine proteins, mainly step 2 
factors, as well as the trimeric disassembly NTR complex join the spliceosome during C 
complex formation (Fabrizio et al., 2009). Due to the limited number of proteins recruited 
during B
act
 to C complex transition, it has been possible to investigate the requirements of 
some of these factors for step 1 or 2 by complementing purified spliceosomes (B
actprp2
), 
which were stalled before the catalytic activation step mediated by Prp2, with purified 
recombinant splicing factors (Warkocki et al., 2009). The ability to rescue both steps of 
splicing in yeast using purified components could possibly help to elucidate the role of some 
RNA helicases implicated in RNP remodeling during activation. 
It is important to mention that not only the protein composition during the splicing cycle 
changes but also the extent to which these proteins are modified. Several spliceosomal 
proteins are post-translationally modified prior to or during their involvement in the splicing 
cycle (Mathew et al., 2008; Soulard et al., 1993). Post-translational modification patterns 
constitute a code for recruitment of mRNA processing factors once they generate structural-
mediated transitions that provide new interaction platforms. Consequently, these 







Figure 1.7: Compositional dynamics of the yeast spliceosome. The protein composition of B, B
act
 and C 
complexes of S. cerevisiae, identified by mass spectrometry, are shown. Proteins are grouped according to their 
function or association with a snRNP. The relative abundance of the proteins is indicated by the light 
(substoichiometric) or dark (stoichiometric) lettering. Considering that the compositional dynamics of the 
splicing machinery are evolutionarily conserved between yeast and human, only the representative scheme of the 
compositional dynamics of the yeast spliceosome is shown for simplicity. 
Several enzymes responsible for introduction or removal of post-translational 
modifications are found in the spliceosomal complexes, such as SR protein kinases 1 and 2, 
Prp4 kinase and Clk/Sty kinase. In general, phosphorylation predominantly occurs during 





catalysis and disassembly. Furthermore, spliceosomal proteins seem to undergo other types of 
modifications such as ubiquitination (Bellare et al., 2008) and acetylation (Kuhn et al., 2009). 
1.2 Helicases: enzymatic motors of the spliceosome  
The sequential rearrangements in the RNA-RNA and RNA-protein networks during 
assembly, activation and catalysis of the spliceosome are mainly driven by RNA 
unwindases/RNPases (Staley and Guthrie, 1998). The energy of nucleotide triphosphate 
hydrolysis is harnessed by these enzymes and is coupled to structural/compositional 
rearrangements, such as remodeling of snRNA conformations and positioning of splice sites 
at the catalytic center, at several steps of the splicing cycle. The activity of spliceosomal 
helicases must be highly coordinated; a task carried out by other spliceosomal proteins and 
modulated, in some cases, by post-translational modifications. These RNA helicases also 
govern timing and fidelity of splicing by facilitating the discard of aberrant/nonproductive 
splicing intermediates (Smith et al., 2008). 
1.2.1 RNA helicases 
Helicases are highly conserved enzymes that bind or remodel DNA/RNA or protein-
nucleic acid complexes in an energy-dependent manner utilizing the energy of hydrolysis of 
nucleotide triphosphate (Cordin et al., 2006). DNA helicases unwind double-stranded DNA 
regions and are involved in DNA replication, recombination and repair as well as overall 
genome stability (Singleton et al., 2007). RNA helicases are found in all kingdoms of life, 
where they are the largest group of enzymes involved in RNA metabolism (Anantharaman et 
al., 2002). Many RNA helicases play critical roles during conformational changes of RNA 
and RNP complexes (Linder, 2006), in displacing proteins from RNA-protein complexes 
(Fairman et al., 2004), in mediating RNA annealing or unwinding (Yang and Jankowsky, 
2005; Halls et al., 2007; Rajkowitsch and Schroeder, 2007), as well as during timing and 
proofreading events (Tanner and Linder, 2001; Staley and Guthrie, 1998). Although most 
RNA helicases receive their helicase designation based on highly conserved sequence motifs 
(Fairman-Williams et al., 2010; Jankowsky et al., 2011), ATP-driven RNA duplex unwinding 
has been shown only for a subset of proteins in vitro (Jankowsky et al., 2005; Linder, 2006; 
Tanner and Linder, 2001). Therefore, it is assumed that most of the proteins categorized as 






Both DNA and RNA helicases fall into two categories, those that form oligomeric (mostly 
hexameric) rings and those that do not. Based on sequence and comparative structural and 
functional analyses, all helicases are classified into six superfamilies (SFs). The ring-forming 
helicases comprise SFs 3 to 6 and the non-ring forming ones comprise SFs 1 and 2. All 
eukaryotic RNA helicases belong to SFs 1 and 2. Ring-shaped RNA helicases are found in 
bacteria and viruses (Jankowsky, 2011). 
SF1 and SF2 include DNA and RNA helicases that contain a structurally conserved 
helicase core formed by two highly similar α-β RecA-like domains. Both SF1 and SF2 
helicases share 12 characteristic sequence motifs at defined positions in the helicase core and 
seem to act as monomers or dimers (Jankowsky, 2011; Fairman-Williams et al., 2010). 
However, not all motifs are present in each helicase family. The highest level of conservation 
across both SFs is seen in the residues that coordinate binding and hydrolysis of the 
triphosphate (motifs I, II and VI). These residues are located in the cleft between the two 
conserved RecA-like domains. Interestingly, the spatial arrangement displayed by these 
residues is highly conserved in other NTPases (Walker et al., 1982; Fairman-Williams et al., 
2010). 
Most RNA helicases are members of SF2. RNA helicases are found in five families 
belonging to SF2 (Ski2-like, RIG-I-like, DEAD-box, DEAH/RHA and NS3/NPH-II) and in 
one family of SF1 (Upf1-like) (Fairman-Williams et al., 2010). In RNA helicases of SF1 and 
SF2, the two RecA-like domains are separated by a linker that allows movement of the 
domains relative to each other upon substrate binding. The binding of a single-stranded RNA 
substrate to the core of these helicases is achieved when residues of motifs Ia, Ib and Ic in the 
RecA-1 domain and of motifs IV, IVa, V and Vb in the RecA-2 interact with the phosphate 
backbone of the oligonucleotide. Concomitant binding of RNA substrate and ATP brings 
together the two RecA domains resulting in the formation of an NTP binding pocket 
competent for hydrolysis (Weir et al., 2010; Montpetit et al., 2011; Sengoku et al., 2006). For 
the enzymes of all these families, NTP binding is executed in a similar manner with residues 
from motifs I, II and VI contacting the phosphates and the coordinated magnesium ion, while 
residues from motif VI are coordinating the ribose (reviewed by Cordin et al., 2012). 
In addition to the helicase core region which contains the conserved motifs, most RNA 
helicases contain variable N- and/or C-terminal extensions. These amino- and carboxyl-
terminal extensions are highly variable in size and composition. This modular organization 
suggests that the core region functions as an NTP-dependent motor while the terminal 





might direct the protein to a specific subcellular localization (Wang and Guthrie, 1998). 
Consistent with the critical roles in establishing physiological specificity for individual 
enzymes, C-terminal and N-terminal accessory domains are usually not conserved within a 
family. However, recent studies have revealed some degree of structural conservation of the 
C-terminal extension in the Ski2-like and DEAH families (He et al., 2010; Büttner et al., 
2007). Additionally, most helicases that unwind duplexes with defined polarity have 
functionally important accessory domains located on top of the nucleic acid binding site on 
the helicase core. This arrangement encloses the bound nucleic acid strand to some extent, 
possibly facilitating directional translocation upon which polar unwinding is based (Fairman-
Williams et al., 2010). 
 
Figure 1.8: The conserved motifs of SF2 helicases. The motifs and functionally important features of DEAD-
box, DEAH/RHA and Ski2-like helicases are represented. The length of the boxes is not to scale. All the 
characteristic sequence motifs summed to comparative structural and functional analyses determine the family to 
which a helicase belongs. For the Ski2-like family, the N-terminal cassette of Brr2 is represented. 
Since all spliceosomal helicases belong to the Ski2-like, DEAD-box and DEAH/RHA 
families of SF2, a brief description of these families will follow. 
1.2.1.1 DEAD-box family 
The DEAD-box proteins were first identified by sequence alignments of eight homologues 
of yeast eIF4A translation initiation factor that highlighted the presence of several conserved 
motifs in the RecA-like domains (Linder and Slonimski, 1989). The name of the family 
derives from the amino acid sequence D-E-A-D (Asp-Glu-Ala-Asp) of its Walker B motif 
(motif II). The DEAD-box family is the largest within SF2 and appears to contain exclusively 
RNA helicases (Tanner et al., 2003; Fairman-Williams et al., 2010). DEAD-box helicases 
only hydrolyze ATP since they possess an adenine recognition motif (Q-motif) that interacts 
specifically with the adenine base. Furthermore, an interaction between an -helix in the end 





binding by DEAD-box helicases results in local duplex separation. Subsequently, ATP 
hydrolysis leads to RNA release. Interestingly, removal of stabilizing proteins can bypass the 
requirement of these helicases in the spliceosome (Kistler and Guthrie, 2001; Perriman and 
Ares, 2007; Chen et al., 2001). Consequently, it is plausible that ATP hydrolysis by 
spliceosomal DEAD-box helicases may be required to time conformational switching events 
rather than to force conformational rearrangements through mechanical movement (Cordin et 
al., 2012). 
1.2.1.2 DEAH/RHA family 
DEAH/RHA helicases hydrolyze any nucleotide tri-phosphate in vitro (Fairman-Williams 
et al., 2010). In this family, the base of the bound nucleotide is twisted by 150º compared to 
the position adopted by the base in DEAD and Ski2-like helicases (He et al., 2010; Walbott et 
al., 2010; Pyle, 2008). Consequently, the base is sandwiched non-specifically between the two 
RecA-like domains. These helicases also possess a long -hairpin located between motifs Va 
and VI which is proposed to control access to the RNA binding pocket in an ATP-dependent 
manner (He et al., 2010). When ADP is bound, RNA binding is prevented. Additionally, other 
structural features such as winged helix, OB-fold and helical bundle domains cooperate with 
the -hairpin to modulate RNA binding. Alternatively, this -hairpin might be functionally 
similar to the strand separating device in the Ski2-like Hel308 DNA helicase. Interestingly, 
the presence of this -hairpin correlates with polar unwinding, observed in DEAH/RHA, 
NS3/NPH-II and Ski2-like. 
1.2.1.3 Ski2-like family 
Ski2-like, as DEAD-box helicases, selectively hydrolyze ATP due to the presence of the 
Q-motif (Fairman-Williams et al., 2010). In this family, nucleic acid substrates preferentially 
bind with 3' to 5' directionality across the first and second RecA-like domains, which could 
explain the 3' to 5' unwinding directionally observed in these enzymes (Hopfner and 
Michaelis, 2007). In particular, 3' to 5' translocation has been shown for Hel308 (Guy and 
Bolt, 2005), Mer3/HFM1 (Nakagawa and Kolodner, 2002) and Mtr4 (Bernstein et al., 2008). 
Ski2-like helicases also contain a -hairpin which is shorter compared to the one from 
DEAH-box helicases and is probably not involved in controlling RNA binding. This -hairpin 
is proposed to act as a duplex separation device which takes apart the duplex strands when 





1.2.2 Spliceosomal RNA helicases 
SF2 RNA helicases are probably the main driving force behind the extensive structural 
remodeling of the spliceosome, conferring speed, accuracy and directionality (Staley and 
Guthrie, 1998). They act at specific steps of splicing to facilitate transactions between 
mutually exclusive RNA-RNA or RNA-protein interactions. These helicases displace 
interaction partners (RNA or proteins) from particular regions of the pre-mRNA and/or 
snRNAs and, consequently, liberate RNA regions allowing them to engage in new base 
pairing interactions or bind a protein (Pyle, 2008; Staley and Guthrie, 1998).   
Of the eight spliceosomal SF2 RNA helicases, three belong to the DEAD-box family 
(Sub2/UAP56, Prp5 and Prp28), four to the DEAH/RHA family (Prp2, Prp16, Prp22 and 
Prp43) and one to the Ski2-like family (Brr2). All of them are conserved between yeast and 
humans. 
The DEAD-box proteins Prp5 and Sub2/UAP56 are required for pre-spliceosome 
formation. Sub2/UAP56 facilitates U2 addition to the spliceosome by displacing U2AF and/or 
BPP from the BPS (Kistler and Guthrie, 2001). Prp5 is implicated in remodeling of U2 
snRNP, thereby facilitating U2 snRNA binding to the BPS. Prp5 may also play a role in 
proofreading the stability of the U2/BPS duplex (Xu and Query, 2007). Prp28 catalyzes the 
exchange of U1 for U6 at the 5' SS (Staley and Guthrie, 1999) during the transition from B to 
B
act
 complexes. Prp28 actively dissociates U1-C from the 5' SS, which is the protein that 
stabilizes the U1/5' SS base pairing interaction (Chen et al., 2001). In humans, 
phosphorylation of Prp28 is required for its association with the tri-snRNP and the subsequent 
integration of this snRNP during B complex formation (Mathew et al., 2008). It is presently 
not known if this post-translational modification regulates the function of Prp28. Thus, 
Sub2/UAP56, Prp5 and Prp28 seem to catalyze RNA-protein rearrangements in the 
spliceosome rather than unwind RNA duplexes. This is in agreement with the fact that, in the 
spliceosome, the targets of these DEAD-box helicases are unstable RNA structures requiring 
stabilization by proteins which are then displaced as a consequence of the helicase activity 
(Kistler and Guthrie, 2001; Perriman and Ares, 2007; Chen et al., 2001; Staley and Guthrie, 
1999).  
The Ski2-like helicase Brr2 catalyzes a crucial step in spliceosome activation, the 
unwinding of the U4/U6 di-snRNA. Since the Brr2 helicase is the topic of this thesis, it will 





The DEAH/RHA protein Prp2 plays a role before step 1 of splicing promoting a poorly 
understood remodeling that converts B
act
 into B* complex (Warkocki et al., 2009). The 
association of Prp2 with the spliceosome is transient and Prp2 is recruited through the 
interaction of its C-terminal region with Spp2, a G-patch protein (Roy et al., 1995; Last et al., 
1987). In vitro biochemical experiments with purified Prp2 showed that ATP hydrolysis is 
stimulated by single-stranded RNA but not by DNA or RNA duplexes (Kim et al., 1992). In 
contrast to the other DEAH/RHA spliceosomal helicases, Prp2 seems not to unwind RNA 
duplexes in vitro (Kim and Lin, 1996; Wang and Guthrie, 1998; Wagner et al., 1998; Tanaka 
et al., 2007; Martin et al., 2002). Prp16 promotes conformational rearrangements in the 
spliceosome required for step 2 of splicing. However, the precise nature of such remodeling is 
unclear. In yeast, Prp16 interacts genetically with Prp8 (Query and Konarska, 2004) and U6 
snRNA (Madhani and Guthrie, 1992) suggesting that it may act on a structure containing 
these components. Prp16 unwinds double-stranded RNA in vitro (Schwer and Guthrie, 1992; 
Wang and Guthrie, 1998) and also joins the spliceosome transiently. After NTP-mediated 
activity, Prp16 dissociates from the spliceosome (Schwer and Guthrie, 1992). Prp16 also 
regulates fidelity of BPS recognition, promoting the discard of aberrant lariat intermediates 
(Burgess and Guthrie, 1993). Another DEAH/RHA helicase, Prp22 not only functions 
subsequent to Prp16 in an ATP-dependent fashion in the catalysis of step 2 but it is also 
required for the ATP-independent release of the mRNA from the spliceosome. It is suggested 
that Prp22 displaces U5 snRNP from the mRNA by disrupting Prp8 and U5 snRNA 
interactions with the exon, leading to mRNA release (Aronova et al., 2007; Schwer, 2008; 
Schwer and Gross, 1998). Prp22 is also involved in maintaining fidelity of exon ligation by 
repressing the splicing of aberrant splicing intermediates (Mayas et al., 2006). Prp43 is 
implicated in the release of the excised intron from the post-splicing complex, which is 
accompanied by release of U2, U5 and U6. In yeast, Prp43 forms a complex with Ntr1 and 
Ntr2 which recruit Prp43 to the spliceosome and are further required for spliceosome 
disassembly (Tsai et al., 2007). Additionally, Ntr1 stimulates the helicase activity of Prp43 
(Tanaka et al., 2007). In contrast to the DEAD-box family, DEAH/RHA and Ski2-like 
helicases can load on the RNA substrate through a 3' single stranded overhang and, by means 
of an ATP-dependent ratcheting mechanism, pull the substrate strand into the RNA binding 
groove. Therefore, these DEAH/RHA and Ski2-like helicases are involved in remodeling the 
extensive RNA-RNA and RNA-protein networks of a fully assembled spliceosome fulfilling 





Furthermore, the regulatory mechanisms controlling the ATPase/helicase/RNPase 
activities of spliceosomal helicases are largely unknown. Most of these RNA helicases join 
the spliceosome transiently at the stage at which their activities are required. Therefore, the 
sequential recruitment of these helicases may be explained by overlapping binding sites 
and/or by conformational rearrangements elicited by one helicase that could activate or create 
the substrate for the following one. Additionally, specific partners mediate the recruitment of 
a helicase, such as Spp2 recruiting Prp2 (Roy et al., 1995), and/or modulate its activity, as for 
Ntr1 and Prp43 (Tsai et al., 2007). Interestingly, DEAH/RHA and Ski2-like helicases share 
C-terminal structural features such as the winged helix and helical bundle domains. Since 
these domains participate in RNA binding and contact the RecA domains, binding of an 
effector protein to such structures might remodel the active site and affect RNA binding 
and/or ATP hydrolysis. Along the same line, Prp2, Prp16, Prp22 and Prp43 exhibit high 
sequence conservation within their C-terminal regions, which comprise a winged helix (WH), 
a helix-loop-helix (HLH) and an oligonucleotide/oligosaccharide-binding (OB fold) domain 
(Arenas and Abelson, 1997; Burgess et al., 1990; Chen and Lin, 1990; Company et al., 1991; 
Kudlinzki et al., 2009), also suggesting a conserved regulatory mechanism. Although DEAD-
box proteins possess poorly conserved N- and C-terminal domains, recent reports indicate that 
such helicases can bind effector proteins through a conserved surface in their RecA-2 domain 
(Montpetit et al., 2011; Oberer et al., 2005; Tritschler et al., 2009). 
As mentioned previously, Prp5, Prp16 and Prp22 are considered important guarantors of 
splicing fidelity. It has been suggested that the function of these helicases is similar to the role 
played by the elongation factor eEF1A/EF-Tu during translation (Burgess et al., 1990). The 
kinetic proofreading model for splicing fidelity suggests that the rate of ATP hydrolysis by an 
RNA helicase acts as a timer and influences the equilibrium between two competing events: 
stalling of the spliceosome or splicing catalysis (Burgess and Guthrie, 1993). The stalled 
spliceosome can either reorganize and proceed in the splicing cycle or be discarded. Prp43 is 
then implicated in the disassembly of such rejected spliceosomal complexes (Koodathingal et 
al., 2010; Pandit et al., 2006; Mayas et al., 2010). However, the mechanisms underlying 
kinetic proofreading and spliceosome rejection are poorly understood. 
1.2.3 Brr2: a helicase essential for spliceosome catalytic activation 
Brr2 is an integral component of the U5 snRNP (Lauber et al., 1996; Noble and Guthrie, 
1996) and enters the spliceosome as part of the U4/U6.U5 tri-snRNP. Thereafter, Brr2 





Brr2 is much larger than other spliceosomal helicases (ca. 245 kDa for the human enzyme) 
and is the only member of the Ski2-like family in the spliceosome. Sequence analysis 
revealed that the protein comprises ca. 450 amino acid N-terminal region, predicted to be 
largely unstructured with exception to the region corresponding to residues 258-338 that are 
predicted to adopt a PWI-like helical bundle fold (Korneta et al., 2012). This motif has also 
been encountered in the N-terminus of other spliceosomal helicases such as Prp2 and Prp22 
and seems to be implicated in nucleic acid binding. The N-terminal extension is followed by a 
tandem repeat of helicase units, herein referred to as "cassettes". Both cassettes are envisaged 
to contain dual RecA-like ATPase domains followed by a domain that bears resemblance to 
the Sec63 subunit of the protein translocation apparatus of the endoplasmic reticulum, 
henceforth referred to as Sec63 units (Fig. 1.9) (Ponting, 2000). Although RecA-like domains 
are common to all helicases, only Brr2, the Ski2-like helicase 1 (Slh1p, an RNA helicase 
involved in antiviral defense (Martegani et al., 1997), ASCC3 (DNA helicase of the activating 
signal cointegrator complex involved in genome maintenance) (Dango et al., 2011) and 
Hfm1p/Hfm1 DNA helicase (Ponting, 2000) are predicted to contain Sec63 units. 
 
Figure 1.9: Special structure organization of Brr2. Sequence analysis predicts that Brr2 is comprised of an N-
terminal region thought to be mostly unstructured, with exception of the PWI domain, and a tandem repeat of 
helicase cassettes. Each cassette (represented as N-terminal and C-terminal cassettes) harbors typical dual RecA-
like domains followed by a Sec63 homology unit. The numbers indicated refer to the human sequence. 
The dual cassette organization of Brr2 is not found in any other spliceosomal helicase and 
is shared by only few other known enzymes, including the RNA helicase Slh1p (Martegani et 
al., 1997) and the ASCC3 DNA helicase (Dango et al., 2011). The conserved domain 
structure and sequence suggest that the two cassettes of Brr2 originated from a gene 
duplication event and subsequently diverged. Genetic analyses suggested that only the 
ATPase and helicase activities of the N-terminal cassette of Brr2 are required for splicing 
(Kim and Rossi, 1999). Nevertheless, the C-terminal cassette is essential for yeast viability 
(Zhang et al., 2009), represents a versatile protein-protein interaction platform (Liu et al., 
2006; van Nues and Beggs, 2001), may have retained nucleotide binding capacity (Hahn and 
Beggs, 2010) and may influence the activity of the N-terminal helicase (Zhang et al., 2009; 





Catalytic activation of the spliceosome involves the unwinding of the U4 and U6 snRNAs, 
which are extensively base-paired via two regions (stems 1 and 2) when delivered to the 
spliceosome in the framework of the U4/U6.U5 tri-snRNP. Brr2 is thought to elicit these 
rearrangements since the enzyme unwinds U4/U6 duplexes in vitro (Laggerbauer et al., 1998; 
Raghunathan and Guthrie, 1998) and Brr2 mutations interfere with catalytic activation (Noble 
and Guthrie, 1996; Kim and Rossi, 1999; Zhao et al., 2009). Furthermore, Brr2 and its U4/U6 
substrate are pre-assembled in the U4/U6-U5 tri-snRNP before incorporation into the 
spliceosome. However, U4/U6 dissociation must be delayed until splice sites have been 
reliably located during spliceosome assembly. Additionally, unlike other spliceosomal 
helicases, Brr2 is stably associated with the spliceosome throughout the splicing cycle and is 
required again during spliceosome disassembly (Small et al., 2006). Thus, Brr2 has to be 
strictly controlled to prevent premature unwinding of U4/U6 in the tri-snRNP and to allow its 
repeated on- and off-switching during splicing.  
At least some regulation of Brr2 activity is exerted by two other U5 snRNP proteins, Prp8 
(Maeder et al., 2009) and Snu114 (Small et al., 2006). A C-terminal fragment of Prp8, 
comprising an RNase H like and a Jab1/MPN domain, has been shown to interact with Brr2 
and stimulate its helicase activity (Maeder et al., 2009). In yeast, Prp8 is reversibly 
ubiquitinylated and its ubiquitinylated form represses Brr2 activity (Bellare et al., 2008). 
Furthermore, Jab1/MPN domain of Prp8 binds ubiquitin (Bellare et al., 2006), implying that 
upon deubiquitinylation of Prp8, this domain could be liberated to stimulate Brr2 activity. 
These findings suggest that this post-translational modification plays a role in regulating Brr2 
activity. The GTPase Snu114, homologous to the ribosomal elongation factor eEF2 that 
catalyzes structural rearrangements in the ribosome during translocation, also seems to be 
required during catalytic activation. It was shown that GDP-bound Snu114 impairs Brr2 
helicase activity while the GTP-bound form seems to elicit helicase activity (Small et al., 
2006). Snu114 and Brr2 interact with the same C-terminal region of Prp8 (Liu et al., 2006) 
implying that Prp8  may function as a platform coordinating the activities of both proteins. 
Additional support for this idea comes from studies showing that Prp8, Sn114 and Brr2 form 
a stable salt-resistant complex (Achsel et al., 1998) and may act as a functional unit within the 
spliceosome. 
A crystal structure of the archaeal DNA helicase Hel308 in complex with DNA (Büttner 
et al., 2007) has shown that Ski2-like helicases bind one strand of a nucleic acid duplex in a 
central tunnel surrounded by both RecA domains, a winged helix (WH) domain and a seven 





on the bound strand in 3'-to-5' direction with an extended ß-hairpin (the separator loop - SL), 
inserted between helicase motifs Vb and VI of the second RecA-like domain, positioned 
between the two substrate strands. This element contains aromatic residues that stack with the 
DNA bases in the structure and was suggested to work as a strand separation device in 
Hel308. A long helix (ratchet helix) of the HB domain, which employs positively charged and 
aromatic residues to contact the substrate, was thought to function as a ratchet allowing the 
helicase to processively unwind DNA. The encircled DNA strand was seen to exit across a C-
terminal helix-loop-helix domain (HLH) (Büttner et al., 2007), which is required for coupling 
ATPase and helicase activities (Richards et al., 2008; Woodman et al., 2007).  
Structural analyses of the C-terminal Sec63 units of yeast (Zhang et al., 2009; Pena et al., 
2009) and human (PDB ID 2Q0Z) Brr2 have shown that these elements contain Hel308-like 
HB and HLH domains followed by a Brr2-specific immunoglobulin-like (IG) domain and 
have led to the proposal that Brr2 comprises two expanded Hel308-like helicase cassettes. In 
these studies, a model of the N- and C-terminal cassettes of Brr2 was devised showing that the 
Sec63 unit is preceded by a WH domain and that both cassettes could be modeled into a 
similar circular domain arrangement. Additionally, the model predicted many mechanistic 
features associated with the N-terminal cassette that are crucial for Brr2 activity (Pena et al., 
2009). In the devised model of the N-terminal cassette, an equivalent element of the separator 
loop in Hel308 also contains aromatic residues that, when mutated, did not support cell 
growth suggesting that this element may act as a strand separator in Brr2 as well. 
Furthermore, the modeling exercise predicted that the N-terminal HB domain form the roof of 
the single stranded nucleic acid binding tunnel. As in Hel308, aromatic and positively charged 
side chains protrude from the under-side of the ratchet helix and are expected to contact the 
RNA substrate. Mutation of these residues gave rise to cellular defects and affected in vivo 
splicing efficiency. These results support a role for the HB domain of the N-terminal Sec63 
unit in RNA binding and possibly as a ratchet coupling conformational changes to nucleic 
acid translocation. Finally, in order for the HB domain to act as a ratchet, it has to be 
functionally connected to the RecA-like domains. In Hel308, the winged helix domain 
connects the second RecA-like domain with the HB domain through a hydrophobic interface 
and residues in this interface are conserved in Brr2. Mutations affecting the hydrophobic 
interface residues in Brr2 led to growth defects as well as pre-mRNA splicing deficiency. 
Therefore, these results are consistent with the idea that the WH domain acts as a positioning 





Furthermore, in analogy to Hel308, Brr2 is also thought to translocate in 3'-to-5' direction 
on one of the substrate strands. However, in the U4/U6 di-snRNP both 3'-ends are sequestered 
in a stem-loop structure and/or are occluded by bound Sm/LSm proteins (Achsel et al., 1999; 
Leung et al., 2011). Thus, it is presently unclear how Brr2 can engage its U4/U6 substrate.  
Regardless of the numerous studies on Brr2, the overall organization of this helicase and 
the nature of the putative communication between its cassettes are unknown. The unusual 
architecture of Brr2 is likely instrumental for its unique functions and may form the basis for 
the required regulation of the enzyme.  
1.2.4 Brr2 and Renititis pigmentosa 
Renititis pigmentosa (RP) is a progressive rod-cone dystrophy that leads to night 
blindness, gradual reduction of the peripheral visual field and, in severe cases, to total 
blindness. The incidence of RP is approximately 1 in 4000 individuals, summing up to a total 
of 1.5 million affected people. The disease is genetically diverse and can be inherited as an 
autosomal-dominant (adRP) (30 - 40% of the cases), autosomal-recessive (arRP) (50 - 60%), 
X-linked (xl-RP) (5 - 15%) and, in rare cases, as a non-Mendelian trait (Hartong et al., 2006). 
To date, 23 genes have been associated to adRP. Most of these genes are predominantly 
expressed in the retina and are determinant for the survival and function of the retinal cells 
(Swarrop and Zack, 2002). Surprisingly, five genes related to adRP code for ubiquitously 
expressed pre-mRNA splicing factors: hPrp8 (RP13 form of adRP) (McKie et al., 2001), 
hPrp31 (RP11) (Vithana et al., 2001), hPrp3 (RP18) (Chakarova et al., 2002), hBrr2 (RP33) 
(Zhao et al., 2006, 2009) and PAP-1 (RP9) (Li et al., 2010; Benaglio et al., 2011).  
Considering the widespread expression of these splicing factors, it is intriguing that 
mutations in these proteins only affect retinal cells. A possible explanation rests on the fact 
that the retina normally expresses up to seven fold more major snRNAs and approximately 
twice as many minor snRNAs compared to other human tissues. The high level of snRNA 
expression in the retina is due to the highest amount of processed mRNAs in these cells 
within the whole body. Therefore, the deficiency in spliceosomal components is more 
deleterious for the retina than for any other human tissue, implying a possible molecular link 
between RP-proteins and the pathogenesis of RP (Tanackovic et al., 2011). Additionally, 
since adRP patients carry heterozygous mutations, the wild type copy of the affected genes is 
always expressed and compensates for the effects of the defective proteins in other cell types. 
The RP33 form is of great interest for this thesis since all mutations map to the N-terminal 





terminal cassette are required for splicing (Kim and Rossi, 1999). One set of affected residues 
(R681C, R681H, V683L, Y689C) lies in between the N-terminal RecA domains of Brr2. 
Another set of mutations maps to the predicted ratchet helix of the N-terminal HB domain 
(S1087L, R1090L) and corresponding changes in yBrr2 were detrimental to U4/U6 
unwinding and splicing (Zhao et al., 2009; Zhang et al., 2009; Pena et al., 2009). Therefore, 
we can hypothesize that these mutations in the N-terminal cassette could possibly impair 
RNA binding and/or unwinding. 
1.2.5 Structural studies of spliceosomes and their components 
Obtaining structural information at the atomic level of a highly dynamic and complex 
machinery such as the spliceosome is extremely challenging. The amounts, for example, of 
affinity-purified spliceosomes stalled at a particular stage that can presently be obtained allow 
investigations by electron cryo-microscopy (cryo-EM) at intermediate to low resolution (Stark 
and Lührmann, 2006; Alcid and Jurica, 2008; Jurica et al., 2004). Interpretation of such 
structures is difficult. Immuno-labeling of specific components allows the assignment of 
selected subunits to structural elements (Häcker et al., 2008) 
High resolution structural analysis by X-ray crystallography and/or NMR is currently 
possible for individual spliceosomal proteins/protein fragments or sub-complexes, typically 
produced recombinantly or, more rarely, natively purified material. The crystal structures of 
the an RNA recognition motif of the U1-A protein alone and in complex with stem-loop II of 
U1 snRNA (Oubridge et al., 1994), the U2-A'/B" heterodimer bound to U2 snRNA stem-loop 
IV (Price et al., 1998), the 15.5K protein complexed with the 5' SL of U4 snRNA (Vidovic et 
al., 2000) and two heteromeric Sm protein dimers (Kambach et al., 1999) were the pioneer 
structures of spliceosomal components. Further progress towards elucidating the structures of 
proteins and RNA fragments involved in the splice site recognition (rev. in Ritchie et al., 
2009) includes the structure of SF1 bound to a branch site RNA sequence (Liu et al., 2001), 
U2AF65 bound to a polypyrimidine tract (Sickmier et al., 2006), an RRM of U2AF65 bound 
to an amino-terminal SF1 peptide (Selenko et al., 2003), a heterodimer of U2AF65 and 
U2AF35 (Kielkopf et al., 2001), and SF3b14a/p14 bound to a SF3b155 peptide (Schellenberg 
et al., 2006; Spadaccini et al., 2006). More recently, the crystal structure of the U4 snRNA 
stem-loop complexed with the 15.5K protein and a fragment of the hPrp31 was reported (Liu 
et al., 2007) as well as the structure of the complex between 15.5K and the GYF domain of 
52K (Nielsen et al., 2007), followed by crystal structures of the carboxy terminus of the S. 





domain with insertions and appendices and with an impaired metal ion binding site. 
Furthermore, three groups independently solved the structure of a ~250 amino acid RNase H-
like domain, located just upstream of the Jab1/MPN domain, of human and/or yeast Prp8, 
which encompasses amino acids that contact the 5' SS of the pre-mRNA (Pena et al., 2008; 
Ritchie et al., 2008; Yang et al., 2008). Two independent groups have solved the crystal 
structure of the C-terminal Sec63 unit of S. cerevisiae Brr2 (Pena et al., 2009; Zhang et al., 
2009). Further achievements include the structure of Prp43 (Walbott et al., 2010), the 
structure of the complex of a fragment of the Aar2 protein with the RNase H-like domain of 
Prp8 (Weber et al., 2011), the structure of the C-terminal domain of human Prp22 (Kudlinzki 
et al., 2009) and finally the structure of the Cwc2 protein, solved independently by two 
groups (Lu et al., 2012; Schmitzová et al., 2012). An important milestone on the way to 
elucidating the spliceosomal structural organization was reached recently with the crystal 
structures of U1 snRNP recombinantly assembled (Pomeranz Krummel et al., 2009) and 
natively purified (Weber et al., 2010) and of a recombinant U4 snRNP core (Leung et al., 
2011). While they will not provide a complete picture of entire spliceosomal assemblies, such 
structures of spliceosomal components/complexes are very useful for guiding functional 
studies by biochemical, biophysical or genetics methods. 
The two approaches, global structural analysis by cryo-EM and high resolution partial 
structures by crystallography or NMR, have also been successfully combined. Spatial 
arrangements of snRNP components have been elucidated by fitting partial high resolution 
structures into intermediate resolution cryo-EM maps, thereby devising quasi-atomic models 
(Stark et al., 2001; Golas et al., 2003, 2005). In a similar fashion, quasi-atomic models of 
entire spliceosomes may become available in the future. 
1.3 Aim of this study 
A hallmark of the spliceosome is that it is put together anew on a substrate pre-mRNA for 
each splicing event in a stepwise fashion. Transitions from one assembly intermediate to the 
next are invariably associated with profound compositional and conformational 
rearrangements. The most dramatic rearrangements ensue during the conversion of an initial 
assembly, which contains all snRNPs but is still catalytically inactive, to an activated 
spliceosome that can carry out the splicing transesterification reactions. Spliceosome catalytic 
activation requires a 650 kDa RNP remodeling machinery, composed of the U5 snRNP-
specific proteins Prp8, Snu114 and Brr2. The three proteins are large, multi-domain factors 





scaffold of this machinery and is also considered the master regulator of the entire 
spliceosome (GRAINGER and BEGGS, 2005). Snu114 is a complex G-protein that bears 
close resemblance to the eukaryotic translation elongation factor 2 (eEF2) and the bacterial 
elongation factor G (EF-G). Due to its resemblance of the ribosomal translocases, Snu114 has 
been suggested to also act as a motor protein during spliceosome assembly (Bartels et al., 
2002). More recently, it has been suggested to also function as an on/off switch for the 
activity of Brr2 (Small et al., 2006). Brr2 is a Ski2-like RNA helicase that functions as an 
RNP remodeling enzyme in the spliceosome under tight control of Prp8 and Snu114 (Small et 
al., 2006; Maeder et al., 2009; Wahl et al., 2009). During catalytic activation, it is thought to 
unwind the U4/U6 di-snRNA duplex and dispose of all U4/U6 associated proteins 
(Raghunathan and Guthrie, 1998; van Nues and Beggs, 2001). Additionally, the same 
machinery is thought to be also involved in the ordered disassembly of the spliceosome 
(Small et al., 2006; Staley and Guthrie, 1998). 
At the start of this thesis, very little was known about the molecular mechanisms by which 
Prp8, Snu114 and Brr2 accomplish spliceosome remodeling and how these events are 
regulated. In particular, very little experimental structural information was available on this 
machinery. Thus, the overall goal of my thesis was to advance our understanding of the Prp8-
Snu114-Brr2 RNP remodeling machinery by elucidating molecular mechanisms via a 
structural biochemical approach. To this end, I pursued the following specific aims: 
 
1. Establishment of an efficient recombinant production pipeline for Prp8, Snu114, Brr2 or 
complexes of these proteins, using proteins from different organisms to increase chances of 
success. 
2. Establishment of efficient purification protocols for recombinantly produced proteins or 
complexes that yield sufficient amounts of highly homogeneous material for further 
structural and functional studies. 
3. Experimental definition of stable folding units within factors that can be produced and 
purified in suitable form but do not crystallize. 
4. Crystallization and crystal structure analysis of proteins, folding units or complexes that 
can be produced in suitable amount and homogeneity. 
5. Structure-based functional analyses, such as targeted mutagenesis followed by enzymatic 






I started my work with attempts at the co-production of the ternary Prp8-Snu114-Brr2 
complexes from human and yeast and then zoomed in on the analysis of a ca. 200 kDa 
fragment of human Brr2, encompassing both of its helicase cassettes. For the latter fragment, 
high resolution crystal structures were elucidated and a comprehensive in vitro functional 





































































2. Materials and methods 
2.1 Materials 
2.1.1 Chemicals 
Standard chemicals that are not listed here were purchased from Sigma-Aldrich, Merck or 
Fluka. 
Table 2.1: Chemicals 
Chemical Supplier 
1 kb DNA ladder, 2-log DNA ladder New England Biolabs, Germany 
1,4-Dithiothreitol (DTT) Roth, Germany 
2-Mercaptoethanol (β-ME) Roth, Germany 
2-Propanol  Merck, Germany 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) Roth, Germany 
Acetic acid  Merck, Germany 
Acetone  Merck, Germany 
Acrylamide solutions: 
Rotiphorese Gel 40 (38% acrylamide, 2% B N,N'-methylene-bis-acrylamide) 
Rotiphorese Gel 30 (29.2% acrylamide, 0.8% N,N'-methylene-bis-acrylamide) 
Rotiphorese Gel A (30% acrylamide) 
Rotiphorese Gel B (2% N,N'-methylene-bis-acrylamide) 
Roth, Germany 
Agarose (electrophoresis grade)  Invitrogen, Germany 
Ammonium peroxodisulfate (APS) Merck, Germany 
Ammonium sulfate Fluka, Switzerland 
Ampicillin, sodium salt  Fluka, Switzerland 
Bluo-Gal  Invitrogen, Germany 
Boric acid  Merck, Germany 
Bovine serum albumin Sigma-Aldrich, Germany 
Bradford assay reagent  Bio-Rad, Germany 
Bromophenol blue, sodium salt  Merck, Germany 
Calcium chloride dihydrate  Merck, Germany 
Chloramphenicol  Roche, Germany 
Complete-EDTA free protease inhibitor Roche, Germany 





Coomassie brilliant blue G-250 Serva, Germany 
Coomassie brilliant blue R-250 Serva, Germany 
Dimethylsulfoxide (DMSO) Roth, Germany 
Ethanol Merck, Germany 
Ethidium bromide solution (10mg/ml) Roth, Germany 
Ethylene glycol Serva, Germany 
Ethylenediaminetetraacetic acid, disodium salt dihydrate (EDTA) Roth, Germany 
Express Five® SFM Invitrogen, Germany 
Formaldehyde Merck, Germany 
Gel filtration standard  Bio-Rad, Germany 
Glycerol Merck, Germany 
Guanidine hydrochloride Roth, Germany 
Heparin, sodium salt  Sigma-Aldrich, Germany 
Hydrochloric acid (HCl) Merck, Germany 
IgepalR CA-630 (NP-40) Sigma-Aldrich, Germany 
Imidazole  Merck, Germany 
Isopropyl-β-D-1-thiogalactopyranoside (IPTG) Roth, Germany 
Izit protein crystal stain  Hampton research, USA 
Kanamycine sulfate  Roth, Germany 
LB medium  Q-Bio-gene, USA 
LB-agar medium  Q-Bio-gene, USA 
L-glutamine Invitrogen, Germany 
Lithium chloride  Fluka, Switzerland 
Magnesium chloride hexahydrate  Fluka, Switzerland 
Methanol  Merck, Germany 
Milk powder, dry, instant Heirler, Germany 
N,N,N',N'- Tetramethylethylenediamine (TEMED) Sigma-Aldrich, Germany 
N-Z-Amine AS Casein enzymatic hydrolysate  Sigma-Aldrich, Germany 
Phenylmethylsulfonyl fluoride (PMSF) Roche, Germany 
Piperazine-N,N′-bis-(2-ethanesulfonic acid) (PIPES) Roth, Germany 
Polyethylene glycol 200-35000 Fluka, Germany 
Polyethylene glycol 3350  Sigma-Aldrich, Germany 
Ponceau S Serva, Germany 
Potassium chloride  Merck, Germany 





Potassium hydroxide  Merck, Germany 
Protein molecular weight marker (unstained, pre-stained)  Bio-rad, Germany 
Sf-900™ III SFM Invitrogen, Germany 
Silver nitrate  Merck, Germany 
Sodium azide  Fluka, Switzerland 
Sodium carbonate  Merck, Germany 
Sodium chloride Merck, Germany 
Sodium dodecylsulfate (SDS) Serva, Germany 
Sodium hydroxide  Merck, Germany 
SYPRO Orange Protein Stain Invitrogen, USA 
Tetracyclin Fluka, Switzerland 
Trifluoroacetic acid  Fluka, Switzerland 
Tris-(hydroxymethyl)-aminomethane (TRIS) VWR International, Germany 
Triton X-100  Merck, Germany 
Tween-20 Roth, Germany 
Urea  Merck, Germany 
X-tremeGene 9 Transfection Reagent   Roche, Germany 
Xylene cyanol FF  Sigma-Aldrich, Germany 
Yeast extract powder  Roth, Germany 
2.1.2 Buffer solutions and media components 
Buffers were prepared with Milli-Q water and filter-sterilized (0.22 μm) or autoclaved. 
The pH of buffers was adjusted by the addition of buffered stock solutions or by titration with 
37% HCl or 10 M NaOH if not stated otherwise. 
Table 2.2: Buffers, solutions and media components 
Buffers Composition 
5×T7 buffer 1 M HEPES-KOH, pH 7.5, 160 mM MgCl2, 10 mM spermidine, 200 mM DTT 
10×TBE 0.89 M Tris pH 8.0, 0.89 M Boric Acid, 25 mM EDTA 
10×TBS buffer 200 mM Tris pH 7.6, 1.37 M NaCl 
5×SDS loading buffer 250 mM Tris pH 6.8, 8% (w/v) SDS, 10% (v/v) β-ME, 30% (v/v) Glycerol, 0.02% (w/v) 
Bromophenol blue 
4×agarose gel loading buffer 1×TBE, 30% (v/v) Glycerol, 0.05% (w/v) Xylene cyanol, 0.05% (w/v) Bromophenol blue 
10×PBS 1.35 M NaCl, 25 mM KCl, 100 mM NaH2PO4 17 mM KH2PO4 pH 7.4 





10×SDS running buffer 250 mM Tris pH 6.8, 2 mM Glycine, 1% (w/v) SDS 
Coomassie staining solution 0.025% (w/v) Coomassie (R250); 0.025% (w/v) Coomassie (G250); 30% (v/v) 
isopropanol; 7.5% (v/v) acetic acid 
Destaining solution I 40% (v/v) ethanol, 20% (v/v) acetic acid 
Destaining solution II 10% (v/v) acetic acid 
Stacking gel buffer 0.5 M Tris-HCl pH 6.8, 0.4% (w/v) SDS 
Resolving gel buffer 1.5 M Tris pH 8.8, 0.4% (w/v) SDS 
SLAB4 50 mM Tris, 380 mM glycine, 0.1% (w/v) SDS 
Blotting buffer 1.5 l SLAB4, 0.6 l methanol, 0.9 l deionized water 
Blocking buffer 1×PBS, 0.1% (v/v) Tween-20, 5% (w/v) milk powder 
Washing buffer I 1×PBS, 0.1% (v/v) Tween-20, 1% (w/v) milk powder 
Washing buffer II 1×PBS, 0.1% (v/v) Tween-20 
Primary antibody solution 1×PBS, 0.1% (v/v) Tween-20, 1% (w/v) milk powder, primary antibody 
Secondary antibody solution 1×PBS, 0.1% (v/v) Tween-20, 1% (w/v) milk powder, secondary antibody 
TB buffer 10 mM PIPES pH 6.7, 250 mM KCl, 55 mM MnCl2, 15 mM CaCl2 
SOB medium 2% (w/v) Tryptone, 0.55% (w/v) yeast extract, 10 mM NaCl, 10 mM KCl, 10 mM MgCl2, 
10 mM MgSO4 
SOC medium 2% (w/v) Tryptone, 0.55% (w/v) yeast extract, 10 mM NaCl, 10 mM KCl, 10 mM MgCl2, 
10 mM MgSO4, 20 mM Glucose 
ZY 10 g N-Z-amine AS, 5 g yeast extract, 950 ml of deionized water 
ZYM-5052 950 ml ZY media supplemented with 2 ml MgSO4 (1 M), 200 µl trace metals 
(1000×solution), 20 ml of 50×5052, 20 ml of 50×M 
50×M 1.25 M Na2HPO4, 1.25 M KH2PO4, 2.5 M NH4Cl, 0.25 M Na2SO4 
50×5052 25% glycerol, 2.5% glucose, 10% α-lactose 
1000×Trace Metals 50 mM FeCl3, 20 mM CaCl2, 10 mM MnCl2, 10 mM ZnSO4, 2 mM CoCl2, 2 mM CuCl2,  
2 mM NiCl2, 2 mM Na2MoO4, 2 mM Na2SeO3, 2 mM H3BO3 in ~60 mM HCl 
2.1.3 Consumables 
Table 2.3 lists the items used routinely in this thesis. 
Table 2.3: Consumables 
Item Supplier 
Acupuncture needle Moxom Medical, Germany 
Amersham Hyperfilm ECL GE Healthcare, Germany 
Amersham Hybond-P PVDF membrane GE Healthcare, Germany 
Autoradiography films BioMax MR Kodak, USA 





Concentrators (Amicon Ultra) Millipore, USA 
CrysChem plates, 24 well, hanging drop  Hampton Research, USA 
CrysChem plates, 24 well, sitting drop  Hampton Research, USA 
Crystallization plates MRC, 96 well, sitting drop  Molecular Dimensions, UK 
Dialysis membranes  Spectra/Por, USA 
Electroporation cuvettes  Bio-Rad, Germany 
Eppendorf safe-lock micro test tubes  Eppendorf, Germany 
Fluotrac-600, 96-well plates Greiner-Bio-One, Germany 
Gloves, Dermatril KCL, Germany 
Linbro plates, 24 well, hanging drop  Jena Biosciences, Germany 
Linbro plates, 24 well, sitting drop  Jena Biosciences, Germany 
Needles  Henke Sass Wolf, Germany 
Parafilm  Pechiney Plastic Packaging, USA 
Slide-A-lyzer  Pierce, USA 
Sterile filters 0.22 μm, 0.45 μm Sarstedt, Germany 
Surgical blades Martin, Germany 
Syringes  Braun, Germany 
Tubes (5 ml, 10 ml, 15 ml and 50 ml)  Greiner-Bio-One, Germany 
Whatman 3MM paper  Whatman plc, UK 
Weighting dishes Roth, Germany 
2.1.4 Chromatographic resins and columns 
Table 2.4: Chromatographic resins and columns 
Matrix Supplier 
Ni-NTA agarose Qiagen, Germany 
HisTrap FF Crude, MonoQ 5/50 GL, MonoQ HR 10/10, Superdex 200 26/60, 
Superdex 200 16/60, Superdex 200 10/300, Superdex 200 PC 3.2/30, HiPrep Heparin 
FF  
GE Healthcare, Germany 











2.1.5 Molecular biology kits 
Table 2.5: Commercial molecular biological kits 
Kit Supplier 
BCA protein assay kit Pierce, USA 
QIAquick PCR Purification Kit, QIAprep spin miniprep Kit,  
QIAquick Gel Extraction Kit 
Qiagen, Germany 
Amersham ECL Western Blot Detection Reagent GE Healthcare, Germany 
QuikChange II XL Site-Directed Mutagenesis Kit Agilent Technologies, Germany 
PureLink™ HiPure Plasmid FP (Filter and Precipitator) Maxiprep Kit Invitrogen, Germany 
2.1.6 Nucleotides 
Table 2.6: Nucleotides 
Nucleotides Supplier 
Deoxynucleoside-5′-triphosphate (dNTPs, 100mM each) (dATP, dCTP, dGTP, 
dTTP) 
New England Biolabs, Germany 
2'/3'-O-(N-methylantranyloil)-nucleotides (mant-ATP, mant-ATPγS, mant-ADP, 
mant-GTP, mant-GTPγS, mant-GDP) 
Jena Biosciences, Germany 
TNP-nucleotides (TNP-ATP, TNP-CTP, TNP-UTP) Invitrogen, Germany 
ATP, ADP, AMP-PNP, AMP-PCP Sigma-Aldrich, Germany 
Nucleoside-5′-Triphosphate (rNTPs, 100mM) 
(ATP, CTP, GTP, UTP) 
Jena Biosciences, Germany 
[γ-³²P] dATP (6000 Ci/mmol; 10 mCi/ml)  Perkin Elmer, Germany 
2.1.7 Crystallization screens and kits 
The crystallization screen solutions were transferred to 96-well MRC crystallization plates 
for automated pipetting using a Cartesian robot. All heavy atom compounds used in this work 
were part of the "Heavy Atom Screen Kit" from Hampton Research or the Tantalum Cluster 
Derivatization Kit from Jena Bioscience. The heavy metals were dissolved in reservoir 
solution and utilized for the preparation of heavy-atom derivatives for structure determination 
of hBrr2 by X-ray analysis. 
Table 2.7: Crystallization screens 
Screen Supplier 
Additives, Index, SaltRX, Silver Bullets, Silver Bullets Bio, PCT (pre-
crystallization screen), Heavy atom screen Au, Pt, Hg, M1, M2 
Hampton Research, USA 





Classics Suite, Classics Lite Suite, Classics II Suite, Cryos Suite, PEGs Suite, 
AmSO4 Suite, MPD Suite, Anions Suite, Cations Suite, pHClear Suite, pHClear 
II Suite, MBClass Suite, MBClass II Suite, Protein Complex Suite, PEGs II Suite, 
ComPAS Suite, PACT Suite, Nucleix Suite, JCSG+ Suite 
Qiagen, Germany 
JBS Rainbow, Tantalum Cluster Derivatization Kit Jena Bioscience, Germany 
Wizard I+II, Wizard III+ IV Emerald BioSystems, USA 
2.1.8 Instrumentation 
Table 2.8: Devices 
Device Manufacturer 
Äkta Explorer, Purifier, Prime, Micro GE Healthcare, Germany 
Allegra X-15R Beckman Coulter, Germany 
Autoclaves  H+P Labortechnik, Germany 
Avanti J-26 XP Beckman Coulter, Germany 
Axiovert100  Zeiss, Germany 
Beamline 14.1 HZB, Berlin, Germany 
Beamline 14.2 HZB, Berlin, Germany 
Beamline 14.3 HZB, Berlin, Germany 
Beamline PXII X10SA SLS, PSI, Villigen, Switzerland 
Beamline P14, Petra III DESY, Hamburg, Germany 
Biofuge fresco, Biofuge pico  Heraeus, Germany 
Cartesian crystallization robot, 4 channels Zinsser Analytic, Germany 
Cartesian crystallization robot, 8 channels Digilab, USA 
CASY TT Counter  Innovatis, Germany 
Cryofuge 6000i  Heraeus, Germany 
Electroporator EasyjecT Prima  Equibio, England 
Elexsys 500 EPR spectrometer Bruker ASX B.V., Netherlands 
Filter KV 408 Schott, Germany 
Gel documentation system Bio-Rad, Germany 
Geldryer model 583 Bio-Rad, Germany 
Gel electrophoresis equipment Bio-Rad, Germany 
Glass-ware VWR International, Germany 
Heating blocks Eppendorf, Germany 
HT multitron culture shaker Infors, Switzerland 





Ice machine  Ziegra, UK 
Jasco J-810 CD Spectropolarimeter Jasco, Inc., USA 
4800 MALDI ToF/ToF Applied Biosciences/MDS Sciex, Germany 
QToF Ultima Waters, UK 
LTQ-Orbitrap XL Thermo Scientific, Germany 
Kodak X-Omat 2000 Processor Kodak, USA 
Milli-Q synthesis A10  Millipore, USA 
Magnetic stirrer  IKA, Germany 
Megafuge 1.0R, swing out rotor type 2704  Heraeus, Germany 
Micro fluidizer M110S Micro fluidics, USA 
Microliter syringes  Hamilton, Switzerland 
Microwave oven Bosch 
12-way multichannel pipette Eppendorf, Germany 
Mx3000P QPCR Systems Agilent Technologies, Germany 
NanoDrop 2000 Spectrometer Thermo Fisher Scientific, USA 
PCR cycler T-Professional Biometra, Germany 
PCR cycler Peqstar 2x gradient PeqLab, Germany 
pH-meter, Orion 2-Star  Thermo Fisher Scientific, USA 
pH-meter, Professional Meter PP-20 Sartorius, Germany 
Phosphorimager Typhoon 8600  GE Healthcare, Germany 
Photometer DU 530  Beckmann, Germany 
Pipettes, Pipetman  Eppendorf, Germany 
Rocking platform  Biometra, Germany 
Scintillation counter LS 1701/TRI-CARB 2100TR  Beckman/Packard, USA 
Power supplies  Bio-Rad, Germany 
Quartz Cuvette 1 mm, 110-QS Hellma, Germany 
Scales BP4100 Sartorius, Germany 
Scales XS4002S DeltaRangeR Mettler Toledo, Germany 
Scales XS205 DualRangeR Mettler Toledo, Germany 
SMART  GE Healthcare, Germany 
Sonifier II 250 Digi  Heinemann, Germany 
Sonopuls Ultrasonic Homogenizer HD 3100 Bandelin, Germany 
Sorvall Evolution RC, Sorvall SA-300 rotor, Sorvall SLC-6000 
rotor, Sorvall SS-34 rotor, Sorvall HB-6 rotor 
Thermo Fisher Scientific, USA 





Spectrophotometer Ultrospec 3000 pro GE Healthcare, Germany 
Speed vac concentrator 5301  Eppendorf, Germany 
VICTOR™ X3 multilabel plate reader Perkin-Elmer, Germany 
Vortex Genie 2  Scientific Industries, USA 
Table centrifuge 5415R Eppendorf, Germany 
Tecan Evo liquid dispensing robot Tecan Group, Germany 
Thermomixer comfort  Eppendorf, Germany 
Trans-Blot Cell Bio-Rad, Germany 
Tunair flasks Sigma-Aldrich, Germany 
SX-20MV stopped-flow apparatus 
Applied Photophysics, Leatherhead, UK 
2.1.9 Enzymes and proteins 
Table 2.9: List of enzymes, proteins and enzyme inhibitors used in this study 
Enzyme, proteins and peptides Supplier 
Bovine serum albumin (BSA) Sigma-Aldrich, Germany 
Bovine serum albumin (BSA) solution (10mg/ml) New England Biolabs, Germany 
Carboxypeptidase Y Sigma-Aldrich, Germany 
Chymotrypsin  Roche, Germany 
Cloned Pfu DNA polymerase (10 U/μl)  Agilent Technologies, Germany 
DNase I  Roche, Germany 
Elastase  Sigma-Aldrich, Germany 
Endoproteinase Lys-C  Sigma-Aldrich, Germany 
Endoproteinase Asp-N  Sigma-Aldrich, Germany 
Endoproteinase Glu-C  Sigma-Aldrich, Germany 
Endoproteinase Arg-C  Sigma-Aldrich, Germany 
Herculase enhanced DNA polymerase  Agilent Technologies, Germany 
Lysozyme Merck, Germany 
Peroxidase-AffiniPure Goat Anti-Rabbit IgG Jackson ImmunoResearch Laboratories, USA 
Rabbit IgG against hBrr2 I. Oechsner, MPI-BPC, Göttingen 
Proteinase K Sigma-Aldrich, Germany 
Restriction endonucleases  New England Biolabs, Germany 
RNase A, T1 Ambion, Germany 
RNasin  Promega, Germany 




Enzyme, proteins and peptides Supplier 
Subtilisin Sigma-Aldrich, Germany 
TEV Protease Home-made, recombinant 
T4 DNA ligase New England Biolabs, Germany 
T4 polynucleotide kinase New England Biolabs, Germany 
T7 RNA polymerase Self-made, recombinant 
Thermolysin Sigma-Aldrich, Germany 
Trypsin Roche, Germany 
2.1.10 DNA oligonucleotides 
All DNA oligonucleotides used in this work were purchased from Eurofins MWG-
Operon, Germany. The oligonucleotides were dissolved in autoclaved Milli-Q water to a 
stock concentration of 100 pmol/µl and stored at -20°C. 
Table 2.10: DNA oligonucleotides 
Name Used for Sequence (5' → 3') 
Prp8ct_1_for Cloning in pETM11 via BsaI ATATATGGTCTCACATGAAGGCCAACCCCG
CCCTGTACG 
Prp8ct_2_for Cloning in pETM11 via BsaI ATATATGGTCTCACATGAACTCCTCTAACTA
CGCCGAGC
 
Prp8ct_rev Cloning in pETM11 via NotI ATACATTTATGCGGCCGCTACTTGTCGTCGT
CGTCCTTGTAGTCG 
Prp8ct_GEX1_for Cloning in pGEX6P1 via BamHI ATATATGGATCCATGAAGGCCAACCCCGCC
CTGTACG 
Prp8ct_GEX2_for Cloning in pGEX6P1 via BamHI ATATATGGATCCAACTCCTCTAACTACGCC
GAGC 
HsBrr2FL_for Cloning in pFL via BamHI CCGGAATTCATGGCTGACGTGACCGCTCG
 
HsBrr2FL_rev Cloning in pFL via HindIII TTAATTAAAAGCTTTTAGTCAGAGTCGGAG
TCAGTCTCAGC 
Brr2N_Ntrun1_For Cloning in pFL10 His via EcoRI CCGGAATTCGACCTGGACCAGGGTGGCGAG
GC 
Brr2N_Rev Cloning in pFL10 His via HindIII TTAATTAAAAGCTTTTAGTCAGAGTCGGAG
TCAGTCTCAGC 
Brr2N_Ctrun_Rev Cloning in pFL10 His via HindIII TTAATTAAAAGCTTTTAAGCTTCTTTCACGT
CAACGG 
Brr2N_Ntrun2_For Cloning in pFL10 His via EcoRI CCGGAATTCTCCGAGGAACAGCTGCTGCCC 
Brr2C_Ntrun1_For Cloning in pFL via EcoRI CCGGAATTCATGGACCTGGACCAGGGTGGC
GAGGC 




Name Used for Sequence (5' → 3') 
Brr2C_His_Rev Cloning in pFL via HindIII TTAATTAAAAGCTTTTAATGGTGATGGTGGT
GGTGGTCAGAGTCGG 










HSN_cas_For Cloning in pFL10 His via EcoRI CCGGAATTCGACCTGGACCAGGGTGGCGAG
G 
HSN_cas_Rev Cloning in pFL10 His via HindIII TTAATTAAAAGCTTTTACTTGTCCTGGTACA
GGGACTCG 
HSC_cas_For1 Cloning in pFL10 His via EcoRI CCGGAATTCCTGCCCGTGTCCTTCCGTCACC 
HSC_cas_Rev Cloning in pFL10 His via HindIII TTAATTAAAAGCTTTTAGTCAGAGTCGGAG
TCAGTCTCAGC 
ScBrr2_for Cloning in pFL10 His via SacI ATATATGAGCTCTAATGACCGAACACGAAA
CCAAGGACAAGG 
ScBrr2_rev Cloning in pFL10 His via HindIII TTAATTAAAAGCTTTTACTTGACGTTGATCT
CGAAAGACAGTTCC 
C_cas_For2 Cloning in pFL10 His via SalI ATATATGTCGACAGTCTGAAGTGTTCGAAT
TCAAGACC 
C_cas_Rev Cloning in pFL10 His via XbaI TTAATTAATCTAGATTACTTGACGGTGATCT
CGAAAGACAGTTCC 
Mut1_1F Mutagenesis of hBrr2HR,RP R1133/K1134E GCCCCCTGCGCCAGTTCGAGGAACTGCCCG
AGGAAGTGG 
Mut1_1R Mutagenesis of hBrr2HR,RP R1133/K1134E CCACTTCCTCGGGCAGTTCCTCGAACTGGC
GCAGGGGGC 
Mut1_2F Mutagenesis of hBrr2HR,RP R1176E GGCAAGACCATCCACGAGTACGTGCACCTG
TTCC 
Mut1_2R Mutagenesis of hBrr2HR,RP R1176E GGAACAGGTGCACGTACTCGTGGATGGTCT
TGCC 
Mut2F Mutagenesis of hBrr2HR,RP deletion of the 
first HLH domain 
GCCCCCTGCGCCAGTTCTCCTCCGCTTACGT
GCACCTGTTCCCC 
Mut2R Mutagenesis of hBrr2HR,RP deletion of the 
first HLH domain 
GGGGAACAGGTGCACGTAAGCGGAGGAGA
ACTGGCGCAGGGGGC 
Mut4F Mutagenesis of hBrr2HR,RP Q1332R CCTTCTTCAACCCCATCCGTACCCAGGTGTT
CAACACC 
Mut4R Mutagenesis of hBrr2HR,RP Q1332R GGTGTTGAACACCTGGGTACGGATGGGGTT
GAAGAAGG 




Name Used for Sequence (5' → 3') 
Mut4R Mutagenesis of hBrr2HR,RP Q1332R GGTGTTGAACACCTGGGTACGGATGGGGTT
GAAGAAGG 




































Mut8_4F Mutagenesis of hBrr2HR,RP Y1295A ATCCTGCCCGAGAAGGCTCCCCCTCCCACC
GAG 
Mut8_4R Mutagenesis of hBrr2HR,RP Y1295A CTCGGTGGGAGGGGGAGCCTTCTCGGGCAG
GAT 
Mut6F Mutagenesis of hBrr2HR,RP close the 
separator loop of the C-cassette 
CATCATGGACACTCAGTCCGACTACCCCAT
CTACG 
Mut6R Mutagenesis of hBrr2HR,RP close the 
separator loop of the C-cassette 
CGTAGATGGGGTAGTCGGACTGAGTGTCCA
TGATG 
Mut7a_F Mutagenesis of hBrr2HR,RP R637A GGTGGCTCGTGCTATCGCTAACATCGAGAT
GACC 
Mut7a_R Mutagenesis of hBrr2HR,RP R637A GGTCATCTCGATGTTAGCGATAGCACGAGC
CACC 
Mut7b_F Mutagenesis of hBrr2HR,RP T1578A GCTATCGACATCCTGGCTACCTGCGCTGCTG
ACATCC 
Mut7b_R Mutagenesis of hBrr2HR,RP T1578A GGATGTCAGCAGCGCAGGTAGCCAGGATGT
CGATAGC 
Mut7c_F Mutagenesis of hBrr2HR,RP R603A CGTAAGGGTGGAGAGGCTACCTACACCCAG
CTGG 
Mut7c_R Mutagenesis of hBrr2HR,RP R603A CCAGCTGGGTGTAGGTAGCCTCTCCACCCTT
ACG 




Name Used for Sequence (5' → 3') 
Mut7d_F Mutagenesis of hBrr2HR,RP K1544A CGTCTGCTGTCTATGGCCGCTCCCGTGTACC
ACGCTATCACC 
Mut7d_R Mutagenesis of hBrr2HR,RP K1544A GGTGATAGCGTGGTACACGGGAGCGGCCAT
AGACAGCAGACG 
Mut7e_F Mutagenesis of hBrr2HR,RP H1548A TGGCCAAGCCCGTGTACGCTGCTATCACCA
AGCACTCC 
Mut7e_R Mutagenesis of hBrr2HR,RP H1548A GGAGTGCTTGGTGATAGCAGCGTACACGGG
CTTGGCCA 
Mut9_1F Mutagenesis of hBrr2HR,RP R1090L ACCCAGCTGGCTGGTCTGCTGATGCGTGCT
ATCTTCG 
Mut9_1R Mutagenesis of hBrr2HR,RP R1090L CGAAGATAGCACGCATCAGCAGACCAGCCA
GCTGGGT 
Mut9_2F Mutagenesis of hBrr2HR,RP, N-cassette RP 
and Brr2 RP L1087S 
GGTGTACGTGACCCAGTCCGCTGGTCGCCT
GATGC 
Mut9_2R Mutagenesis of hBrr2HR,RP, N-cassette RP 




Table 2.11: List of plasmids 
Name Description Reference 
pETM11 Vector for expression of genes with a TEV protease-cleavable N-
terminal His6 tag in E. coli; Kan
R 
EMBL, Heidelberg 
pGEX6P1 Vector for expression of genes with a PreScission protease-
cleavable N-terminal GST tag in E. coli; AmpR 
GE Healthcare 
pFL MultiBac acceptor vector for bacmid preparation; AmpR and 
GenR 
Dr. I. Berger,  
EMBL, Grenoble 
pFL-10His MultiBac acceptor vector for bacmid preparation; MCSII was 
modified to code for an N-terminal His10 and a TEV protease 
cleavage site; AmpR and GenR 
This study 
pFL hBrr2RP C-His6; full length hBrr2
 RP cloned via BamHI and HindIII This study 
pFL-10His hBrr2HR,RP N-His10; TEV protease cleavage site; hBrr2
395-2129 Truncation 1 
cloned via EcoRI and HindIII 
This study 
pFL-10His hBrr2395-2136,RP N-His10; TEV protease cleavage site; hBrr2 Truncation 2 cloned 
via EcoRI and HindIII 
This study 
pFL-10His hBrr2458-2129,RP N-His10; TEV protease cleavage site; hBrr2 Truncation 3 cloned 
via EcoRI and HindIII 
This study 
pFL-10His hBrr2458-2136,RP N-His10; TEV protease cleavage site; hBrr2 Truncation 4 cloned 
via EcoRI and HindIII 
This study 




Name Description Reference 
pFL hBrr2395-2136,RP C-His6; hBrr2 Truncation 5 cloned via EcoRI and HindIII This study 
pFL hBrr2458-2136,RP C-His6; hBrr2 Truncation 6 cloned via EcoRI and HindIII This study 
pFL-10His HsN RP N-His10; TEV protease cleavage site; hBrr2
395-1324 (N-cassette) 
cloned via EcoRI and HindIII 
This study 
pFL-10His HsC N-His10; TEV protease cleavage site; hBrr2
1282-2136 (C-cassette) 
cloned via EcoRI and HindIII 
This study 
pFL yBrr2 N-His6; full length yBrr2
 cloned via SacI and HindIII This study 
pFL-10His T2 N-His10; TEV protease cleavage site; yBrr2
271-2163 Christian Becke, FU-Berlin 
pFL-10His ScC N-His10; TEV protease cleavage site; hBrr2
1339-2163 (C-cassette) 





































































N-His10; TEV protease cleavage site; cloned via EcoRI and 
HindIII 
This study 




Name Description Reference 
pFL-10His 
hBrr2HR,RP,H1548A 





N-His10; TEV protease cleavage site; cloned via EcoRI and 
HindIII 
This study 
pFL-10His hBrr2HR,WT N-His10; TEV protease cleavage site; hBrr2 wild type cloned via 
EcoRI and HindIII 
This study 
pFL hBrr2WT C-His6; full length hBrr2 wild type cloned via BamHI and 
HindIII 
This study 
pFL-10His HsNWT N-His10; TEV protease cleavage site; hBrr2
395-1324 (N-cassette) 
wild type cloned via EcoRI 
This study 
pETM11 Prp8ct1806-2413 N-His6; TEV protease cleavage site; via BsaI and NotI This study 
pETM11 Prp8ct1836-2413 N-His6; TEV protease cleavage site; via BsaI and NotI This study 
pGEX6P1 Prp8ct1806-2413 N-GST; TEV protease cleavage site; via BamHI and NotI This study 
pGEX6P1 Prp8ct1836-2413 N-GST; TEV protease cleavage site; via BamHI and NotI This study 
pETM11 Prp8ct1836-2398 N-His6; TEV protease cleavage site; via BsaI and NotI Dr. Gert Weber, FU-Berlin 
2.1.12 Insect cell lines 
Sf9 and Sf21 cells were used to isolate and propagate recombinant baculovirus stocks. 
High Five
TM 
cells were used for large scale expression of recombinant proteins. All cell lines 
above are adapted to serum-free suspension culture.  
Table 2.12: Insect cell lines 
Cell line Description Supplier 
Sf9 cells clonal isolate derived from the parental Spodoptera frugiperda (Fall 
Armyworm) cell line IPLB-Sf21-AE. Originated at the USDA Insect 
Pathology Laboratory (Vaughn et al., 1977) 
Invitrogen, Germany 
Sf21 cells isolated from Spodoptera frugiperda (Fall Armyworm) pupal ovarian 
tissue (Vaughn et al., 1977) 
Invitrogen, Germany 
High FiveTM cells BTI-TN-5B1-4 was developed by the Boyce Thompson Institute for Plant 
Research, Ithaca, NY and originated from a clonal isolate derived from the 
ovarian cells of the cabbage looper, Trichoplusia ni  (Wickham et al., 
1992) 
Invitrogen, Germany 
2.1.13 Bacterial strains 
Escherichia coli strains XL1 blue and XL2 blue were used for routine cloning applications 
of plasmid DNA. BL21 (DE3) "Rosetta2" strain was utilized for production of protein from 




target genes cloned in T7-driven expression vectors. DH10MultiBacY strain was used for 
recombinant bacmid preparation. 
Table 2.13: Bacterial strains 
Strain Description Reference 
XL1 blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ 
proAB lacIqZΔM15 Tn10 (TetR)] 
Agilent, Germany 
XL2 blue endA1 supE44 thi-1 hsdR17 recA1 gyrA96 relA1 lac [F´ 






-) gal dcm pRARE2 (CamR) Novagen, USA 
DH10 MultiBacY F– mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 
recA1 endA1 araD139 Δ(ara leu) 7697 galU galK λ– rpsL 
nupG  / bMON14272 Δ(chiA, v-cath) / pMON7124 
Dr. I. Berger, EMBL, 
Grenoble 
2.1.14 Software 
Table 2.14: Software 
Software Reference 
CNS (Brünger et al., 1998) 
Collaborative Computational Project Number 4 (CCP4i) 
program suite 
(Potterton et al., 2003) 
Coot (Emsley and Cowtan, 2004; Emsley et al., 2010) 
Corel Draw Corel Corporation, USA 
GraphPad Prism GraphPad Software, Inc., USA 
HKL2000 (Minor et al., 2006) 
Pro-Data Viewer Applied Photophysics Ltd. 
Pymol Schrödinger LLC, USA 
Sharp/Autosharp (Bricogne et al., 2003) 
ShelX suite (Sheldrick, 2008) 
XDS (Kabsch, 2010) 




2.2 Methods   
Unless otherwise stated, all molecular biological methods were performed as described in 
(Sambrook et al., 1989). Commercial kits were used according to the instructions of the 
manufacturer. 
Special attention is given to some methods used extensively during this thesis. In such 
cases, the technique will be first introduced in more details followed by a description of how 
it was specifically applied to this work.  
2.2.1 Nucleic acid methods 
2.2.1.1 Determination of nucleic acid concentration 
To determine the concentration of nucleic acids, the light absorption of an aqueous 
solution was measured at the wavelength of 260 nm using a Nanodrop spectrophotometer. 
The concentration was then calculated using theoretical absorption values at 260 nm (as 
described in Sambrook, 1989). 
 double-stranded DNA  1 OD260 = 50 μg/ml 
 single-stranded DNA  1 OD260 = 33 μg/ml 
 single-stranded RNA   1 OD260 = 40 μg/ml 
2.2.1.2 Agarose gel electrophoresis for DNA 
To separate nucleic acids, agarose gel electrophoresis was used for both analytical 
visualization and purification of preparative amounts of DNA. Depending on the size of the 
DNA fragments, the gels were prepared with varying agarose concentrations of 0.8–1.5% in 
1×TBE buffer. Commercial DNA ladders were used as marker on each gel. Before casting, 
ethidium bromide was added to the final concentration of 0.7 μg/ml in gel solution. Samples 
were mixed with DNA loading dye. Gels were run at a constant voltage of 100 V in 1×TBE 
buffer. DNA bands were visualized by UV illumination at 254 nm. 
2.2.1.3 DNA purification using agarose gel electrophoresis 
DNA bands were illuminated at a wavelength of 254 nm and excised from the gel with a 
sterile razor blade. DNA was extracted from the gel using QIAquick gel extraction kit 
following the instruction of the manufacturer. 
2.2.1.4 Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) was used for amplification of genes or gene fragments. 
Depending on the target gene, cloned Pfu polymerase or Herculase enhanced polymerase 




were used according to the instructions of manufacturers. Typical PCR conditions are shown 
below. 
Table 2.15: Typical conditions for PCR 
Parameter Typical condition 
10×polymerase reaction buffer  1× 
dNTP mixture (10 mM of each dNTP)  0.2 mM 
DNA template (plasmid DNA)  10-50 ng 
Primers  0.3 μM each 
DNA polymerase  0.1 – 0.2 U/μl 
DMSO  0 – 4% 
Denaturing temperature  98°C 
Annealing temperature  Tm-5°C 
Extension time  0.5 – 2 min per kb 
Extension temperature  72°C 
Number of cycles  30 
2.2.1.5 Site-directed mutagenesis 
Desired mutations were introduced using the QuikChange II XL Site-Directed 
Mutagenesis Kit according to the manufacturer's instructions. The resulting clones were 
verified by DNA sequencing. 
2.2.1.6 Restriction digestion and ligation of DNA 
Restriction digestions were carried out to generate compatible ends in vectors and PCR 
products for subsequent ligation reactions. Buffers and temperatures were chosen according to 
the manufacturer's instruction. The PCR amplified fragments were purified before digestion 
using a QIAquick PCR purification kit. A typical digestion reaction contained 2–4 µg DNA 
and 3 units of restriction enzyme per µg of DNA in a total volume of 50 µl. 
For ligation, the digested DNA was resolved on a preparative agarose gel and extracted as 
explained in sections 2.2.1.2-3. Ligation reactions typically contained 100 ng of plasmid 
DNA, three to five fold molar excess of the insert DNA, 800 units of T4 DNA ligase in 20 μl 
reaction volume. Reaction mixtures were incubated at 16°C overnight or at 25°C for 1 h. 




2.2.1.7 Plasmid isolation from Escherichia coli cells 
A single colony from an overnight grown LB-agar plate was used to inoculate LB 
medium. Cells were grown in LB medium overnight at 37°C. Plasmid purification was carried 
out using Mini- or Maxiprep kits, according to the manufacturer's instructions. 
2.2.1.8 Plasmid verification 
All cloned plasmids were verified for the presence of the correct insert by PCR or 
analytical restriction digestion. Sequences of the inserts which showed the correct size in 
agarose gel analysis were verified by DNA sequencing (Seqlab, Göttingen). 
2.2.1.9 Radioactive labeling of the 5'-end of RNA oligonucleotides 
For electrophoretic mobility shift assays, RNA oligonucleotides were radioactively 
labeled at their 5'-end using γ-[
32
P]-ATP and T4-polynucleotide kinase (PNK). 
A typical labeling reaction contained 10 pmol of the RNA oligo, 1 μl of 10×PNK buffer 
(New England Biolabs), 1 μl of T4 PNK (10 U/μl) and 5 μl of γ-[
32
P]-ATP (6000 Ci/mmol, 10 
mCi/ml). The reaction mixture was incubated at 37°C for 1 h. After incubation, the reaction 
volume was adjusted to 50 μl with ddH2O and loaded on a ProbeQuant G-50 or G-25 column 
to purify the radioactively labeled oligonucleotide from free γ-[
32
P]-ATP. 
Synthethic RNA oligonucleotides from Dharmacon (Bonn, Germany) were deprotected 
before labeling. The 2'-protecting groups were removed by addition of 2'-deprotection buffer 
(100 mM acetic acid, adjusted to pH 3.8 with TEMED) and incubation at 60°C for 30 min. 
Samples were then dried in a Speed-Vac and the RNA pellets were resuspended in ddH2O. 
2.2.2 Cell and cell culture methods 
2.2.2.1 Escherichia coli strains and cultivation 
Escherichia coli (E. coli) cells were grown in liquid medium or on agar plates 
supplemented with adequate antibiotics in the following concentrations: 
- ampicillin 100 μg/ml, 
- chloramphenicol 34 μg/ml, 
- tetracycline 15 μg/ml, 
- gentamicin 7 μg/ml, 
- kanamycin 50 μg/ml. 
2.2.2.2 Preparation of chemically competent Escherichia coli cells 
Chemically competent cells were prepared using the DMSO-method (Inoue et al., 1990). 
For preparation of chemically competent cells, E. coli cells were grown in SOB medium with 




appropriate antibiotics at 18°C to reach an OD600 of 0.5−0.6. Cells were collected in sterile 
bottles by centrifugation at 3000×g for 10 min at 4°C. The cell pellet was resuspended in ice-
cold TB buffer and harvested by centrifugation (3000×g, 10 min, 4°C). This step was repeated 
twice and the final cell pellet was resuspended in ice-cold sterile TB buffer, containing 7% 
(v/v) DMSO. 
The competent cells were aliquoted in cold Eppendorf tubes, flash-frozen in liquid 
nitrogen and stored at -80°C. 
2.2.2.3 Preparation of electro-competent Escherichia coli cells 
To prepare electro-competent bacterial cells, E. coli cells were grown in 500 ml LB 
medium to reach an OD600 of 0.4−0.5. Cells were harvested in sterile bottles by centrifugation 
at 4000×g for 15 min at 4°C. The cell pellet was washed twice with 500 ml ice-cold sterile 
H2O and twice with 200 ml ice-cold sterile 10% glycerol. Cells were finally resuspended in 5 
ml ice-cold sterile 10% glycerol, aliquoted in cold Eppendorf tubes, flash-frozen in liquid 
nitrogen and stored at -80°C. 
2.2.2.4 Transformation of Escherichia coli cells 
For electroporation, 50−100 ng DNA were mixed with 50 μl electro-competent E. coli 
cells on ice. The mixture was transferred to an ice-cold electroporation cuvette (2 mm 
electrode gap) and subjected to a 4.8 ms pulse of 2.5 kV. Cells were collected in 1 ml of SOC 
medium and incubated for 1 to 4 h at 37°C in a shaker. Subsequently, cells were harvested by 
3 min centrifugation at 1500×g. The cell pellet was resuspended in 150 μl of LB medium and 
streaked out on an agar-plate containing the selective antibiotics. 
For chemical transformation, 100−200 ng of plasmid DNA was mixed with 100 μl of 
chemically competent E. coli cells and incubated for 30 min on ice. Ice-cold cells were then 
heat-shocked for 45 sec at 42°C and cooled on ice for 3 min. Cells were mixed with 1 ml of 
SOC medium and incubated at 37°C for 1 h in a shaker. The cells were collected and selected 
on LB-agar plates supplemented with appropriate antibiotics. 
2.2.2.5 Protein expression in Escherichia coli 
For protein expression, cells were grown in ZYM-5052 (50 mM phosphate) auto-inducing 
complex medium (Studier, 2005). TunAir flasks were used to maintain adequate aeration in 
preparative protein production setups. Optical densities of cultures were measured in plastic 
cuvettes with 1 cm path-length in an Ultrospec 3000 pro spectral photometer at 600 nm 
wavelength using the respective plain media as reference. 




Complex media containing enzymatic digests of casein and yeast extract are extensively 
used since they support growth of a wide range of E. coli strains, with different nutritional 
requirements, and cultures typically grow several times faster than in simple mineral salts 
media supplemented with glucose as the only carbon source. However, due to small amounts 
of lactose, inducing activity is fairly common in complex media. 
Auto-induction depends on mechanisms bacteria use to regulate the use of carbon sources 
present in the growth medium. Lactose is prevented from inducing production of target 
protein by compounds that can be depleted during growth, such as glucose, glycerol and 
amino acids. Consequently, if glucose is present in the medium, it prevents the uptake of 
lactose. Ideally, the expression strain would grow to saturation in auto-inducing media, when 
depletion of inhibitory factors would allow cells to take up lactose and convert it to 
allolactose, the natural inducer of the lac operon. Induction unblocks both the lacUV5 and 
T7lac promoters of T7 RNA polymerase and target protein, respectively, and leads to large 
scale expression levels in highly saturated cultures. 
2.2.2.6 Baculovirus expression vector system 
Many eukaryotic proteins fail to be produced properly in E. coli due to protein size 
limitations or particular requirements for chaperone systems or post-translational 
modifications that E. coli cannot support. Overproduction of such proteins demands a 
eukaryotic expression system. Baculovirus expression vector system (BEVS) is robust and 
well suited for producing eukaryotic proteins as it provides a number of advantages: 
- Baculoviruses do not replicate in eukaryotic cells besides their insect cell hosts 
which is associated with low safety requirements; 
- Due to the flexibility of the Autographa californica multiple nuclear polyhedrosis 
virus (AcMNPV) envelope, large DNA insertions can be accommodated in its 130 
kb dsDNA genome and, consequently, large proteins often authentically processed 
can be produced; 
- Insect cell cultures can be grown in regular shaker flasks; 
- Protein yields are comparable to E. coli. 
Baculovirus gene expression takes advantage of the viral life cycle. A well-studied 
baculovirus, the AcMNPV, has three classes of genes that are expressed in a chronologically 
regulated, sequential manner (Smith et al., 1983; Pennock et al., 1984). The first class 
comprises the early genes, controlled by host-like promoter and transcribed by the host 
transcriptional machinery (Friesen, 1997). Once the viral DNA is replicated, the late genes are 




expressed, such as the p10-coding gene, which demand virus-encoded transcriptional 
machinery (Lu and Miller, 1997; Passarelli and Guarino, 2007). In the end of the infectious 
cycle, the very late genes are expressed which code for several proteins including polyhedrin 
(polh). Polyhedrin is one of the most abundantly expressed proteins and is involved in the 
formation of occlusion bodies in the nuclei of insect cells infected with wild type baculovirus. 
In tissue culture, these late and very late proteins (such as p10 and polh) are non-essential for 
viral replication and their genes can be exchanged with other genes to create a recombinant 
baculovirus. This circumstance was exploited for producing the first recombinant 
baculoviruses in 1983 (Smith et al., 1983) by standard homologous recombination using 
transfer plasmids carrying the foreign genes.   
2.2.2.6.1 The MultiBac system 
The MultiBac system (Trowitzsch et al., 2010) is based on an AcMNPV baculovirus 
genome derived from the Tn7-based BAC variant described by Luckow and Summers, 1988. 
The MultiBac baculoviral genome is propagated as a bacterial artificial chromosome (BAC) 
in E. coli cells and utilizes a Tn7 attachment site embedded in a LacZα gene for integrating 
foreign genes via transfer plasmids (Acceptor plasmids) into the baculoviral genome. 
Successful integration of the expression cassette leads to disruption of the LacZα gene and 
enables the selection of positive clones by blue/white screening.  
The MultiBac baculovirus also contains modifications to reduce proteolytic breakdown of 
the overproduced proteins. Baculoviral genes v-cath and chiA, coding for a cathepsin protease 
and a chitinase, were substituted by a LoxP imperfect inverted repeat introduced together with 
an enhanced YFP protein coding gene. The resulting BAC is called EMBacY. 
Two families of modular transfer plasmids denominated Acceptors (pFL and pKL) and 
Donors (pUCDM, pIDC, pIDS, pIDK and pSPL) are currently used to deliver the 
heterologous genes, under control of p10 or polh promoters, to the BAC. Both Acceptor and 
Donor plasmids harbor a LoxP site that can be used to combine one Acceptor with one or 
more Donor plasmids through cre-recombination before integration into the EMBacY. This 
strategy is widely used in case of multiprotein complex expression. The transposition 
involving the Acceptor plasmid or Acceptor/Donor fusions and the EMBacY occurs in vivo in 
E. coli cells, called DH10MultiBacY, tailored for this purpose. These cells provide a helper 
plasmid encoding the Tn7 transposon complex for accessing the Tn7 site on the EMBacY. For 
virus production, the composite EMBacY is isolated from DH10MultiBacY and used to 
transfect insect cells. 




The presence of YFP gene in the EMBacY serves the purpose of directly observing virus 
performance by using a fluorescence spectrophotometer (Trowitzsch et al., 2010). YFP is 
under the control of a very late promoter (polh) as are, typically, the heterologous genes. It is 
observed that when YFP expression reaches a plateau, expression of other heterologous 
proteins under the same promoter (as well as p10 promoter) also reach their peak production. 
Consequently, it is possible to follow protein production levels by monitoring YFP 
expression.  
2.2.2.6.2 Insect cell cultivation 
All handling of insect cell lines was carried out under sterile conditions in a laminar flow 
hood. Sf9, Sf21 and High Five
TM 
cell stocks (25 ml) were maintained in 250 ml shaker flasks 
at 27°C while shaking at 80 rpm. Sf9 and Sf21 cells were cultured in SF900 III SFM and 
High Five
TM 
cells in Express Five
R
 SFM medium supplemented with L-glutamine prior to use. 
Population doubling time for insect cells vary depending on growth conditions: 
- Sf9 and Sf21 cells double approximately every 24 hours; 
- High FiveTM cells double every 18-24 hours. 
The suspension cultures were subcultured every day to a density of 0.5×10
6
 cells/ml to 
maintain log phase growth and maximum viability. Cell viability was assessed every day by 
cell counting using a Casy TT cell counter. Cell count using Casy TT is performed by 
suspending 50 µl of cells in 10 ml CASY
R
ton, an electrolyte developed specifically for cell 
counting. The solution (400 µl) is then aspirated through a precision measuring capillary (150 
µm) of defined geometry at a constant flow speed. During the three measuring cycles, a 
pulsed low voltage field with 1 MHz is applied to the measuring capillary via two platinum 
electrodes. During the passage of the cells through the measuring capillary, they displace a 
quantity of electrolyte corresponding to their volume. Since intact cells can generally be 
considered insulators, an increased level of resistance is achieved over the measuring pore. 
This resistance corresponds to the dimension for the volume of the cells. In contrast, dead 
cells, whose membrane no longer acts as an electrical barrier, are recorded by the size of their 
cell nucleus. The size range used to calculate the measuring results for Sf9 and Sf21 was 
10.70–40.00 µm and for High Five
TM
 was 13.00–40.00 µm. The normalization cut off 
determines the size range for which all percentage calculations indicate 100% (% viability, % 
counts or % volume). The normalization cut off for Sf9 and Sf21 was 6.80–40.00 µm and for 
High Five
TM
 was 7.80–40.00 µm. The lower range of the normalization cut off defines the 
size range for determining debris. 




2.2.2.6.3 Bacmid preparation, transfection and virus amplification 
Recombinant bacmid was prepared using the MultiBac system as described by Fitzgerald 
et al., 2006.  
The genes of hBrr2 as well as mutants and fragments were cloned in a pFL vector or in a 
modified version called pFL10His and transformed to electrocompetent DH10MultiBacY 
cells. Following electroporation, cells were incubated at 37°C for 4 h in SOC medium and 
plated on LB-agar media containing 50 μg/ml kanamycin, 7 μg/ml gentamicin, 10 μg/ml 
tetracycline, 100 μg/ml ampicillin, 100 μg/ml Bluo-Gal and 1 mM IPTG and incubated 
overnight. 
The Cre-lox recombination process was used to join Acceptor and Donor plasmids to 
create constructs for co-expression of the human Prp8-Snu114-Brr2 and the yeast Prp8-
Snu114 proteins. For this purpose, we have cloned hPrp8 in a Donor plasmid (pIDS), hBrr2 
with a C-terminal His6-tag in an Acceptor plasmid (pFL) and hSnu114 with a C-terminal 
strepII-tag in another Donor plasmid (pIDK) while yPrp8 with a C-terminal FLAG tag was 
cloned in an Acceptor plasmid (pFL) and ySnu114 in a Donor plasmid (pIDS). 
For the reaction, donor and acceptor plasmids were mixed in equal amounts (1-2 μg each) 
in the Cre reaction buffer and Cre recombinase was added. The reactions were incubated at 
37°C for 1h. The electrocompetent DH10MultiBacY cells were, then, transformed with the 
reaction mixtures. After electroporation, SOC media was added and cells were incubated at 
37°C for 4h. The cells were plated on LB-agar media containing the desired combination of 
antibiotics and incubated overnight. 
The transformants were verified by an antibiotic challenge. For this purpose, the colonies 
from the plate were picked and inoculated into LB without antibiotics. After incubation at 
37°C for about 1h, aliquots of pre-incubated cell cultures were added to the wells of a 96-well 
plate containing the desired antibiotics in different combinations. The plate was left shaking at 
37°C overnight. The cultures which demonstrated resistance to all of the antibiotics were 
selected for amplification of the recombination product. Finally, all Acceptor/Donor 
assemblies were verified by digestion to confirm the presence of the desired genes. 
The expression constructs (Acceptor plasmid or Acceptor/Donor fusions) were integrated 
via Tn7 transposition into the EMBacY during the DH10MultiBacY transformation 
procedure. The Tn7 transposition site is embedded in a lacZα gene allowing the selection of 
positive EMBacY recombinants by blue/white screening. White positive clones were re-
streaked on a new LB-agar plate containing antibiotics as well as IPTG and BluoGal. After 
the second round of blue-white screening, the single white colonies were inoculated into LB 




media containing the desired antibiotics and cultivated O.N. with vigorous shaking. 
Recombinant EMBacYs were isolated from the bacterial hosts using QIAprep miniprep kit, 
omitting the column purification step.  
The recombinant bacmids were further precipitated by addition of isopropanol and 
pelleted by centrifugation in a table-top centrifuge at 17000×g for 30 min. The pellets were 
washed with 70% ethanol and the dried bacmid pellets were dissolved in 40 μl ddH2O and 
mixed with 200 μl of SF-900 III medium in a sterile laminar flow hood. The transfection 
reagent, X-tremeGene 9, was diluted in the same medium (1:10, 10 μl X-tremeGene 9 in 100 
μl medium) and mixed with the bacmid solution. The mixture was incubated for 1 h and 




To obtain initial virus (V0 generation), Sf9 cells grown as adhesive culture in 6-well plates 
were transfected with composite EMBacY BACs. The efficiency of transfection was 
monitored by eYFP fluorescence using an Axiovert 40 CFL microscope equipped with an 
HBO illuminator and a proper filter set for eYFP fluorescence visualization. The V0 
generation was harvested 60 h post-transfection and immediately used to infect a 25 ml 
suspension culture of Sf21 cells in an Erlenmeyer shaker flask for further virus amplification 
(V1 generation). It is important to maintain a low multiplicity of infection (MOI – number of 
infectious virus particles per cell in a cell culture) during virus production and amplification. 
Low MOI regime is the best way to avoid detrimental gene deletions which can occur during 
virus amplification, adversely affecting protein yields (Braunagel et al., 1998). Low MOI is 
ascertained by allowing one doubling time of the Sf21 cells after addition of V0 (Bieniossek et 
al., 2008). Infected Sf21 were diluted to a cell count below 10
6
 cells/ml every 24 h until cell 
proliferation arrest (typically 2–4 days). After proliferation arrest, 10
6
 cells were sampled 
from the infected culture every 12 h for cell counting and diameter determination using a 
Casy TT cell counter. For YFP fluorescence signal measurements (performed in a 
FLUOTRAC-600 black 96 well polystyrene plates using a Victor X3 multilabel plate reader), 
the cells were resuspended in 500 µl PBS and lysed by sonication. The amplified virus (V1 
generation) was harvested by centrifugation and the supernatant containing the virus 60 h 
after cell proliferation arrest was stored at 4°C. Usually, the same volume of fresh media was 
replenished to the culture. YFP signal from the 10
6
 cells sampled every 12 h continued to be 
recorded until it reached a plateau. At this point, cells were harvested and protein production 
was analyzed by SDS-PAGE using a fraction of the samples used for YFP fluorescence 
measurements. 




2.2.2.6.4 Protein expression in insect cells 
To determine the appropriate concentration of V1 to be used for large scale expression, 3 




 cells/ml were infected with varying 
volumes of V1, such as 30 µl, 60 µl and 90 µl. Cell counting and diameter determination was 
performed every 24h as described above. The amount of V1 that allowed one round of cell 
division and yielded high protein production was chosen for scalling up the expression. 
For large scale expression, 400 ml of High Five
TM
 cells kept in suspension in an 
Erlenmeyer shaker flasks at 0.5×10
6
 cells/ml were infected with 0.4 to 1 ml of V1 virus. 
Samples of 10
6
 cells were taken from the infected culture every 12 h for cell counting and 
diameter determination as described previously. The samples were further used for YFP 
fluorescence signal measurements as described above and for protein production analysis by 
SDS-PAGE. The infected cells were harvested when the YFP fluorescence signal reached a 
plateau (typically 2–3 days) or before the cell viability dropped below 90%.      
2.2.3 Protein methods 
2.2.3.1 Determination of protein concentration 
Protein concentrations were determined using either the Bradford assay (Bradford, 1976) 
the BCA assay (Smith et al., 1985) or by measuring the absorbance of denatured protein at the 
wavelength of 280 nm. The Bradford and BCA assays were used according to the 
manufacturer's instructions. When using the absorbance at 280 nm, the proteins were 
denatured in 20 mM phosphate buffer, pH 6.5, 6.0 M guanidinium hydrochloride and the 
theoretical extinction coefficients of the proteins were used to calculate the concentration 
(Walker, 2005). 
2.2.3.2 Protein precipitation 
Protein samples were precipitated to reduce the volume before running the gel. 5 volumes 
of ice-cold acetone were added to one volume of protein solution. The sample was rapidly 
mixed and incubated overnight at -20°C. The mixture was centrifuged for 15 min at 4°C in a 
tabletop centrifuge at 17000×g, leftover acetone was evaporated and the pellet was 
resuspended in SDS loading buffer. 
2.2.3.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
To analyse proteins, SDS-polyacrylamide gels were used. According to the protein sizes 
to be separated, 10–12% (final acrylamide solution) gels were prepared and run vertically in 
SDS-PAGE running buffer. SDS-PAGE was basically performed as described elsewhere 




(Laemmli, 1970; Weber et al., 1972). In brief, a typical gel contained a stacking part, 
consisting of 1×stacking gel buffer and 16% (v/v) Rotiphorese Gel 30 solution, polymerized 
with 0.3% (w/v) APS and 0.03% (v/v) TEMED, and a separating part, consisting of 
1×resolving gel buffer and 25–40% (v/v) Rotiphorese Gel 30 solution, polymerized with 0.5% 
(w/v) APS and 0.1% (v/v) TEMED. Protein samples were denatured in protein loading buffer 
and heated to 95°C for 5 min. Electrophoresis was typically stopped when the bromophenol 
blue border reached the bottom of the gel. To visualize the protein bands, SDS-PAGE gels 
were first fixed for 30 min with a solution containing 4.7% (v/v) formaldehyde and 50% (v/v) 
methanol. Subsequently, the gels were incubated in Coomassie staining solution for 5-15 
minutes and destained by the sequential addition of destaining solution I until bands became 
visible. The gel was destained further with destaining solution II (Fairbanks et al., 1971).  
2.2.3.4 Silver staining of protein gels 
For silver staining of protein gels, the gel was first fixed in 50% (v/v) methanol and 5% 
(v/v) acetic acid solution for 20 min and then washed with 50% (v/v) ethanol, 30% (v/v) 
ethanol and ddH2O water for 10 min each. The gel was further treated with 1.25 mM Na2S2O3 
for exactly 60 sec and immediately rinsed thrice with ddH2O to remove the thiosulfate from 
the gel surface. For staining, the gel was incubated in a solution containing 6 mM AgNO3 and 
0.0185% (v/v) formaldehyde for 20 min followed by three times washing with ddH2O. For 
stain developing, the gel was rinsed with 0.19 M Na2CO3, 0.026% (v/v) formaldehyde. The 
solution was replaced when it turned yellow. Development continued until protein or RNA 
bands were visible. The developing procedure was stopped with cold 5% (v/v) acetic acid 
solution. 
2.2.3.5 Western Blotting 
Proteins were separated by 10–12% SDS PAGE and electro-blotted on a PVDF transfer 
membrane in a Trans-Blot Electrophoretic Transfer Cell according to the membrane 
manufacturer's instruction. A pre-stained MW standard was applied onto one lane to assess 
the transfer efficiency. The gel, membrane and filter paper were soaked in the blotting buffer 
prior to the transfer. Special care was taken to remove air bubbles trapped between the layers 
of the assembly. The transfer was performed in blotting buffer for 2 h at 70 V, 4°C. To 
decrease non-specific binding of antibodies, the membrane was blocked in blocking buffer 
overnight at 4°C. To detect hBrr2, the membrane was first incubated with a primary antibody 
solution for 1 h at room temperature and washed three times 15 min each wash with washing 
buffer I at room temperature. Subsequently, the membrane was incubated with goat 




horseradish peroxidase-conjugated anti-rabbit anti-rabbit IgG (secondary antibody solution) 
for 1 h at room temperature and then washed three times for 15 min each wash with washing 
buffer II. Proteins were detected by enhanced chemiluminescence using an ECL kit according 
to the manufacturer's instructions. The luminescence was detected by exposure on the ECL 
Hyperfilm. The film was developed on an X-Omat 2000 developer. 
2.2.3.6 Purification of human and yeast Brr2 
If not mentioned otherwise, the same purification protocol was used for all human and 
yeast Brr2 constructs. The High Five
TM
 cell pellet was resuspended in 50 mM HEPES, pH 
7.5, 600 mM NaCl, 2 mM β-mercaptoethanol, 0.05% NP40, 10% glycerol, 10 mM imidazole, 
supplemented with EDTA-free protease inhibitors and lysed by sonication using a Sonopuls 
Ultrasonic Homogenizer HD 3100. Cell debris was removed by centrifugation and the soluble 
extract was filtered using a 0.44 µm filter. The target was captured on a 5 ml HisTrap FF 
column and eluted with a linear gradient from 10 to 250 mM imidazole. The His-tag was 
cleaved with TEV protease during overnight dialysis at 4ºC against 50 mM HEPES, pH 7.5, 
600 mM NaCl, 2 mM β-mercaptoethanol, 10% (v/v) glycerol and 15 mM imidazole. The 
cleaved protein was again loaded on a 5 ml HisTrap FF column to remove the His-tagged 
protease, uncut protein and cleaved His-tag. The flow-through containing the protein of 
interest was diluted to a final concentration of 80 mM sodium chloride and loaded on a 
MonoQ 10/100 GL column equilibrated with 25 mM Tris-HCl, pH 8.0, 50 mM NaCl, 2 mM 
β-mercaptoethanol. The protein was eluted with a linear 50 to 600 mM sodium chloride 
gradient and further purified by gel filtration on a 26/60 Superdex 200 column in 10 mM Tris-
HCl, pH 7.5, 200 mM NaCl, 2 mM DTT. In case of yeast Brr2, after the recycling step, the 
protein was diluted to a final concentration of 80 mM sodium chloride and loaded on a HiPrep 
Heparin FF column equilibrated with 25 mM Tris-HCl, pH 8.0, 50 mM NaCl, 2 mM β-
mercaptoethanol. The protein was eluted with a linear 50 to 600 mM sodium chloride gradient 
and further purified by gel filtration on a 26/60 Superdex 200 column in 10 mM Tris-HCl, pH 
7.5, 200 mM NaCl, 2 mM DTT. For the purification of the N-terminal cassette construct and 
hBrr2
HR
 mutants, all solutions used were buffered at pH 8.0. All proteins produced for activity 
assays retained an N-terminal His-tag since the TEV cleavage and HisTrap FF recycling steps 
were omitted.  








was expressed in E. coli Rosetta 2(DE3). Cells were grown in autoinducing 
medium (Studier, 2005) to an OD600 of 0.3 at 37°C, shifted to 16°C for 60 h and harvested by 
centrifugation. Cell pellets were resuspended in 25 mM HEPES, pH 7.5, 500 mM NaCl, 0.5 
mM DTT, 0.5% NP40, 5% (v/v) glycerol, supplemented with EDTA-free protease inhibitors, 
and lysed by five passes through a microfluidizer. The cell lysate was clarified by 
centrifugation and then loaded onto a 5 ml HisTrap FF column equilibrated in resuspension 
buffer without detergent. Protein was eluted with a linear gradient from 10 mM to 500 mM 
imidazol. Fractions containing the protein of interest were pooled, mixed with TEV protease 
and dialyzed over night at 4ºC against 25 mM HEPES, pH 7.5, 200 mM NaCl, 5% (v/v) 
glycerol, 0.5 mM DTT. The digested sample was again loaded on a 5 ml HisTrap FF column 
equilibrated in resuspension buffer (without detergent) in order to remove TEV protease, 
uncut protein and the cleaved His6-tag. The flow-through containing Prp8ct
1836-2398 
was 
diluted to a final concentration of 30 mM sodium chloride before being applied to a MonoQ 
HR 5/5 column equilibrated with 25 mM Tris-HCl pH 8.0, 30 mM sodium chloride and 1 mM 
DTT. Protein was eluted in a 50 ml linear gradient from 30 mM to 1.5 M sodium chloride. 
The fractions containing Prp8ct
1836-2398 
were pooled and injected directly onto a 26/60 
Superdex 200 column equilibrated in 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM DTT. 
2.2.3.8 Limited proteolysis 
Limited proteolysis experiments can inform on conformational features of proteins. In a 
number of studies, it has been demonstrated that the sites of limited proteolysis along the 
polypeptide chain of a protein are characterized by enhanced backbone flexibility, implying 
that proteolytic probes can pinpoint the sites of local unfolding in a protein chain (Fontana 
and Laureto, 1997; Fontana et al., 2004). This means that only flexible regions of the target 
protein such as disordered termini, exposed loops, or flexible domain linkers can be cleaved. 
Removing such flexible parts from a protein generates more compact and conformationally 
homogeneous molecules or compact single domains. These proteolytic fragments or domains 
of a protein may crystallize more readily or form better diffracting crystals than the intact 
protein. 
Proteolysis of a protein substrate can occur only if the polypeptide chain can bind and 
adapt to the specific stereochemistry of the protease active site. However, since the active 
sites of the proteases have not been designed by nature to fit a specific sequence and fixed 




stereochemistry of a stretch of at least 8–10 amino acid residues of a particular protein, an 
induced-fit mechanism of adaptation of the protein substrate to the active site of the protease 
is required for binding and formation of the transition state of the hydrolytic reaction 
(Herschlag, 1988). Therefore, the native rigid structure of a globular protein generally is not a 
good substrate for a protease, as documented by the fact that folded proteins under 
physiological conditions are rather resistant to proteolytic degradation. Nevertheless, native 
globular proteins can be attacked by proteases given the fact that it is not a static entity, but, 
instead, a dynamic system capable of fluctuations around its average native state. Indeed, 
crystallographers analyze this protein mobility in terms of B-factors for both side chain and 
Cα-backbone. The main chain B-factor is a measure of the fluctuations of the molecule energy 
around the potential minimum. These fluctuations can be visualised as the displacement of the 
polypeptide chain from its native structure. Naturally, these displacements can lead to local 
unfolding. It can be envisaged that the higher energy, locally unfolded states are those 
required for a native protein to be attacked by a proteolytic enzyme. Evidence for this 
mechanism of local unfolding required for limited proteolysis has been provided by 
demonstrating a close correspondence between sites of limited proteolysis and sites of higher 
backbone displacements or areas that are poorly resolved in the electron density map of 
proteins which have their 3D structures elucidated (Fontana et al., 1986). Therefore, it was 
concluded that limited proteolysis of globular proteins preferably occurs at flexible loops or 
mobile and disordered stretches of amino acid residues (for example, N- or C-terminal 
extensions or conformationally unstable regions often found between domains). In particular, 
chain segments in a regular secondary structure (such as helices) are generally not good sites 
for limited proteolysis. Based on the fact that sites for limited proteolysis require large 
conformational changes (local unfolding), a possible explanation that rigid elements of 
secondary structure are not easily hydrolysed by proteases is that it would be energetically 
disadvantageous. If proteolysis is occurring at the center of a helical segment, likely the helix 
is fully destroyed and, consequently, all hydrogen bonds, which cooperatively stabilize it, are 
broken. On the other hand, a peptide bond fission at a disordered flexible site likely does not 
change much the energetic state of that site, since the peptide hydrolysis can easily be 
compensated by some hydrogen bonds with water. 
It is plausible to suggest that limited proteolysis also requires that a specific chain segment 
of the folded protein substrate is sufficiently exposed to bind at the active site of the protease. 
Although the notion of exposure/protrusion/accessibility is a required property, it is clearly 
not sufficient to explain the selective hydrolysis of just one or few peptide bonds, since it is 




evident that there are many exposed sites (the whole protein surface) which could be a target 
of proteolysis. Instead, enhanced chain flexibility appears to be the key feature of the site(s) of 
limited proteolysis (Fontana and Laureto, 1997).  
Limited proteolysis has been widely used to define the boundaries of single domains or a 
set of tightly interacting domains in a molecule by trimming its flexible and unstructured parts 
and, thus, increasing its propensity to crystallization. The increased likelihood of a domain or 
a smaller set of domains to yield structural information can be explained, in a way, by the 
observation that large proteins are often composed of many individual domains. The 
conformational heterogeneity that results from motion between such domains is a severe 
impediment to crystallization.  
2.2.3.8.1 Practical approach to limited proteolysis 
The generation of domains by limited proteolysis relies directly on the tertiary structure of 
the protein under investigation and provides much firmer evidence for their existence than 
that provided by sequence homology and secondary structure predictions. 
In practice, limited proteolysis is achieved by dilution of the proteases sufficiently so that 
they will only digest the most accessible and flexible regions of the protein substrate leaving 
the domains intact. Initially, the protein substrate should be digested with various proteases to 
establish which conditions are optimal for generating a protease-resistant domain. Three 
parameters are routinely varied: enzyme/substrate ratio, temperature and time of digestion. At 
first, it is common practice to perform the experiment for 30 min at room temperature using 
up to 6 proteases at 3 different dilutions each. More specifically, to determine the appropriate 
enzyme/substrate ratio for a particular protease, the same amount of substrate is digested with 
at least three different dilutions of the protease. The appearance of a discrete band, on SDS-
PAGE, resistant to further degradation (even if only transiently), is evidence for the existence 
of a domain.  
For optimization of the experiment, variation of reaction time, for example taking samples 
from the reaction mixture at regular time intervals for SDS-PAGE analysis, at different 
temperatures is used. The conditions which yield a clear band of the protease resistant 
fragment on SDS-PAGE are further analyzed. 
Once a domain has been observed after the proteolysis experiment, N-terminal sequencing 
and mass spectrometry analysis of the band corresponding to the fragment on SDS-PAGE 
should enable unambiguous identification of the domain sequence. This information can be 
exploited for subsequent cloning, expression, purification and crystallization of the respective 
fragment/domain. 




Scaling up the digestion is not generally a problem and can be a very suitable alternative 
to cloning the stable fragment/domain. It is possible that the fragment of a protein that would 
have the best crystallization properties cannnot be expressed in recombinant form. Indeed, it 
has been observed that unstructured N- or C-terminal extensions are sometimes required for 
recombinant expression. Limited proteolysis in large scale also appears advantageous in cases 
when the product of the proteolysis is a nicked protein (the non-covalent complex of usually 
two protein fragments).  
Usually, digestion of a large quantity (several milligrams) of a specific protein is achieved 
under optimized conditions and the reaction is stopped by addition of an appropriate inhibitor. 
The stable fragment is, then, further purified and used for crystallization trials. 
Note that instead of choosing the large scale proteolysis approach, in situ proteolysis can 
be performed by adding a protease digestion step to crystallization trials (Dong et al., 2007). 
2.2.3.8.2 Limited proteolysis of yeast and human Brr2 
To search for stable fragments, full-length human and yeast Brr2 were treated with 
various proteases. For each reaction, 9 µg of protein were incubated with increasing amounts 
(0.004, 0.04 and 0.4 µg) of protease in the absence or presence of ATP/MgCl2 at 20ºC for 30 
min in buffer containing 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM DTT. The reactions 
were stopped by addition of 2 µl PMSF (saturated solution in isopropanol) and 10 µl SDS-
PAGE loading buffer. Half of each sample was separated by SDS-PAGE and bands were 
analyzed by tryptic mass spectrometric fingerprinting (Facility for Mass Spectrometry, Max-
Planck-Institute for Biophysical Chemistry, Göttingen, Germany). The remainder of the 
sample was separated by SDS-PAGE, blotted on a PVDF membrane, stained with Ponceau S 
and stable fragments were subjected to N-terminal sequencing (Microchemistry Core Facility, 
Max-Planck-Institute for Biochemistry, Martinsried, Germany). 
2.2.3.9 Analytical gel filtration analysis 
The hBrr2 constructs were analyzed by analytical size exclusion (gel filtration) 
chromatography on a Superdex 200 PC3.2 column in 10 mM Tris-HCl, pH 7.5, 200 mM 
NaCl, 2 mM DTT at a flow rate of 70 μl/min. For analysis of complex formation, proteins 
were mixed in defined ratios in a total volume of 60 μl and incubated for 30 min on ice prior 
to the chromatography. Fractions were concentrated and analyzed by SDS-PAGE. 




2.2.3.10 Circular dichroism spectroscopy 
Plane polarised light consists of two circularly polarised components of equal magnitude, 
one rotating counter-clockwise (left handed) and the other clockwise (right handed). Circular 
dichroism (CD) refers to the differential absorption of these two components. This effect will 
occur when a chromophore is chiral (optically active) by reason of its structure (for example, 
a carbon atom with four different substituents or a disulphide bond which is chiral because of 
the dihedral angles of the C-S-S-C atoms), or by being covalently linked to a chiral center or 
by being placed in an asymmetric environment by virtue of the three-dimensional structure 
adopted by the molecule. In practice, the plane polarized radiation is split into its two 
circularly polarized components by passage through a modulator. If one of the components is 
absorbed by the sample to a greater extent than the other after passage through the sample, the 
resultant radiation would be elliptically polarized. The CD spectropolarimeter does not 
recombine the two components but rather detects them separately. The dichroism at a given 
wavelength is then expressed as either the difference in absorbance of the two components or 
as the ellipticity in degrees (θ). A CD spectrum is obtained when the dichroism is measured as 
a function of the wavelength. 
CD measurements were carried out on a J-810 spectropolarimeter in a quartz cuvette (0.1 
cm path length). Far-UV spectra (190–240 nm) were recorded with proteins at 0.1 mg/ml in 
50 mM potassium phosphate, pH 7.6, at 10°C with a scan rate of 100 nm/min and a data pitch 
of 0.2 nm. Ten consecutive scans were accumulated and averaged. Data were baseline 
corrected and secondary structure contents were calculated using software provided by the 
spectropolarimeter manufacturer. Melting profiles were recorded between 10 and 100°C with 
the proteins at 0.25 mg/ml in the same buffer plus 0.5 M urea by monitoring the CD signal at 
220 nm. The temperature was ramped at 1°C per minute with data sampling at every 0.1°C. 
2.2.3.11 Differential scanning fluorimetry (DSF) 
Identifying conditions in which protein samples are stable over long periods of time, are 
prevented to aggregate or denature is extremely helpful for experiments involving analytical 
and biophysical techniques that require high protein concentrations. 
Many factors can influence protein stability such as: buffers (chemical composition as 
well as pH), salts, detergents whose interactions with the protein are non-specific. Ligands, 
which bind proteins at specific sites, may also produce noticeable effects as protein 
stabilizers. The stability of a protein is characterized the Gibbs free energy of unfolding, ΔGu, 
which is temperature-dependent. The stability of most proteins decreases as the temperature 




increases, meaning that ΔGu decreases and reaches zero at the equilibrium point where the 
concentrations of folded and unfolded protein are equal. At this equilibrium point, the 
temperature is called melting temperature (Tm).  
DSF monitors the thermal unfolding of proteins in the presence of a fluorescent dye that is 
highly fluorescent in non-polar environment compared to aqueous solution where the 
fluorescence is quenched. To date, SYPRO orange is the dye possessing the most favorable 
properties for DSF owing to its signal to noise ratio. Additionally, the relatively long 
wavelength of excitation of SYPRO orange (near 500 nm) decreases the likelihood that buffer 
components would interfere with the optical properties of the dye. Practically, DSF is 
performed using a real-time PCR instrument and monitors the fluorescence intensity of the 
dye as a function of the temperature. Upon protein unfolding by thermal denaturation, the dye 
preferentially binds to the now exposed hydrophobic patches of the protein and the 
fluorescence intensity increases. This generates a sigmoidal curve that can be described as a 
two-state transition and the Tm can be extracted from the curve by determining the first 
derivative (Niesen et al., 2007).  
DSF is an excellent method to screen for conditions/compounds that stabilize proteins due 
to the small amounts and low protein concentrations required as well as for providing an easy 
readout for identification of such stabilizing conditions. Basically, the Tm value of the protein 
under each condition of the screen needs to be compared with the reference Tm, which is 
generally provided by protein in purification buffer. 
DSF experiments were done in a 96-well plate in a plate reader combined with a 
thermocycler (Stratagene Mx3005P). In order to determine a suitable protein concentration, 
purified protein was diluted to series of concentrations varying from 1 μM to 10 μM in the 
final purification buffer supplemented with 10×SYPRO orange (1:500 dilution of the stock) in 
a total volume of 20 μl and pipetted into a 96-well plate. The temperature was increased from 
25°C to 95°C and the fluorescence emission was monitored in steps of 1°C/min with hold 
steps of 30 sec between reads. The fluorescence intensity was then plotted as a function of 
temperature. The protein concentration that showed a clear sigmoidal curve was chosen for 
buffer optimization and compound screens. Different buffer compositions and compounds 
were tested for their stabilizing effect on the protein at the defined protein concentration. The 
sigmoidal curve from each condition was normalized and corrected for the background signal 
of the fluorophore in the buffer. The inflection points of the curves, representing the thermal 
melting temperature of the protein in the respective conditions, were compared.  




2.2.3.12 ATP binding studies 
Transient kinetic measurements allow the detection of reaction intermediates and the 
determination of rate constants of individual steps on the reaction pathway. Therefore, in pre-
steady state kinetics, the processes generally observed are reactions of changes in the enzyme, 
substrate or products from one species to another, when the reaction undergoes a single 
turnover event. The recorded time courses show an exponential dependency. Stopped flow is 
a suitable technique to study pre-steady state kinetics of reactions occurring in solution in the 
millisecond to second time range. These reactions can be followed directly and in real time 
using spectroscopic changes as observables. 
In stopped-flow machines, two syringes, each filled with enzyme or substrate for example, 
are connected to a mixing chamber. These syringes are compressed to deliver about 50 to 200 
µl each. The two reactant solutions are mixed rapidly in the mixing chamber and the reaction 
mixture is then transferred to an observation cuvette. The flow of the mixture into the cuvette 
is stopped with the help of a stop syringe and a photomultiplier mounted at 90° to the 
excitation beam records the progress of the reaction occurring after 1 ms. The spectroscopic 
changes are measured as a function of time. 
Several observables can be used when working with a stopped-flow apparatus. 
Fluorescence changes due to binding or conformational rearrangements of a fluorescence-
labeled component can be monitored. Additionally, two fluorescence-labeled components can 
be used which serve as a fluorescence donor and acceptor in a fluorescence resonance energy 
transfer (FRET) measurement.  
The mechanism of FRET involves a donor fluorophore in an excited electronic state 
which can transfer its excitation energy to a nearby acceptor chromophore in a non-radiative 
fashion through long-range dipole-dipole interactions. The phenomenon of FRET is not 
mediated by photon emission and does not require the acceptor chromophore to be 
fluorescent. However, in most cases, both donor and acceptor are fluorescent and the 
occurrence of energy transfer manifests itself through quenching of donor fluorescence 
accompanied by an increase in acceptor fluorescence emission. Several criteria must be 
satisfied in order for FRET to occur. The FRET pair should be chosen in such a way that the 
emission spectrum of the donor overlaps with the excitation spectrum of the acceptor. 
Furthermore, the two involved fluorophores must be positioned within a range of 1 to 10 
nanometers of each other. As described by the Förster equation, the efficiency of the energy 
transfer process varies in proportion to the inverse sixth power of the distance separating the 
donor and acceptor molecules. An additional requirement is that the fluorescence lifetime of 




the donor molecule must be long enough to permit the event to occur. According to Förster's 
















where R0 is the Förster critical distance, TD is the donor life time in the absence of the 
acceptor and r is the distance separating the donor and acceptor chromophores. When the 
radius r equals the R0, the transfer efficiency equals to 50%. 
All requirements fulfilled, FRET is observed when the sample is excited with a light of 
wavelength corresponding to the absorption maximum of the donor fluorophore and detecting 
light emitted at wavelengths centered near the emission maximum of the acceptor. The FRET 
method is particularly suitable to follow the kinetics of ligand binding, although subsequent 
rearrangements are often observed as well.  
2.2.3.12.1 Practical approach to rapid kinetic measurements 
The kinetics of interaction of hBrr2 and its mutants/fragments with adenine nucleotides 
was studied by fluorescence stopped-flow, performed in a stopped-flow apparatus (SX-
20MV). The fluorescence of mant-labeled nucleotides was excited at 290 nm by FRET from 
tryptophan residues in the proximity of the ATP biding pockets of hBrr2 and measured at 90° 
after passing a cut-off filter (KV 408). FRET was observed only when both donor and 
acceptor were present since negligible fluorescence change of tryptophan was observed when 
adenine nucleotides bound to hBrr2. Experiments were performed by rapidly mixing equal 
volumes (60 µl each) of the reactants in 20 mM HEPES pH 8.0, 150 mM NaCl and 1.5 mM 
MgCl2 and monitoring fluorescence change over time. In all cases, 1000 data points were 
acquired in logarithmic sampling mode. This mode yields reliable data since it collects an 
appropriate number of points both in the initial part of the curve (where signal changes occur 
rapidly) and at the end of the curve (where the signal changes slowly or becomes constant). 
The data was visualized using the software Pro-Data Viewer. The final curves were obtained 
by averaging 7–10 individual traces. Data were evaluated by fitting to a single exponential 
function with a characteristic time constant (kapp), amplitude (F1) and another variable for the 
final signal (F∞) according to the equation: 
 tkFFF app  exp1 , 
where F is the fluorescence at time t. Where necessary, two exponential terms were used with 
two characteristic time constants (kapp1, kapp2), amplitudes of the signal change (F1, F2) and 
another variable for the final signal (F∞) according to the equation: 




   tkFtkFFF appapp 2211 expexp   . 
Calculations and statistical analysis were performed using Prism (GraphPad software).  
2.2.3.13 Electrophoretic mobility shift assay (EMSA) 
[
32
P]-5'-end labeled RNA oligonucleotides were mixed with varying concentrations of 
protein in an appropriate binding buffer. S. cerevisiae tRNA was added, when stated, to a final 
concentration of 0.5 µg/µl, as a non-specific competitor. Reactions were incubated at 20°C for 
30 min. Samples were mixed with native gel loading buffer and fractionated on a 6% 
polyacrylamide gel (acrylamide/N,N'-methylene-bis-acrylamide ratio 29:1) in 1×TBE at 4°C. 
The gel was dried and visualized using a phosphorimager (Typhoon 8600). 
2.2.3.14 Mass spectrometry 
Mass spectrometry was used to analyze the protein fragments produced by limited 
proteolysis and the contaminants in protein preparations. The proteins/protein fragments were 
separated by SDS-PAGE and stained with Coomassie staining solution and further supplied to 
Monika Raabe, who performed the mass spectrometric analyses of the protein fragments 
(Group of Dr. Henning Urlaub; Bioanalytical Mass Spectroscopy, Max Planck Institute of 
Biophysical Chemistry, Göttingen). 
Bands of interest were excised and proteins were digested in-gel with trypsin and 
extracted as previously described by Shevchenko et al., 1996. Tryptic fragments were 
analyzed in a LC-offline MALDI-ToF/ToF-MS (4800 MALDI ToF/ToF) or in a LC-coupled 
ESI Q-ToF (QToF Ultima) and/or in an orbitrap (LTQ-Orbitrap XL) mass spectrometer under 
standard conditions. Proteins were identified by searching fragment spectra against the NCBI 
non-redundant database using Mascot as a search engine. 
2.2.4 Crystallographic methods 
2.2.4.1 Principles of X-ray crystallography 
The first protein structure models based on X-ray diffraction data were derived in the 
1950s, beginning with the structure of haemoglobin by Max Perutz and Sir John Cowdery 
Kendrew, whose pioneer work was rewarded with the Nobel Prize in Chemistry in 1962. 
Since this successful example, the crystal structure of thousands of biological molecules have 
been determined. 
The main goal in X-ray crystallography is to derive the three dimensional structure of a 
given protein, other biomacromolecules or complex based on a set of X-ray scattered 




intensities measured at different directions in space. This process can be divided in three basic 
steps and will be briefly explained as follows.   
The first step is to obtain a protein crystal. The scattering of X-rays by a single protein 
molecule is extremely weak and still not possible to detect routinely. However the periodic 
arrangement of proteins inside a crystal creates interference effects, which greatly enhance the 
intensity of the scattered X-rays in particular directions allowing them to be measured. For the 
purpose of structure determination, there are specific concerns about the quality of the crystals 
of proteins. A crystal useful for X-ray diffraction should be relatively large, in the range of 50 
µm to about 0.5 mm, with a single internal structure and no significant imperfections such as 
cracks and twinning. 
In the second step, the crystal is exposed to an intense monochromatic beam of X-rays 
generating a distribution of scattered radiation in different directions in spaces, known as the 
diffraction pattern. A detector records the snapshots of the scattered X-rays as the crystal is 
rotated. The complete pattern is then retrieved based on the measured snapshots and 
symmetry considerations.  
The third step consists of the determination of a structural model from the computational 
analysis of the diffraction pattern. Firstly, an electron density map is derived from the 
diffraction pattern. Then, the initially derived map is fitted with a structural model, which 
describes the position of every atom inside the protein. New phases are calculated and the 
structural model is refined by repeating this process iteratively until some statistical quantities 
related to the goodness of fitness achieve a certain desired value.     
The most crucial part in step 3 is the determination of the initial electron density map from 
the diffraction pattern. It relies on the knowledge of both the amplitude and phase of the 
scattered X-rays, however only amplitudes can be derived from the experimentally measured 
intensities. This lack of experimental information about the phases constitutes a fundamental 
limitation, commonly known as the phase problem of X-ray crystallography. Many methods 
exist to retrieve the phase information including experimental substructure phasing, density 
modification, direct methods and molecular replacement, which will be further explained. 
In the kinematic theory of diffraction, the amplitude and phase of the scattered X-rays in a 
particular direction in space are expressed by a complex function known as the structure 
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in which (x) is the electron density at the position determined by the vector x = (x, y, z), h is 
a vector in the reciprocal space with components (h, k, l) that represent the Miller indices and 
the integration is performed over the entire volume of the unit cell, which generates the 
crystal lattice.  
This equation expresses the structure factor as the superposition of the X-rays scattered by 
each infinitesimal volume element dV within the crystal unit cell with an amplitude that 
depends on the number of electrons and a phase angle that depends on its position inside the 
crystal and the diffraction geometry.  
Within this formalism, the structure factor is related to the electron density by a Fourier 
transform. Hence, if the structure factor is known, the electron density can be retrieved by an 
inverse Fourier transform:  
xh
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In general, an inverse Fourier transform would involve an integral like the forward Fourier 
transform, but if the object is periodic (like a crystal), it can be substituted with a summation.  
The measured intensities provide only the real part of the complex number F(h), i.e. its 
amplitude which is proportional to the square root of the intensity. Since the phase, that is the 
complex part of F(h), is unknown, the Fourier transform equation cannot be directly used to 
determine the electron density.  
Experimental phasing methods do not depend on any prior structural information about 
the protein molecule. The basis of experimental phasing lies in recording differences in 
intensity data resulting from electronic differences caused by heavy or anomalous marker 
atoms. In general, X-rays do not change their phase when scattered by atoms, only their 
amplitudes vary proportionally to the atom's electron density. However, for X-rays with 
energies in the vicinities of an absorption edge of an atom, quantum mechanical effects induce 
an additional phase shift in the scattered X-rays and modify their amplitude. This process, 
known as resonant or anomalous scattering, is mathematically represented by adding a 
complex energy/wavelength dependent term to the normal atomic scattering factor (F0): 
)(")('0  iffFFan  . 
The real term, f', is the modification in the scattering amplitude while the phase shift is given 
by the complex term, f''.  
According to Friedel's law, in the absence of anomalous scattering, centrosymmetrically 
opposed pairs of structure factors F(h) and F(-h) have exactly the same magnitude 




(|F(h)|=|F(-h)|) and conjugate phase angle (φ(h)=-φ(-h)). Therefore, the diffraction intensities 
I(h) and I(-h) are equal. The complex contribution due to anomalous scattering change both 
phase and amplitude of the structure factor, leading to differences between the paired 
intensities. As a consequence, Friedel's law no longer holds under these conditions.  
The great majority of biological molecules do not contain atoms with absorption edges at 
energies typically used for X-ray diffraction experiments. Hence, to exploit anomalous effects 
in solving the phasing problem, foreign atoms (typically heavy metals) need to be introduced 
in the protein crystal. 
Marker atom positions can be determined using Patterson analyses. Paterson maps can be 
reconstructed directly from intensities, unlike electron density maps, which require both the 
phases and the structure factor amplitudes as Fourier coefficients. The Patterson function is 
the Fourier transform of the reflection intensities and a contoured 2- or 3-dimensional 
representation of this function provides the Patterson map. A difference Patterson map 
constructed from anomalous intensity differences reveals the interatomic distances between 
anomalous marker atoms and is used for marker atom substructure solution. The difference 
data provide only the marker atom substructure and this information is enough to solve the 
phasing equations for the protein phases. Because of the centrosymmetry of the Patterson 
space, the handedness of the substructure solution is not determined. The solution can either 
be the correct substructure enantiomorph or have the wrong handedness. 
Various methods to determine the protein phases exist and are often combined. Single 
isomorphous replacement (SIR), generic single wavelength anomalous dispersion (SAD) and 
native sulfur based single wavelength anomalous dispersion (S-SAD) require the support of 
direct methods or density modification to break the inherent twofold phase ambiguity of the 
phasing equations. Direct methods exploit the deviations from random-atom structure factor 
distributions as a result of the non-random distribution of atoms in a true molecular structure. 
The non-randomness leads to implicit relations between structure factor amplitudes and phase 
relations. Density modification techniques are powerful phase improvement methods, do not 
require an atomic model and can be considered an extension of experimental phasing. 
The phase ambiguity can be also broken by adding orthogonal anomalous signal from the 
same crystal (SIRAS) or providing phases from at least a second derivative in multiple 
isomorphous replacement (MIR) or by combining both possibilities (MIRAS). Multi-
wavelength anomalous dispersion (MAD) provides orthogonal dispersive and anomalous data 
from the same crystal and the phase ambiguity can be resolved directly from the phasing 
equations. 




Another phasing method is molecular replacement (MR). The term replacement should, 
however, be interpreted in the sense of relocating and not substitution. In practice, a known 
structure model, presumed to be similar to the unknown structure with a sequence identity of 
usually 30% or higher, is rotated and translated in the unit cell or asymmetric unit the solution 
with the best fit between the calculated diffraction data from the replaced model and the 
observed data from the unknown structure is obtained. The 3-dimensional rotational and 
translational searches can be done based on Patterson search methods, 6-dimensional 
stochastic searches or modern maximum likelihood-based search functions. While the map 
reconstruction by Fourier synthesis is robust against noisy and poorly measured structure 
factor amplitudes, the phase errors strongly affect the electron density reconstruction. 
Therefore, model phases can seriously bias the resulting map towards the model when no bias 
minimization method is applied. 
2.2.4.2 General crystallography setup 
To identify initial crystallization conditions, different commercially available 
crystallization reagents were screened in 96-well MRC plates by sitting drop vapor diffusion 
technique. Drops of 200 nl (100 nl protein solution + 100 nl reservoir) were dispensed using a 
Cartesian liquid dispensing robot with 4 or 8 channels. 
Initial hits were usually refined by manual setups in a 24-well format. Commercial 
additive screens were routinely tested to improve crystallization conditions. 





 was carried out at 20ºC using the sitting drop 
vapor diffusion method. Crystals were obtained by mixing 1 μl of protein solution at 10 
mg/ml with 1 μl of reservoir solution (0.1 M sodium acetate or sodium citrate, pH 4.6 or pH 
5.0, 1.2 M sodium malonate) and optimized by microseeding and addition of a cocktail of 
additives (Silver Bullets condition 12; Hampton Research). The crystals were cryo-protected 
by transfer into a solution containing 0.1 M sodium acetate or sodium citrate, pH 4.6 or pH 
5.0, 3.0 M sodium malonate and 0.1 M sodium chloride and then flash-cooled in liquid 
nitrogen. 
Co-crystallization with nucleotides failed due to the high salt concentration required for 
hBrr2
HR
 crystallization. To soak nucleotides into the crystals, hBrr2
HR
 crystals were stabilized 
by cross-linking (Lusty, 1999) and transferred for 30 min at 20ºC into a fresh 2 μl drop 
containing a low salt soaking buffer (0.1 M sodium acetate or sodium citrate, pH 4.6 or pH 
5.0, 0.1 M sodium malonate, 10 mM MgCl2, 25 mM nucleotide). The soaked crystals were 




cryo-protected by transfer into soaking buffer plus 30% (v/v) glycerol or ethylene glycol and 
then flash-cooled in liquid nitrogen. Diffraction data were collected at beamline 14.2 of 
BESSY II (HZB, Berlin, Germany), beamline PXII of SLS (Paul Scherrer Institute, Villigen, 
Switzerland) and beamline P14 of PETRA III (DESY, Hamburg, Germany) and processed 
with XDS (Kabsch, 2010) and HKL2000 (Minor et al., 2006). 
2.2.4.4 Structure solution, model building and refinement 
The structure of hBrr2
HR,S1087L
 was solved by multiple isomorphous replacement with 
anomalous scattering (MIRAS). Samarium and tantalum derivatives were prepared by soaking 
crystals in mother liquor containing 0.3 mM samarium chloride (Hampton Research) or 5 mM 
tantalum bromide (Jena Bioscicence) for 12 h at 20ºC. Derivatized crystals were cryo-
protected by transfer into a solution containing 0.1 M sodium acetate or sodium citrate, pH 
4.6 or pH 5.0, 3.0 M sodium malonate, 0.1 M sodium chloride, and flash-cooled in liquid 
nitrogen. A bromide derivative was prepared by soaking a crystal for 1 min in cryo-buffer 
supplemented with 1 M sodium bromide and flash-cooling in liquid nitrogen. 
Samarium sites were located and initial phases were calculated using the SHELX program 
suite (Sheldrick, 2008). Initial phases were used to locate tantalum and bromide sites by 
difference Fourier analyses. MIRAS phases were calculated and refined using SHARP 
(Bricogne et al., 2003) and improved by solvent flattening with DM (Cowtan, 1994). Model 
building was done using COOT (Emsley and Cowtan, 2004; Emsley et al., 2010) and 
refinement using REFMAC5 (Vagin et al., 2004). To verify the chain tracing, a highly 
redundant data set was collected from a native crystal at 2.071 Å X-ray wavelength and used 
with combined model and experimental phases to calculate an anomalous difference Fourier 
map, which revealed the position of sulfur atoms in cysteine and methionine side chains. The 
structure of hBrr2
HR
 and nucleotide-bound structures were solved with Molrep (Vagin and 
Teplyakov, 1997) using the coordinates of the hBrr2
HR,S1087L
 structure as a search model and 
refined using REFMAC5, including TLS refinement (Winn et al., 2003), with manual model 






3.1 Expression of Prp8, Snu114 and Brr2 
Prp8, Brr2 and Snu114 form a salt-stable complex that can be detached from the U5 
snRNP (Achsel et al., 1998), suggesting that these proteins are organized as a functional unit, 
which is essential for spliceosome catalytic activation and disassembly. Prp8 is the largest and 
most highly conserved protein in the spliceosome (Fig 3.1A). Sequence and structural 
similarities between Prp8 and other protein domains indicate the presence of a putative 
bromodomain (Br) in the N-terminal region of Prp8 which is preceded by a proline rich region 
(P) and a nuclear localization signal (NLS) (Dlakić and Mushegian, 2011). Additionally, the 
N-terminus of Prp8 contains a Snu114-Cwc21-interacting domain (SCwid) (Grainger et al., 
2009). The central conserved domain of Prp8 is related to the catalytic domain of reverse 
transcriptases (RT) (Dlakić and Mushegian, 2011). The RT domain is followed by a 
functionally and structurally uncharacterized sequence region, which may be functionally 
equivalent to maturase-specific X/thumb (Th/X) domain of retroelements (Dlakić and 
Mushegian, 2011). Finally, the C-terminal domain displays RNase H-like and Jab1/MPN 
folds. The latter domains are presently the only experimentally characterized folds of Prp8 
(Pena et al., 2007, 2008; Ritchie et al., 2008; Zhang et al., 2007). 
Snu114 is a large G-protein that bears close resemblance to the eukaryotic ribosomal 
elongation factor 2 (eEF2) (Bartels et al., 2002). Aside from an N-terminal acidic domain, 
which is predicted to be intrinsically unstructured, Snu114 exhibits the same domain structure 
as eEF2, including the G-domain (Fig. 3.1B). It seems that the GTP/GDP state of Snu114 
regulates the unwindase activity of Brr2 (Small et al., 2006). Based on this finding, it has 
been suggested that Snu114 functions as a classical signalling G protein transducing signals to 
Brr2 to control spliceosome dynamics. Presently, it is not known by which mechanisms this 
regulation occurs and whether it requires direct involvement of Prp8. However, considering 
the similarity with the ribosomal translocase, it is also expect that Snu114 may additionally 
provoke translocation-like events during splicing, e.g. during restructuring of the active site 
between the two transesterification steps (Wahl et al., 2009).  
The Brr2 helicase is a U5 snRNP protein, which is stably associated with the spliceosome 
during catalytic activation and splicing catalysis. Brr2 seems to be required twice during each 





et al., 1998) and second, during spliceosome disassembly (Small et al., 2006). Sequence 
analyses indicate that Brr2 is composed of a mostly unstructured N-terminal domain followed 
by a tandem repeat of helicase cassettes. Each cassette is predicted to be comprised of dual 
RecA-like domains linked via a WH domain to a Sec63 homology unit (Pena et al., 2009). 
Due to the structural similarities shared between the Sec63 domains of Brr2 and the DNA 
helicase Hel308, it has been proposed that Brr2 consists of two expanded Hel308-like helicase 
cassettes (Zhang et al., 2009; Pena et al., 2009) (Fig. 3.1C). Only the N-terminal cassette of 
Brr2 appears to be catalytically active (Kim and Rossi, 1999) while the C-terminal cassette 
may comprise a versatile protein-protein interaction device (Liu et al., 2006; van Nues and 
Beggs, 2001). 
 
Fig 3.1: Domain arrangement of Prp8 (A), Snu114 (B) and Brr2 (C). Numbers indicate start and end amino acids 
of the human proteins. Domains are indicated as coloured boxes and labeled above the schemes. Prp8 – blue 
colors (P – proline rich region; NLS – nuclear localization signal; Br – bromodomain; SCwid – Snu114/Cwc21-
interacting domain; RT – reverse transcriptase domain; Th/X – maturase-specific X/thumb domain; RNase H – 
RNase H-like domain; Jab1/MPN – Jab1/MPN-like domain). Snu114 – green colors (G" – Snu114/eEF-2-
specific insertion in the G-domain; II-V – domains II-V; domain IV is divided in two parts, IVa and IVb). Brr2 – 
red colors (NTD – N-terminal domain; RecA – RecA-like domains; WH – winged helix domain; Sec63 – Sec63 
homology region). The two tandem cassettes of Brr2 are indicated above the scheme. The proteins are not drawn 
to scale relative to each other. Below the Prp8 and Brr2 schemes, experimental structures of domains are 





Multiple interactions have been reported among distinct domains of Prp8, Brr2 and 
Snu114 (Liu et al., 2006). The C-terminus of Prp8 was shown to interact with Brr2. 
Consistent with this finding, a Prp8 fragment encompassing the RNase H and Jab1/MPN 
domains was shown to couple the ATPase activity of Brr2 to its RNA unwinding activity and 
to stimulate Brr2 helicase activity by increasing the association rate of Brr2 with its RNA 
substrate (Pena et al., 2009; Maeder et al., 2009). The N- and C-terminal regions of Prp8 also 
seem to interact with Snu114. Supporting previous Y2H results, an intramolecular fold, 
denoted as a "Snu114-Cwc21 interacting domain" (SCwid), at the N-terminus of Prp8 has 
been identified (Grainger et al., 2009). The documented interaction network among these 
factors is consistent with the strong interaction reported among Prp8, Snu114 and Brr2 in 
native complexes (Achsel et al., 1998). 
The production of significant amounts of pure samples suitable for crystallization is one of 
the most time consuming steps during high resolution structure-based studies. Since all three 
proteins of interest are large nuclear factors, they are notoriously difficult to express in 
heterologous systems. A complex containing these three proteins can be natively purified 
from HeLa and yeast nuclei. However, the material is non-homogeneous and not amenable to 
crystallization. Therefore, for further structural and functional investigations, we set out to 
design strategies for co-expression of these three proteins.  
3.1.2 Expression of the human Prp8-Snu114-Brr2 complex 
Considering that Prp8, Snu114 and Brr2 are among the largest proteins in the 
spliceosome, which additionally may require post-translational modifications, we had to 
devise a strategy to express these U5 snRNP proteins in a eukaryotic system. Therefore, we 
established a baculovirus-based expression facility using insect cells in order to produce this 
ternary complex as well as its individual components. Since we mainly pursued the structural 
investigation of these three factors individually or as complexes by means of X-ray 
crystallography, we worked with expression-optimized synthetic genes and looked in parallel 
at orthologs from several organisms in order to optimize chances for success. 
In order to co-express the human Prp8-Snu114-Brr2 complex, we have cloned hPrp8 in a 
Donor plasmid (pIDS), hBrr2 with a C-terminal His6-tag in an Acceptor plasmid (pFL) and 
hSnu114 with a C-terminal strepII-tag in another Donor plasmid (pIDK). The plasmids 
containing the proper insert were fused by CreLox recombination. Subsequent to the Cre-
mediated fusion of Acceptor and Donor plasmids, we performed in vitro Tn7 transposition 





virus amplification was performed in Sf21 cells. Monitoring of the cell expression showed 
that hBrr2 and hSnu114 were well produced while hPrp8 was produced in only minute 
amounts (Fig. 3.2).  
 
Fig. 3.2: Production of the human ternary complex in insect cells. (A) Coomassie-stained SDS gel showing a 
time course (from 24h to 72h) of the expression of human full-length Prp8-Snu114-Brr2 complex using the 
MultiBac system. The sizes in kDa of the molecular weight marker are given on the left. The abbreviations "C" 
stands for whole cell extract and "S" – for supernatant. (B) By following the YFP fluorescence signal, which 
depends on YFP expression, we could follow heterologous protein production levels. When YFP expression 
reaches a plateau, the expression of heterologous proteins under the same promoter as YFP also typically reaches 
their peak production.  
We next tried to purify the three proteins as a complex through the His6-tag present at the 
C-terminus of hBrr2. However, only hBrr2 was efficiently bound to the Ni
2+
-NTA beads and 
could be eluted in the presence of 250 mM imidazole. We further performed size exclusion 
chromatography where hBrr2 eluted as a single, symmetric peak and migrated as a monomer 
(Fig. 3.3B). We additionally tried to purify the complex through a Strep-Tactin column taking 
advantage of the StrepII-tag present at the C-terminus of hSnu114. Unfortunately, the 
complex could not be isolated using this strategy since hSnu114 did not bind efficiently to the 
column.  
 
Fig. 3.3: Human ternary complex purification trial. (A) Coomassie-stained SDS gels showing the purification of 
full-length hBrr2, which was the only protein of the human ternary complex that could be isolated. The 
molecular weight marker is displayed on the left (sizes are in kDa); B – protein bound to Ni
2+
-NTA beads and E 
– elution from a Ni
2+
-NTA beads. (B) Chromatogram showing the migration profile of hBrr2 on a Superdex 200 





gel of a gel filtration run of hBrr2 on a Superdex 200 column.  
3.1.3 Expression of the yeast Prp8-Snu114 complex 
Our previous results indicated that hBrr2 was not stably bound to hPrp8 and hSnu114 
when co-produced in insect cells. We presently do not know if the C-terminal tags on hBrr2 
and hSnu114 might have affected the interaction among the three factors. Considering that the 
interaction between hPrp8 and hSnu114 is particularly strong and this binary complex 
remains completely intact even in the presence of high concentrations of chaotropic agents 
(0.4 M sodium thiocyanate) (Achsel et al., 1998), we have decided to test the co-production of 
yPrp8 with ySnu114 in insect cells. yPrp8 was cloned in an Acceptor plasmid (pFL) and 
ySnu114 in a Donor plasmid (pIDS) and both plasmids were again fused by Cre-lox 
recombination. We made use of a FLAG-tag in the C-terminus of Prp8 in order to purify a 
stoichiometric complex since previous results obtained with the human protein suggested that 
yPrp8 may be produced only in minor amounts. yPrp8-ySnu114 binary complex may 
subsequently be complemented with individually produced and purified yBrr2. The virus 
amplification was performed in Sf21 cells as before. The protein expression, monitored by 
SDS-PAGE at various times after infection, showed that the yPrp8-ySnu114 complex was 
expressed, although in small amounts. A large scale expression trial in High Five cells 
resulted in a clear production of the complex, although ySnu114 was produced in higher 
amounts than yPrp8 (Fig. 3.4).  
 
Fig. 3.4: Production of the yPrp8-ySnu114 complex in insect cells. (A) Coomassie-stained SDS gel showing a 
time course (from dpa to 96h; dpa – day of proliferation arrest) of the production of yeast full-length Prp8-
Snu114 complex using the MultiBac system. The molecular weight marker is displayed on the left (sizes are in 
kDa). C – whole cell extract, S – soluble supernatant. (B) YFP fluorescence signal measurements were used to 





The complex between yPrp8 and ySnu114 could be purified using Anti-FLAG beads (Fig. 
3.5A and B), albeit in very small amounts. Most of the protein complex could not be eluted 
from the beads using competing FLAG peptides or by a change in pH. Nevertheless, with the 
recovered material, we were able to test the migration of the complex on a Superdex 200 size-
exclusion column. We observed two peaks in the chromatogram, one at the void volume of 
the column containing the protein complex (Fig. 3.5C and D) and the other one at full column 
volume, containing the peptide used for elution from the antibody resin, confirmed by mass 
spectrometry analysis (data no shown). No peaks corresponding to the individual proteins 
were observed.  
 
Fig 3.5: Purification trial of the yPrp8-ySnu114 complex. (A, B) Coomassie-stained SDS gels showing the 
purification of full-length yPrp8-ySnu114 complex. The molecular weight marker is displayed on the left (sizes 
are in kDa). Cell lysate, L, was clarified by centrifugation and the resulting soluble fraction, S, was loaded on 
anti-FLAG antibody beads. The unbound sample was collected, FT, and the beads were washed (W) and further 
tested for bound proteins, B. The proteins were eluted in a single step, E. (C) Chromatogram showing the 
migration profile of yPrp8-ySnu114 complex on a Superdex 200 10/300. (D) The protein complex was purified 
on a Superdex 200 10/300 column. The peak fraction at the void volume of the column (~ 7.5 ml) corresponds to 
the protein complex which was analyzed by SDS-PAGE. 
We, therefore, concluded that these two proteins form a stable complex which can be 
purified for further investigation. However, major improvements in this system are necessary 
in order to achieve stoichiometric expression of the components which could increase the 





purify a homogenous complex suitable for crystallization by selecting proper tags and 
avoiding major loss of protein on the beads. 
3.2 Structural analysis of the Ski2-like helicase Brr2 
Our initial strategy of co-expressing Prp8, Snu114 and Brr2 as a complex failed, since we 
were unable either to isolate the human complex or purify homogeneous material in amounts 
suitable for crystallization in the case of the yeast complex. Nevertheless, we have 
successfully isolated human Brr2 during the purification trials of the human ternary complex 
(Fig. 3.3). 
The full length yeast Brr2 (ca. 250 kDa) has been previously expressed in yeast cell 
culture, but in insufficient amounts for X-ray crystallography studies. Additionally, only a 
small fragment of the yeast enzyme (the C-terminal Sec63 unit) has been expressed in E. coli 
and purified in large scale for structural studies (Zhang et al., 2009; Pena et al., 2009). 
Therefore, relying on our previous achievement in isolating hBrr2, we aimed at producing 
highly purified and homogeneous human and yeast Brr2 for further structural and functional 
investigations.  
3.2.1 Expression and purification of human and yeast Brr2 
The full-length human and yeast Brr2 were initially cloned with a C-terminal His6-tag and 
N-terminal His10-tag, respectively, in an Acceptor plasmid, pFL, and produced in large 
amounts in insect cell culture using the MultiBac system (Fig. 3.6A and B). Both proteins 
could be purified to near homogeneity using Ni
2+
-NTA affinity column followed by an anion 
exchange step. yBrr2 and hBrr2 migrated in size exclusion chromatography as monomers 
(Fig. 3.6C, D, E). The U4/U6 unwinding activities of the human and yeast enzymes were 
assessed in collaboration with Sina Mozaffari-Jovin (MPI-BPC). Human and yeast Brr2 were 
active in ATP-dependent U4/U6 duplex unwinding (Fig. 3.6F) but failed to crystallize.  
In order to remove putatively flexible regions that may hinder crystallization, we treated 
hBrr2 and yBrr2 with proteases, several of which gave rise to a stable ca. 200 kDa fragment 
(Fig. 3.7). Mass spectrometric fingerprinting and N-terminal micro-sequencing of hBrr2 
samples showed that chymotrypsin yielded a fragment whose N-terminus coincided with the 
predicted start of the first RecA domain (residue 458), while subtilisin left about 60 additional 
N-terminal residues (start residue 395). For yBrr2, elastase yielded a large fragment 
encompassing the PWI domain while the chymotrypsin fragment contained 130 residues 





in the proteolysis experiments indicate that the N-terminal extensions of human and yeast 
Brr2 may show slight structural differences. The regions encompassing the two helicase 
cassettes remained intact even upon prolonged protease treatment for both Brr2 proteins. 
 
Fig. 3.6: Production and purification of h and yBrr2. Coomassie-stained SDS gels showing expression (A and B) 
and purification (C and D) of full-length human and yeast Brr2. The molecular weight marker is shown on the 
left (sizes in kDa). Both yeast and human Brr2 were solubly expressed in insect cells and purified using Ni
2+
-
NTA affinity followed by an anion exchange and size exclusion chromatography. C – whole cell extract, S – 
supernatant. (E) As a final purification step, yeast and human proteins were loaded on a Superdex 200 16/60 size 
exclusion column. We concluded that both proteins migrated as monomers by comparison with the retention 
volume of commercial molecular weight standards. (F) Native gel analysis of U4/U6 unwinding. 0.25 nM of in 
vitro transcribed, annealed and gel-purified U4/U6 di-snRNA (U4* – [
32
P]-labeled U4 snRNA) were treated with 








We designed and screened for production a large number of fragments based on the 
proteolysis experiments. Based of their efficient production, we subsequently mainly focused 
on producing hBrr2 fragments. Furthermore, we gave priority to the human enzyme 
considering its medical relevance. We expressed and purified six truncated proteins, 
differently tagged at the N- or C-terminus, corresponding to the protease-resistant portions of 
hBrr2 (residues 395-2136; 395-2129; 458-2136 and 458-2129) with and without a short C-
terminal peptide that lacked electron density in the crystal structure of the hBrr2 Sec63 unit 
(PDB ID 2Q0Z) (Fig. 3.8).  
 
Fig. 3.7: Experimental definition of yeast and human Brr2 stable fragments. (A) Limited proteolysis of full-
length hBrr2 and (B) yBrr2. Stable, ca. 200 kDa fragments obtained with subtilisin and chymotrypsin for hBrr2 
and chymotrypsin and elastase for yBrr2 are boxed.  
 
Fig. 3.8: Coomassie-stained SDS gels showing an expression time course of the various hBrr2 constructs in 
insect cells. The molecular weight marker is shown on the left (sizes in kDa). Although all constructs were well 




with N-terminal His10 tags, were completely soluble 
and yielded high amounts of purified protein. C – whole cell extract, S – supernatant.  
While removal of the last seven residues had no effect on the helicase activity, deletion of 
the ca. 60 residues preceding the first RecA domain led to a severe drop in duplex unwinding 






Fig. 3.9: Helicase activity of hBrr2 fragments. Borders of the fragments analyzed are shown above the gel. 
Running positions of the U4/U6 duplex (U4* – U4 labeled) and U4 snRNA are indicated. 
We thus focused in further work on the hBrr
395-2129 
fragment, henceforth referred to as 




 was among the two most solubly produced 
constructs (Fig 3.8) and could be produced in large amounts in High Five cells (Fig. 3.10A). 
The MultiBac system indeed allowed us to routinely produce 10–15 mg of Brr2
HR 
per liter of 
insect cell culture. hBrr2
HR
 was purified to near homogeneity through Ni
2+
-NTA 
chromatography, followed by an anion exchange and a size exclusion step (Fig. 3.10B, C, D). 
 




(A) Coomassie-stained SDS gel showing an expression time 
course of hBrr2
HR
 in insect cells. The molecular weight marker is shown on the left (sizes in kDa). C – whole 
cell extract, S – supernatant. (B) Cell lysate, L, was clarified by centrifugation and the resulting soluble fraction, 
S, was loaded on a HisTrap FF column. The protein was eluted with a linear gradient from 10 to 250 mM 
imidazole. (C) The protein was transferred to low salt buffer and loaded on a MonoQ 10/100 GL column. 
hBrr2
HR
 was eluted with a linear 50 to 600 mM sodium chloride gradient and further purified by (D) gel 
filtration on a 26/60 Superdex 200 column. The peak fractions corresponding to the protein were analyzed by 
SDS-PAGE.  
3.2.2 Structural analysis of an active, protease-resistant portion of hBrr2 
We have obtained crystals of hBrr2
HR
 as well as of a Brr2 point mutant linked to the RP 
disease. As crystals for the mutant protein were first available and diffracted to 2.65 Å 
resolution (Fig. 3.11A), we have solved its structure by multiple isomorphous replacement 





good stereochemistry (Table 3.1). The structures of hBrr2
HR
 in the absence and presence of 
nucleotides were solved by molecular replacement. Residues 403–2125 of hBrr2
HR
 could be 
fully traced with only a few exposed loop regions exhibiting weaker than average electron 
density. Chain tracing was verified using the anomalous scattering of sulfur atoms, which 
revealed the positions of the vast majority of cysteine and methionine side chains (Fig. 3.11 
B, C). 
 
Fig. 3.11: Structural model. (A) Crystal and a diffraction image of hBrr2
HR
. (B) Anomalous difference Fourier 
map contoured at the 3σ level (golden mesh) superimposed on a Cα-trace of hBrr2
HR,S1087L
 (gray). The map was 
calculated using the anomalous differences collected on a native crystal at an X-ray wavelength of 2.071 Å and 






























The structure of hBrr2
HR
 is very compact and comprises two globular helicase cassettes 
(N-terminal: residues 463–1288; C-terminal: residues 1310–2125), which are closely 
associated with each other and bury ca. 1200 Å
2
 of combined surface area at their interface 
(Fig. 3.12). Both cassettes exhibit similar overall architectures (Cα root-mean-square 
deviation [rmsd] of 2.5 Å; Fig. 3.12), in spite of only 27% sequence identity (Fig. 3.13). 
Relative to the N-terminal cassette, the C-terminal cassette is rotated by 115° and translated 
by 63 Å within hBrr2
HR
 (Fig. 3.12). Both cassettes comprise two prototypical RecA-like 
ATPase domains followed by a winged helix (WH), a seven helix bundle (HB), a helix-loop-
helix (HLH) and an immunoglobulin-like (IG) domain (Fig. 3.12A, B). The latter three 
domains constitute the Sec63 homology region and resemble the structure of the isolated C-
terminal Sec63 units from yeast (Zhang et al., 2009; Pena et al., 2009) and human Brr2 (PDB 
ID 2Q0Z). In each cassette, two RecA domains and a HB domain form the floor and the roof, 
respectively, of a central tunnel (Fig 3.14). The second RecA domain is connected through an 
extended peptide (residues 886-896/1721-1731 in the N-/C-terminal cassette) to a WH 
domain, which constitutes one side of the tunnel and fastens the first RecA domain to the HB 
domain. On the other side, the second RecA and the HB domain approach (N-terminal 
cassette) or contact (C-terminal cassette) each other. A prominent loop of the RecA-2 domain 
extends across the tunnel entry towards a long scaffolding helix of the HB domain (Fig. 3.14). 
Equivalents of these elements have been suggested to constitute a strand separation device 
and a ratchet, respectively, in other SF2 proteins (Büttner et al., 2007). Although direct 
evidence for a ratcheting function of the HB scaffolding helix is missing, it has been shown to 
contact the substrate nucleic acid in related enzymes (Büttner et al., 2007; Weir et al., 2010). 
The HLH and IG domains lie on one flank of the HB domain, forming a similar triangular 
arrangement in both cassettes (Cα rmsd of 3.1 Å) as previously seen for the isolated C-
terminal Sec63 units from yeast (Zhang et al., 2009; Pena et al., 2009) and human Brr2 (PDB 
ID 2Q0Z). In both Sec63 units, the IG domain is wedged between the HB and HLH domains 
(Fig. 3.12), which in turn do not directly contact each other except immediately around their 
linking peptide. Our structural findings suggest that the individual Brr2 cassettes resemble the 
complete SF2 DNA helicase Hel308 (Büttner et al., 2007) expanded by an IG domain. As in 
Hel308, the circular domain arrangement in both hBrr2
HR
 cassettes leads to the clustering of 
conserved ATPase and helicase motifs, known to bind and hydrolyze nucleotide tri-






Fig. 3.12: Overall structure of hBrr2HR. (A) Top: Ribbon plot of hBrr2HR. Coloring by domains and functional elements: N-
terminal extension – pink; RecA-1 – light gray; RecA-2 – dark gray; WH – black; HB – blue; HLH – red; IG – green; linker 
– magenta; separator loop (SL) – cyan. Rotation/translation symbols below the panel indicate the relationship between the 
cassettes within hBrr2HR. Bottom: combined ribbon (N-terminal cassette) and surface plot (C-terminal cassette) showing the 
inter-cassette linker. The linker can be divided into three regions. The N-terminal part (region 1; residues 1289–1295) lies 
along a cleft between the N-terminal IG domain and the C-terminal WH domain and contacts the tip of the C-terminal RecA-
1 domain. A central triple-Pro motif (region 2; residues 1296–1298) lacks interactions with any domain, while the C-terminal 
part (region 3; residues 1299–1309) runs snugly around the C-terminal RecA-1 domain. Rotated 150° counter-clockwise as 
indicated. (B) Schematic representations of Brr2HR. Top: Domain borders. Bottom: 2D scheme of Brr2HR. Inter-cassette 






























Figure 3.13: Multiple sequence alignment of Brr2 orthologs. First block of sequences – N-terminal cassette, 
second block of sequences – C-terminal cassette. Residue numbers refer to the human Brr2 sequence. The 
cassettes have been aligned within each block and with respect to each other. The background coloring of the 
residues is according to the conservation within each cassette, darker background corresponding to a higher 
degree of conservation. Residues that are invariant across both cassettes are shown with a purple background. 
Secondary structure elements are indicated by icons and colored according to their domains (N-terminal 
extension – pink; RecA-1 – light gray, RecA-2 – dark gray, WH – black, HB – blue, HLH – red, IG – green, 
inter-cassette linker – magenta). ATPase/helicase motifs (Q and Roman numerals) are indicated below each 
block by a black line (Fairman-Williams et al., 2010). Open circles denote residues involved in inter-cassette 
contacts. Filled triangles denote point mutations investigated herein. Organisms: Homo sapiens, Mus musculus, 
Meleagris gallopavo, Xenopus tropicalis, Danio rerio, Drosophila melanogaster, Caenorhabditis elegans, 
Arabidopsis thaliana, Saccharomyces cerevisiae. 
In our hBrr2
HR
 structure, the N-terminal cassette is preceded by 60 conserved residues 
(Fig. 3.12A top) that adopt an irregular but well defined structure along conserved surfaces 
(2219 Å
2
 buried), surrounding both RecA domains and the WH domain (Fig. 3.12A top). The 
reduction in helicase activity upon deletion of this N-terminal expansion (Fig. 3.9) shows that 
it may support a productive domain orientation or contact substrate RNA. 
 
Fig. 3.14: Organization of the individual cassettes. Ribbon plots of N-terminal (left) and C-terminal (right) 
cassettes with expanded views on the domain closure and contacts between the separator loops and the ratchet 
helices. Domains and elements are colored as in Fig. 3.12. Interacting residues are shown as sticks and colored 
by atom type (carbon – as the respective structural element; nitrogen – blue; oxygen – red). Dashed lines – 
hydrogen bonds or salt bridges. 
A conserved 20 residue linker (residues 1289–1309; Fig. 3.12B) that runs along an 





the two cassettes. The linker can be divided into three regions. Its N-terminal part (region 1; 
residues 1289–1295) lies along a cleft between the N-terminal IG domain and the C-terminal 
WH domain and contacts the tip of the C-terminal RecA-1 domain. A central triple-Pro motif 
(region 2; residues 1296–1298) lacks interactions with any domain, while its C-terminal part 
(region 3; residues 1299–1309) runs snuggly around the C-terminal RecA-1 domain. 
 
Fig. 3.15: Helicase motifs and surface electrostatics. (A) Ribbon plots of both cassettes showing the location of 
the helicase motifs: Red – motifs involved in nucleotide binding and hydrolysis; blue – motifs involved in RNA 
binding; cyan – SF2-specific motifs (ratchet helix and separator loop). The view of the N-terminal cassette (top) 
is the same as in Fig. 3.12, bottom. The C-terminal cassette is shown in an identical orientation. (B) Electrostatic 
surface potential mapped at the surface of the cassettes. Blue – positive charge; red – negative charge. Black 
outlines mark the central tunnels.  
The cassette interface can be divided into two areas. The first involves the N-terminal IG 
domain fitted squarely between the second RecA domain and the WH domain of the C-
terminal cassette (Fig. 3.12, 3.16). The second involves contacts between the RecA-1 and WH 
domains of the N-terminal cassette and the RecA-2 domain of the C-terminal cassette (Fig. 
3.12, 3.16). The extensive contacts observed between the two cassettes suggest that they form 






Fig. 3.16: Inter-cassette interactions. (A) Book view onto the interacting surfaces of the N-terminal (left) and C-
terminal (right) cassettes. Domains are shown in surface representation and colored as in Fig. 3.12. Inter-cassette 
contact residues are colored in yellow. Interaction region I involves the N-terminal IG domain contacting the C-
terminal RecA-2, including the C-terminal equivalent of the separator loop, and WH domains. Interaction region 
II ensues between the N-terminal RecA-1 and WH domains and the C-terminal RecA-2 domain. Indicated views 
are relative to Fig. 3.12A, top. (B) View along the central tunnel of the C-terminal cassette with the N-terminal 
cassette as a semi-transparent outline covering part of the tunnel. The orientation of the C-terminal cassette is the 
same as the orientation of the N-terminal cassette in Fig. 3.12A, bottom. 
3.2.3 Functional analysis of the hBrr2 cassettes 
Previous genetic analyses have shown that the ATPase and helicase activities of the N-
terminal cassette of Brr2 are required for splicing, while putatively inactivating mutations 
were tolerated at the C-terminal cassette (Kim and Rossi, 1999), suggesting that the C-





have observed that both cassettes interact intimately. 
To address the ATPase and helicase activities of the individual cassettes as well as 
whether the inter-cassette interactions translate into a functional cooperation, we 
systematically screened for soluble fragments encompassing the N- or C-terminal cassette 
alone. Among 26 different constructs tested (13 encompassing the N-terminal cassette and 13 
encompassing the C-terminal cassette), only fragments 395–1324 (hBrr2
NC





N-terminal extension, N-terminal cassette and the inter-cassette linker) and 1282–2136 
(hBrr2
CC
, comprising the inter-cassette linker and the C-terminal cassette) could be solubly 
expressed and purified. All fragments that did not contain the inter-cassette linker were either 
not expressed or insoluble. Melting analyses (with proteins based on the wt sequence) showed 
that both fragments underwent cooperative unfolding with similar melting temperatures 
(44.7°C and 42.8°C, respectively) (Fig. 3.20), suggesting that both cassettes are independent 
folding units. In gel filtration analysis, no stable complex was formed between the separately 
produced and mixed cassette constructs, possibly due to the overlap in the linker element 
(data not shown). 
While hBrr2
NC
 retained ATPase and U4/U6 di-snRNA unwinding activities, hBrr2
CC
 was 
entirely inactive as an ATPase or helicase (Fig. 3.17B, C), which is consistent with some of 
its ATPase/helicase motifs deviating from the consensus (Noble and Guthrie, 1996; Oyama et 
al., 2009) and with the lack of severe phenotypes upon mutating these motifs in yBrr2 (Kim 
and Rossi, 1999). Surprisingly, hBrr2
NC
 exhibited diminished intrinsic (~0.01 ATP/hBrr2
NC
/s) 
and U4/U6-stimulated (0.30±0.05 ATP/hBrr2
NC
/s) ATPase activities compared to hBrr2
HR
 
(Fig. 3.17C). In addition, U4/U6 di-snRNA unwinding by hBrr2
NC
 was markedly reduced 
compared to the dual cassette construct, hBrr2
HR
 (Fig. 3.17C and D). hBrr2
HR 
also more 
efficiently unwound a simple model duplex with a single-stranded 3'-overhang (Fig. 3.17D) 
compared to hBrr2
NC
, showing that the stimulatory effects are not simply due to special 
sequences or structures of U4/U6 di-snRNA, but rather reflect an intrinsic organizational 
feature of hBrr2
HR
. These results show that the N-terminal cassette harbors the helicase 
activity of Brr2, while the C-terminal cassette acts as an intramolecular cofactor for this 
helicase. 
To investigate why the C-terminal cassette is inactive as an ATPase and whether it may 
nevertheless still bind ATP, we attempted to determine structures of hBrr2
HR
 in complex with 
Mg
2+
-ATP, a non-hydrolysable analog (Mg
2+
-AMPPNP) or transition state analogs (ADP-
AlFx, ADP-BeFx). Co-crystallization attempts failed due to the high salt concentrations 
required by hBrr2
HR
. To soak nucleotides into the crystals at lower ionic strength, hBrr2
HR
 
crystals were stabilized by cross-linking. Soaking of cross-linked crystals with ATP or non-
hydrolysable ATP analogs yielded the same results; nucleotides bound at both cassettes 
without significant conformational changes and in a manner incompatible with ATP 







Fig. 3.17: Activities of the individual cassettes. (A) Intrinsic (gray bars) and RNA-stimulated (black bars) 
ATPase activities of Brr2
HR
 compared to the individual cassettes. Error bars represent standard errors of the 
mean for three independent measurements. (B) Unwinding of U4/U6 di-snRNA by Brr2
HR
 and the isolated N-
terminal cassette and lack of helicase activity in the isolated C-terminal cassette. Lanes were compiled from 





towards U4/U6 and a model duplex with a single-stranded 3'-overhang. Error bars represent standard errors of 
the mean for two independent measurements. Apparent unwinding rate constants (ku) and amplitudes (A): 
hBrr2
HR
/U4/U6 – ku = 0.200±0.006 min
-1
; A = 88.9±0.6%; hBrr2
HR
/model duplex – ku = 0.118±0.006 min
-1
; A = 
85.5±1.2%; hBrr2
NC
/U4/U6 – ku = 0.087±0.016 min
-1
; A = 28.6±1.9%; hBrr2
NC
/model duplex – ku = 0.521±0.13 
min
-1
; A = 22.9±0.9%). The activity assays with hBrr2
HR




 were carried out in 
collaboration with Sina Mozaffari Jovin (MPI-BPC) using proteins provided by Karine Santos. 
Irrespective of the nucleotide employed, an ADP moiety, presumably originating from 
contamination in the nucleotide preparations, was accommodated at the N-terminal cassette 
(Fig. 3.18A). The nucleotide was bound almost exclusively by motifs from the first RecA 
domain and lacked interactions with RecA-2 required for hydrolysis (Fig. 3.18A). Unlike in 
spliceosomal DEAH/RHA helicases (Walbott et al., 2010; He et al., 2010), Q485 (Q loop) 
interacts with the N6 and N7 positions of the adenine, explaining the ATP/CTP specificity of 
hBrr2 (Laggerbauer et al., 1998). While crystal packing may have restricted conformational 
changes upon nucleotide binding, very similar non-hydrolytic binding modes were recently 
seen in Mtr4 (Weir et al., 2010) and Hjm (Oyama et al., 2009) proteins, suggesting that RNA 
binding is additionally required to elicit an active ATPase conformation in Ski2-like helicases 








Fig. 3.18: Nucleotide binding. (A) 2Fo-Fc electron density covering the entire hBrr2
HR,S1087L
 molecule (blue, 
contoured at the 1σ level) with a Cα trace in yellow. Green patches show Fo-Fc "omit" electron density 
(contoured at the 3σ level) at both cassettes upon omission of the nucleotides from the refinement. The view is 
the same as in Fig. 3.12A, top. (B and C) Close-up stereo views of the ATP pockets of the N-terminal (B) and C-
terminal (C) cassettes. Domains and elements are colored as in Fig. 3.12. Nucleotides and selected residues are 
shown as sticks and colored by atom type (carbon – as the respective structural element; nitrogen – blue; oxygen 
– red; ATP carbon – beige; phosphorus – orange). Water molecules and a Mn
2+
 ion are shown as blue and green 
spheres, respectively. Dashed lines – hydrogen bonds or salt bridges. Q and Roman numerals – helicase motifs. 
Gray mesh in (C) – anomalous difference electron density contoured at the 4σ level, indicating the position of 
the Mn
2+
 ion.  
In contrast, a Mg
2+
-ATP (or analog) complex, again selected through a Q loop (Q1332), 
was bound at the C-terminal cassette (Fig. 3.18B). Presence of a single divalent metal ion 
coordinated by the ß and γ-phosphates of the nucleotide, D1454 (motif II) of Brr2
HR





water molecule was verified by anomalous difference density in a long-wavelength data set 
collected on a crystal soaked with Mn
2+
-ATP (Fig. 3.18B). As in the N-terminal cassette, 
contacts of the RecA-2 domain to the bound nucleotide were completely lacking. However, at 
the C-terminal cassette the non-hydrolytic state is specifically stabilized via non-canonical 
residues (Fig. 3.18C). The H1690 (motif VI), which is an arginine in canonical SF2 helicases, 
may be too short to contact the ATP phosphates. The following residue, N1692, is a glycine 
or alanine in active helicases (e.g. G857 in the N-terminal cassette). N1692 engages in a 
hydrogen bond with the backbone carbonyl of G1353 (motif I) from the first RecA domain 
and thereby locks both H1690 and R1693 (motif VI) in orientations pointing away from the 
ATP phosphates, hindering the C-terminal cassette to adopt a conformation conducive to 
hydrolysis. As a further consequence, N1655 (motif V) in the second RecA domain is pushed 
away from the nucleotide sugar, which it contacts in active SF2 helicases (Fig. 3.18B). 
3.2.4 RNA binding to hBrr2 
3.2.4.1 Modelling of the RNA path through Brr2
HR
 
We next investigated whether the C-terminal cassette stimulation of the N-terminal 
helicase activity depends on direct interactions of the C-terminal cassette with RNA during 
unwinding. So far, we have failed to crystallize hBrr2
HR
 in complex with RNA. To investigate 
whether and how the C-terminal domain may contribute to RNA substrate binding, we 
modeled RNA binding at the active N-terminal cassette in analogy to nucleic acid binding by 
the related SF2 DNA helicase Hel308 (Büttner et al., 2007) and the SF2 RNA helicase Mtr4 
(Weir et al., 2010). To this end, we superimposed the Hel308-DNA structure (PDB ID 2P6R) 
onto the N-terminal cassette of Brr2
HR
, converted DNA to RNA and manually adjusted the 
nucleic acid to reduce clashes with the protein. In the model, one RNA strand is threaded 
through the central tunnel of the N-terminal cassette, with 3'-to-5' directionality, running 
across the conserved RNA-binding motifs of the RecA domains, alongside the separator loop 
and beneath the ratchet helix of the HB domain (Fig. 3.19A). The model suggested that upon 
emergence from the N-terminal tunnel, the RNA strand may either turn away from the C-
terminal cassette and exit via a positively charged surface on the N-terminal HLH domain 






Fig 3.19: Model for RNA binding and loading. (A) View along the central tunnel of the N-terminal cassette with 
a modeled RNA ligand (threaded strand – gold; complementary strand – orange). Domains and elements are 
colored as in Fig. 3.12A. Rotated 150° counter-clockwise as indicated compared to Fig. 3.12A, top. (B) Ribbon 
plot of the same model viewed as in Fig. 3.12A, top. The golden arrows indicate two possible paths of the RNA 
strand exiting the N-terminal cassette. (C) Ribbon plot of hBrr2
HR,S1087L
 colored according to the crystallographic 
temperature factors of the Cα atoms. Red – high mobility/flexibility; blue – low mobility/flexibility. Same 





putative separator loop of the C-terminal cassette (Fig. 3.19B, path 2). We resorted to a 
mutational strategy to distinguish between these alternatives. 
3.2.4.2 Design and characterization of mutant proteins 
The following mutational analyses were based on the RP33-linked S1087L variant of 
Brr2
HR
 (GenBank ID: gi|45861371) (see section 3.2.6). The effects of this mutation on Brr2
HR
 
RNA binding, ATPase and helicase activities are rather mild (Fig. 3.23). Furthermore, no 
significant conformational changes were observed compared to the hBrr2
HR
 structure (Cα 
rmsd of 0.4 Å). Additional mutations are expected to show the same trend in hBrr2
HR
 as in 
hBrr2
HR,S1087L
. We reasoned that the primary S1087L mutation would "sensitize" the protein, 
rendering the phenotypes of other mutations more easily experimentally accessible.  
All mutants used in this study were efficiently expressed, purified and migrated as a 
monomer in size exclusion chromatography (data not shown). In thermofluor-based thermal 
melting analyses, all variants exhibited cooperative transitions with comparable melting 
temperatures (Fig. 3.20). Furthermore, equilibrium CD spectra were indicative of a high 
content of regular secondary structure in all hBrr2 variants (data not shown). These data 
indicate that all hBrr2 variants tested herein were well folded and that mutant phenotypes 
were not simply a result of a loss of stable tertiary structure. 
3.2.4.3 Structure-based mutational analyses 
We mutated positively charged residues on the surface of the N-terminal HLH domain 
(RK1133-4EE) that do not directly interact with other residues from the HLH or neighboring 
domains (Fig. 3.21A). Compared to the parent enzyme, the RK1133-4EE double mutant 
exhibited enhanced intrinsic and RNA-stimulated ATPase activities while its helicase activity, 
estimated by single-point unwinding assays, was dramatically reduced (Fig. 3.21E, lane 2; 
Fig. 3.21F, lane 4). Furthermore, binding to an RNA model duplex was almost abrogated in 
the RK1133-4EE double mutant (Fig. 3.21H), supporting the idea that its dysfunction roots in 
impaired RNA binding.  
A tunnel with equivalents of a ratchet helix and a separator loop is also seen in the C-
terminal cassette (Fig. 3.14, left). However, part of the rim and the inner walls of the C-
terminal tunnel are negatively charged (Fig. 3.15B, right). In addition, the C-terminal cassette 
exhibits more extensive contacts between RecA-2 and the HB domain than the N-terminal 






Figure 3.20: DSF analyses of the hBrr2 variants used in this work. Black lines indicate the absence of Mg
2+
-
ATP while dashed lines indicate the presence of Mg
2+
-ATP in the buffer. All variants exhibited cooperative 





Furthermore, the N-terminal cassette contacts the C-terminal RecA-2, including the element 
that is the equivalent of the N-terminal cassette separator loop, as well as the neighboring 
RecA-1 and WH domains, thereby sterically blocking the entrance to the C-terminal cassette 
tunnel (Fig. 3.16B). We, therefore, predicted that the equivalent of the separator loop in the C-
terminal cassette should be dispensable for RNA duplex unwinding. Indeed, replacement of 
this loop (residues Y1668-V1677) by a single serine had essentially no effect on ATPase 
activities (Fig. 3.21E, lane 3) or RNA duplex unwinding (Fig. 3.21F, lane 5; Fig. 3.21G) and 
did not significantly affect the RNA affinity (Kd hBrr2
HR,CC-ΔSL
 – 31.0±6.3 nM; Fig. 3.21H), 
in stark contrast to the essential function of this element in the N-terminal cassette of yBrr2 
(Pena et al., 2009; Zhang et al., 2009). These findings support the idea that an unwound RNA 
strand traverses the N-terminal HLH domain, as seen for DNA in Hel308 (Büttner et al., 
2007), and is guided away from the C-terminal cassette. 
Taken together, these results suggest that RNA contacts essential for duplex unwinding 
are apparently fostered only by the N-terminal cassette, which is consistent with a lack of 
RNA binding to an isolated yBrr2 C-terminal cassette (Zhang et al., 2009). Since the 
stimulatory effect of the C-terminal cassette, therefore, seems to originate from its interaction 
with the N-terminal cassette rather than from binding of the RNA substrate, we investigated 
these inter-cassette contacts in more detail (see section 3.2.5). 
3.2.4.4 RNA loading 
As a member of the Ski2-like family of SF2 helicases, Brr2 is thought to translocate in a 
3'-to-5' direction on one of the substrate strands. However, in the U4/U6 di-snRNP, the 3'-
ends of U4 and U6 snRNA are occluded by secondary structures and/or bound proteins 
(Leung et al., 2011; Achsel et al., 1999) and are thus unavailable for Brr2 binding. Psoralen-
crosslinking of the RNA network in the minor spliceosome indicated that U4atac/U6atac stem 
1 (equivalent to U4/U6 stem I in the major spliceosome) is unwound before stem II during 
catalytic activation, implying that Brr2 translocates on U4 (U4atac) snRNA in 3'-to-5' 
direction (Frilander and Steitz, 2001). We suggest that Brr2 circumvents the sequestered 3'-
end of U4 (U4atac) snRNA by intermittent opening of its N-terminal RecA-2 and HB 
domains and loading onto the internal single-stranded U4 (U4atac) snRNA region 
immediately downstream of stem I. N-terminal cassette opening appears feasible considering 
the limited interactions between the RecA-2 and HB domains (Fig. 3.14) and in light of the 
crystallographic B-factor distribution, showing that the tip of the N-terminal RecA-2 domain 
is one of the most flexible portions of the hBrr2
HR







Fig 3.21: Mutational analysis of hBrr2
HR
. (A) Close-up view on the N-terminal HLH domain. R1133 and K1134 
comprise bona fide RNA contact sites. Gold arrow, putative path of the RNA. Image is in the same orientation as 
in Fig. 3.12A, top. (B) Contacts between the N-terminal RecA-1 and the C-terminal RecA-2 domain. Image is 
rotated 90° about the horizontal axis (top to back) compared with Fig. 3.12A, top. (C) Upper portion of the 
linker. Image is rotated 30° about the horizontal axis (top to front) compared with Fig. 3.12A bottom. (D) Lower 
portion of the linker. Image is rotated 30° about the horizontal axis (top to back) compared with Fig. 3.12A 
bottom. Mutated residues in A–D are underlined. (E) Intrinsic (gray bars) and U4/U6-stimulated (black bars) 
rates of ATP hydrolysis of the hBrr2
HR,S1087L
 variants indicated. NC, N-terminal cassette; CC, C-terminal 
cassette; CC-ΔSL, replacement of the C-terminal separator loop by a single serine. Error bars represent SEMs for 
three independent measurements. (F) Single point unwinding assays comparing the hBrr2
HR,S1087L
 variants 
indicated above the gel. Quantification (percent unwound after 50 min) is shown below the image. Lanes were 
compiled from two identically processed gels. (G) Unwinding time courses of selected hBrr2
HR,S1087L
 variants. 
Apparent unwinding rate constants (ku) and amplitudes (A): hBrr2
HR,S1087L
, ku = 0.064±0.003 min
−1







, ku = 0.062±0.003 min
−1
, A = 82.4±1.8%; hBrr2
HR,PPP1296-8AAA
, ku = 0.27±0.04 min
−1
, 
A = 73.3±2.2%; hBrr2
HR,K1544A
 , ku = 0.015±0.003 min
−1
, A = 39.3±6.5%. Error bars represent SEMs for two 
independent measurements. (H) RNA binding by the indicated hBrr2
HR,S1087L
 variants measured by fluorescence 
polarization. Error bars represent SEMs for three independent measurements. Kd hBrr2
HR,S1087L
, 28.5±3.8 nM; Kd 
hBrr2
HR,RK133-4EE
, not determined; Kd hBrr2
HR,CC-ΔSL
, 31.0±6.3 nM; Kd hBrr2
HR,K1544A
, 35.0±7.2 nM. Mutant 
labels and curves in E–H are colored according to their domains or elements (hBrr2
HR,S1087L
 reference, black). 
Data from panels E-H were acquired by Sina Mozaffari-Jovin using protein provided by Karine Santos. 
3.2.5 Inter-cassette communication 
In all nucleic acid helicases, RecA domains couple nucleotide binding, hydrolysis and 
release to nucleic acid deformation or translocation. Direct contacts of the Brr2 C-terminal 
cassette to the N-terminal RecA domains are thus obvious candidate sites for inter-cassette 
communication. To test the importance of such contacts, we introduced single alanine 
substitutions expected to weaken interactions between the N-terminal RecA-1 or WH and the 
C-terminal RecA-2 domains (R603A, R637A, K1544A, H1548A and T1578A; Fig. 3.21B).  
Residues 603 and R637 (N-terminal RecA-1) form a salt bridge with D1575 and engage in 
a bifurcated hydrogen bond with the backbone carbonyl of A1582 (C-terminal RecA-2), 
respectively (Fig. 3.21B). While mutation of either residue had little effect on the intrinsic 
ATPase, stimulated ATPase was moderately reduced (Fig. 3.21E, lanes 4 & 5) and helicase 
activity was virtually abrogated (Fig. 3.21F, lanes 6 & 7). K1544 and T1578 (C-terminal 
RecA-2) form hydrogen bonds with the side chain of N638 and with the backbone carbonyl of 
M641 (N-terminal RecA-1), respectively (Fig. 3.21B). Upon mutation to alanine, ATPase 
activities were only mildly affected (Fig. 3.21E, lanes 6 & 8), while helicase activity in 
K1544A was strongly and in T1578A slightly reduced (Fig. 3.21F, lanes 8 & 10). As an 
example, we quantified the helicase effect of the K1544A variant by recording full unwinding 
time courses. The apparent rate constant of unwinding in this mutant was reduced more than 
fourfold and the protein unwound only about half the amount of U4/U6 within 50 min 
compared to the parent enzyme (Fig. 3.21G). Finally, we also tested H1548 (C-terminal 
RecA-2) that forms a hydrogen bond with the backbone carbonyl of G908 (N-terminal WH) 
(Fig. 3.21B). The H1548A mutation showed reduced intrinsic and moderately reduced 
stimulated ATPase activities (Fig. 3.21E, lane 7), while helicase activity was again almost 
entirely lost (Fig. 3.21F, lane 9). None of the mutated residues belongs to the canonical 
ATPase/helicase motifs of either cassette, suggesting that all phenotypes are due to disturbed 
cassette interactions. Consistent with this idea, RNA binding by the K1544A mutant was 





Since the linker establishes interaction networks with both cassettes, it may serve as an 
additional tool for inter-cassette communication. To test this idea, we mutated all of its 
structural regions. Residues I1290, L1291 and P1292 (region 1) run between the N-terminal 
IG and C-terminal WH domains (Fig. 3.21C). Concomitant mutation to alanines reduced 
intrinsic as well as RNA-stimulated ATPase activities (Fig. 3.21E, lane 9) and essentially 
wiped out helicase activity (Fig. 3.21F, lane 11). We also tested a reciprocal contact of R1195 
on the N-terminal IG domain to the backbone carbonyl of P1292 in region 1 of the linker (Fig. 
3.21C). The R1195A mutant showed reduced intrinsic ATPase, with its stimulated ATPase 
almost unchanged (Fig. 3.21E, lane 10), and was severely defective in duplex unwinding (Fig. 
3.21F, lane 12). Residues L1307, P1308 and V1309 (region 3) tie the lower part of the linker 
to the C-terminal RecA-1 domain (Fig. 3.21D). Similar to the alanine substitution effects in 
region 1 and R1195, exchange of residues in region 3 for alanines increased the intrinsic 
ATPase but reduced the RNA-stimulated ATPase and helicase activities of hBrr2
HR
 (Fig. 
3.21E, lane 12; Fig. 3.21F, lane 14). Furthermore, mutation of the highly conserved proline 
motif, P1296, P1297 and P1298 (region 2), to alanines is expected to increase the flexibility in 
this part of the linker (Fig. 3.21C). In contrast to residues in regions 1 and 3, residues in 
region 2 do not directly contact the bulk of hBrr2
HR
. This mutant showed reduced intrinsic 
and RNA-stimulated ATPase activities (Fig. 3.21E, lane 11). Strikingly, its apparent 
unwinding rate constant was more than quadrupled (Fig. 3.21F, lane 13; Fig. 3.21G), showing 
that certain modulations of inter-cassette contacts may also lead to up-regulation of Brr2 
helicase activity.  
To investigate whether nucleotide binding at the C-terminal cassette influences the N-
terminal helicase, we introduced changes in the C-terminal ATP pocket of hBrr2
HR,S1087L
 
designed to interfere with nucleotide accommodation (GK1355-6QE; Fig. 3.18C). While 
ATPase activity was only mildly affected (Fig. 3.21E, lane 13), helicase activity was strongly 
reduced in this mutant (Fig. 3.21F, lane 15). 
3.2.6 Structural basis for dysfunctional hBrr2 variants 
The hBrr2
HR
 structure offers explanations for the malfunction of several previously 
investigated Brr2 alleles (Fig. 3.22). Of particular interest, a number of mutations in Brr2 
have been linked to the RP33 form of retinitis pigmentosa (Benaglio et al., 2011; Zhao et al., 
2006, 2009). One set of affected residues lies in the connection between the N-terminal RecA 
domain (R681C, R681H, V683L) and the first ß-strand of the RecA-2 domain (Y689C), 





Another set of mutations maps to the ratchet helix of the N-terminal HB domain (S1087L, 
R1090L; Fig. 3.22C, D, E) and corresponding changes in yBrr2 were detrimental to U4/U6 
unwinding and splicing (Zhao et al., 2009; Zhang et al., 2009; Pena et al., 2009). R1090 
(conserved as R1107 in yBrr2) extends from the underside of the ratchet helix (Fig. 3.22C) 
and is thus likely important for interaction with RNA (Pena et al., 2009). Considering that 
S1087 is an asparagine in yBrr2 (N1104), we directly tested the consequences of a leucine at 
this position in the disease-relevant human protein. hBrr2
HR,S1087L
 exhibited decreased RNA 
binding and reduced ATPase and helicase activities as compared to the wild type (wt) variant, 
Brr2
HR 
(Fig. 3.23).  
 
Fig. 3.22: RP33-linked hBrr2 mutations. (A-E) Ribbon plots showing details of the environments of the RP33-
linked hBrr2 residues with coloring as in Fig. 3.12. Dashed lines – hydrogen bonds or salt bridges. Affected 
residues are underlined. The semi-transparent golden arrow in (C) indicates the modeled RNA path. In (D) and 




 is shown, respectively. Views relative to Fig. 
3.12, top: (A) 60° clockwise about the vertical axis; (B) 90° clockwise about the vertical axis; (C) unchanged; (D 
and E) 90° about the horizontal axis (top to back).  
The crystal structure of hBrr2
HR,S1087L
 at 2.65 Å resolution revealed no significant 
conformational changes compared to hBrr2
HR
 (Cα rmsd 0.4 Å) except that a leucine at 
position 1087 interacts more intimately with a neighboring hydrophobic/aromatic cluster on 
the HB domain (Fig. 3.22D, E). Additionally, only a serine, instead of a leucine, could foster 
hydrogen bonding interactions to bound RNA. Therefore, S1087L abrogates functionally 





helix of the HB domain, which have been postulated in related DEAH/RHA helicases as a 
means to drag RNA across the separator loop (Walbott et al., 2010). 
In addition to the above disease-related mutations, our hBrr2
HR 
structure also offers 
explanations for the malfunction of several other Brr2 mutants that have been investigated in 
the past. Previously reported yBrr2 variants with mutations in helicase motifs I 
(G526D/K527N) and II (D634G) in the N-terminal cassette did not support yeast viability, 
U4/U6 di-snRNA unwinding or yBrr2 ATPase activity (Kim and Rossi, 1999). The equivalent 
residues in other helicases are known to be involved in nucleotide binding and hydrolysis. As 
expected, the corresponding residues in hBrr2 (G508, K509 and D615) line the ATP pocket of 
the N-terminal cassette and contact the nucleotide phosphates (G508, K509) or are expected 
to coordinate a metal ion (D615) upon productive accommodation of ATP (Fig. 3.18B). 
 





measured by fluorescence polarization. Error bars represent standard errors of the mean for three independent 
measurements. Kd hBrr2
HR
 – 12.2±2.0 nM; Kd hBrr2
HR,S1087L
 – 28.5±3.8 nM. (B) Intrinsic (gray bars) and RNA-




. Error bars represent standard 





. Quantification (% unwound after 50 min) at the bottom. Lanes were compiled from two 




. Apparent unwinding rate 
constants (ku) and amplitudes (A): hBrr2
HR
 – ku = 0.200±0.006 min
-1
; A = 89.0±0.6%; hBrr2
HR,S1087L
 – ku = 
0.064±0.003 min
-1
; A = 73.0±1.2%. Data acquired by Sina Mozaffari-Jovin using proteins produced by Karine 
Santos.  
The yeast brr2-1 allele directs the exchange of E610 in yBrr2 for a glycine leading to 





the excised intron and to dissociate snRNAs during spliceosome disassembly (Small et al., 
2006). The equivalent E591 of hBrr2 lies at the center of motif Ic (Fig. 3.24A), which has 
been seen to interact with nucleic acids in other SF2 helicases (Büttner et al., 2007; Sengoku 
et al., 2006; Weir et al., 2010). Consistently, in the present structure, E591 is exposed on the 
inner surface of the presumed RNA-binding tunnel across from the ratchet helix (Fig. 3.24A). 
It also interacts with the neighboring R624, thus positioning this residue for RNA binding and 
contributing to the stability of the first RecA domain (Fig. 3.24A). 
The E909K exchange in yBrr2 led to a block of pre-mRNA splicing before the first 
catalytic step (Xu et al., 1996). The affected glutamate (E890 in hBrr2) is positioned in a 
peptide linking the RecA-2 and WH domains of the N-terminal cassette and stabilizes the 
domain arrangement by interacting concomitantly with the side chains of N657 (second RecA 
domain), R928 and Y936 (WH domain; Fig. 3.24B). 
 
Fig. 3.24: Brr2 variants. (A and B) Structural contexts of Brr2 residues in the N-terminal cassette, which, upon 
mutation, give rise to a dysfunctional enzyme. The bulk of hBrr2
HR
 is shown as a semi-transparent ribbon with 
domains and elements colored as in Fig. 3.12. In (A), the modeled RNA path is indicated by a semi-transparent, 
golden arrow. Selected residues are shown as sticks and colored according to atom type (carbon – as the 
respective structural element; nitrogen – blue; oxygen – red). Dashed lines indicate hydrogen bonds or salt 
bridges. Mutated residues are underlined. Views relative to Fig. 3.12, top: (A) 90° about the horizontal axis (top 
to front); (B) 90° counter-clockwise about the vertical axis. 
3.3 Interaction of hBrr2 with nucleotides in solution 
To obtain an estimate for the affinity of hBrr2 to nucleotides and, specifically, to 
investigate if N- and C-terminal cassettes bind nucleotides with different affinities, we 
performed interaction studies with ADP and with a non-hydrolysable ATP analog, ATPγS. 
Although the intrinsic ATPase activity of hBrr2
HR
 is low, by using ATPγS we intended to 
avoid any degree of conversion of ATP to ADP during the experiments. All data was acquired 





Interactions of nucleotides with hBrr2 were studied using FRET from tryptophan residues 
located in the vicinity of the nucleotide binding pockets of hBrr2 to the mant group of mant-
ATPγS or mant-ADP. It has been shown for many GTPases that nucleotide binding and 
nucleotide exchange reactions are not perturbed by the mant group (Jameson and Eccleston, 
1997; Pittman et al., 2006). 
Control experiments showed that FRET signals were observed only when donor 
(tryptophan residues) and acceptor (mant group) were simultaneously present (Fig. 3.25). 














 were mixed with unlabeled nucleotides or buffer lacking nucleotides (Fig. 3.25). 
 






. Upon mixing in a stopped flow apparatus 
nucleotide-free hBrr2
HR
 or fragments thereof (0.2 µM) with mant-ATPγS or unlabeled ATPγS (5 µM), the 
emitted fluorescence of mant group (acceptor) is recorded as a function of time. In the absence of the 
fluorescence acceptor, no signal change was observed. 
To determine association rate constants, a fixed concentration of nucleotide-free hBrr2 or 
fragments thereof was mixed with varying concentrations of mant-nucleotides. The data were 
analyzed by exponential fitting to determine the apparent rate constant (kapp) value for each 
titration point (Fig. 3.26). 
hBrr2
NC 
titrations curves were fit with a double-exponential equation (Fig. 3.27), resulting 
in apparent rate constants kappNCa, corresponding to a very rapid phase, and kappNCb, associated 
with a second, rapid phase. Nevertheless, due to the fact that this very fast phase (represented 
by kappNCa) results in a very small amplitude change, we only considered the apparent rate 
constant of the rapid phase (kappNCb), which contributes most of the fluorescence signal 
change. The time courses obtained with hBrr2
CC
 were fit using a single-exponential equation 





 time courses were best described by double-





were similar to the apparent rate constants obtained for the individual cassettes. It is important 





) showed a third, very rapid phase, which we could not fit due to the 
very small fluorescence change (amplitude) associated with this phase. Henceforth, we refer 
to kappNC as a fast apparent rate constant corresponding to the ATP/ADP binding velocity to 
the N-terminal cassette, while kappCC is the constant that describes the apparent velocity of 
nucleotide binding to the C-terminal cassette.  
 
Fig. 3.26: Time courses of nucleotide binding at increasing concentrations of mant-ATPγS (A) and mant-ADP 








(top to bottom). Dissociation of hBrr2·mant-ATPγS 
(C) and hBrr2·mant-ADP (D) complexes upon mixing with unlabeled nucleotides (colored traces). Gray traces 
represent the decrease in FRET related to the dissociation of protein·mant-nucleotide by dilution in buffer. For 
each row of graphs, a different protein fragment (indicated) was used to perform nucleotide binding and 







·mant-nucleotide with buffer either reflects the dissociation of the mant-





The apparent rate constants obtained from the single- and double- exponential fittings 
were plotted as a function of the nucleotide concentration (Fig. 3.27). 
In the case of hBrr2
NC
, the concentration dependence of kappNCb deviated from a linear 
behavior. Instead, the kappNCb values tended to saturation at high nucleotide concentration, 
showing a hyperbolic dependency. Such concentration dependency could indicate that the 
fluorescence change observed is a monomolecular rearrangement, rather than a bimolecular 
binding reaction, and would be consistent with a two-step binding mechanism (Fig. 3.27A): 
hBrr2
NC
 + ATPS ⇌ hBrr2NC·ATPS ⇌ hBrr2NC·ATPS*. 
In this case, the first bimolecular reaction: 
hBrr2
NC
 + ATPS ⇌ hBrr2NC·ATPS, 
is too fast to be measured or does not result in an appreciable fluorescence change, whereas 
the first-order reaction (the rearrangement corresponding to the second step): 
hBrr2
NC
·ATPS ⇌ hBrr2NC·ATPS*, 
results in an increase of fluorescence intensity with velocity corresponding to kappNCb. Such 
accommodation step observed for hBrr2
NC
 is not observed for hBrr2
CC
 although nucleotides 
bound to the N and C-terminal cassettes in Brr2
HR
 structure assume similar conformations, i.e. 
nucleotide binding is mainly fostered by motifs from the first RecA domain lacking 
interactions with RecA-2 (Fig. 3.18B and C).  
According to kappNCa, kappNCb and to the proposed model, we assume that binding of 
nucleotide to hBrr2 is significantly faster than the following rearrangement. In this case, we 
imply that the first step is rapid compared to the second step and, therefore, the equilibrium 
dissociation constant for the first step, KSNC, can be calculated from the nucleotide 












 (Fig. 3.27). 
From the same equation, we can also obtain the forward and reverse rates of nucleotide 
accommodation, kNCb and k–NCb. The equilibrium dissociation constant of the second step 
represented by nucleotide accommodation, K2'NC, was calculated as a ratio between forward 
and reverse rates, k–NCb/kNCb. The overall dissociation constant Kd for ADP and ATP could not 
be derived from the amplitude dependencies on nucleotide concentration. Therefore, the 
global Kd for the N-cassette interaction with nucleotides was then calculated using the 





(KSNC) were 6.17±1.83 and 5.74±2.0 µM and for the second step (K2'NC) were 0.50±0.05 and 
0.22±0.1 for ATPγS and ADP respectively. Furthermore, these data indicate that the second 
step greatly contributes to the overall affinity for the nucleotides. Altogether, our structural 
and biochemical data suggest that, during the second step of nucleotide binding, cooperative 




Differently from the isolated cassette construct, hBrr2
NC
, kappNC of nucleotide binding to 
hBrr2 variants containing the C-terminal cassette were linearly dependent on the nucleotide 
 
Fig. 3.27: (A) A two-step model illustrating ATP binding to hBrr2
NC 
(first step, kNCa) and the subsequent 
accommodation (second step, kNCb) (top) and a model depicting ATP binding to hBrr2
CC 
(bottom). Concentration 
dependency of the apparent rate constants for mant-ATPγS (B) and mant-ADP (D) binding to the N-terminal 




 (blue) and hBrr2
NC 
(green). Concentration dependency of 









 (blue) and hBrr2
CC 
(orange). Error bars represent standard errors of the 
mean.  
concentration, consistent with a single bimolecular event and indicating an influence of the C-
terminal cassette on nucleotide binding by the N-terminal cassette. Furthermore, the measured 
apparent rate constants corresponding to kappCC of hBrr2
CC





 also depended linearly as a function of the nucleotide concentration. 
The association rate constants, kNC and kCC, were determined from the slope of the linear 
dependence of kapp on the concentration of mant-nucleotides. The intercept with the y-axis 
provided k–NC and k–CC. When the intercept with the y-axis was close to zero, the value of k–NC 
and k–CC could not be determined with precision therefore dissociation experiments were 
conducted. 
The slope of the linear fitting of kappNC, corresponding to the binding of ATPγS to the N-




, indicated association rate 




, respectively. These rates, with 
the possible exception of kNC for hBrr2, are similar to the ones obtained for ADP binding to 









 rate constants for ATPγS binding to the C-terminal 




. We could observe that ADP binding to 




 was faster compared to ATPγS, 




. This observation is in perfect 
agreement with the kCC obtained for ATPγS and ADP binding to the isolated hBrr2
CC
, 




, respectively. The linear concentration dependency of the 
kapps is consistent with a bimolecular binding reaction, that, in the case of hBrr2
CC
, could be 
represented as follows: 
hBrr2
CC
 + ATPS ⇌ hBrr2CC·ATPS. 
Unfortunately, we still cannot propose a full mechanism for nucleotide turnover for hBrr2 
or hBrr2
HR
. Apart from the difficulties involved in resolving the very rapid phase observed in 
the reactions with hBrr2 or hBrr2
HR
, we presently do not know if nucleotide pre-bound to the 
C-terminal cassette could influence the velocity of nucleotide exchange or modulate 
nucleotide preference of the N-terminal cassette.  
Nucleotide dissociation rate constants, k–NC and k–CC, were determined upon mixing 
hBrr2·mant-ATPγS or hBrr2·mant-ADP with an excess of the respective unlabeled 
nucleotide. The release of the labeled nucleotide from hBrr2 resulted in fluorescence 





rate constant of mant-ATPγS or mant-ADP from hBrr2, since, in the presence of a large 
excess of unlabeled nucleotide, rebinding of labeled nucleotide is negligible. Upon dilution of 
hBrr2
NC
·mant-nucleotide with buffer, some mant-nucleotide dissociated. However, this 
dissociation impelled by the dilution did not occur to the same extent as in the presence of the 
dark nucleotide competitor (Fig. 3.26). Although we lack a complete description of the 
nucleotide binding mechanism to the N-terminal cassette, the observation of a single 
dissociation step for hBrr2
NC
 may suggest that this step is rate limiting in nucleotide turnover. 
However, we cannot exclude other reactions occurring upstream of the pathway to be slower, 
i.e. phosphate release. 
The hBrr2
NC 
dissociation rates (k–NC) for ATPγS and ADP were 1.62±0.016 and 1.89±0.1 
s
-1
. ATPγS and ADP dissociation rates for hBrr2
CC
 (k–CC) were about 0.0020±0.0002 s
-1
, 
extremely slow compared to k–NC. Two phases could be distinguished during nucleotide 




. The first phase is represented by a fast 
dissociation rate constant comparable to that for the N-terminal cassette, k–NC. The nucleotide 





were very similar, 1.40±0.04 s
-1 
for ATPγS and 1.37±0.02 s
-1 
for ADP, respectively. The 
second phase had a dissociation rate constant similar to the one associated with the very slow 
release of nucleotide from hBrr2
CC
, k–CC. Nucleotide release from the C-terminal cassette in 




 was very slow, about 0.0020±0.0002 s
-1
. 







 were calculated from the association (kNC, kcc) and dissociation rate constants (k–NC 
and k–CC), using either k–NC/kNC or k–CC/kCC. The Kd’s for the Brr2
NC
·nucleotide complexes 
were 3.08±0.55 µM and 1.26±0.18 µM for ATPγS and ADP, respectively, while the Kd's for 




were about 0.50±0.07 µM for both nucleotides. This indicates that, in the absence of the C-
terminal cassette, the N-terminal cassette exhibits lower affinities for nucleotides. The Kd's of 
the C-terminal cassette·nucleotide complexes are similar for all Brr2 variants measured, about 
0.01±0.001 µM.  
The results described above show that binding of ATPγS and ADP to the N-terminal 
cassette is faster compared to the velocity of nucleotide association with the C-terminal 
cassette. The same trend is observed for nucleotide dissociation; ATPγS and ADP release 
from the N-terminal cassette is much faster for the N-terminal cassette compared to the C-
terminal cassette. On the other hand, the differences in the mechanism of nucleotide binding 





conformational constrains in the active domain of Brr2 that are released by covalent and 
surface contacts with the C-terminal cassette. In the absence of the C-terminal cassette, the N-
terminal cassette seems to rearrange before achieving a kinetically stable complex with 
adenosine nucleotides. In the presence of the C-terminal cassette, it is possible that the N-
terminal cassette may be already conformationally oriented to accept the nucleotide in a stable 
manner. These solution studies also verified our structural finding that the inactive C-terminal 
cassette binds nucleotides, with a Kd that suggests it will be saturated at cellular 
concentrations. 
The extremely slow nucleotide dissociation from the C-terminal cassette reflects its higher 
affinity for ATPγS or ADP. Considering the slow nucleotide release from the C-terminal 
cassette and the high concentration of ATP in the nucleus compared to ADP, we suggest that 
ATP is stably bound to the C-terminal cassette throughout a whole splicing cycle. This 
scenario may be tuned by other proteins, interacting with Brr2 in the spliceosome, functioning 
as adenine nucleotide exchange factors for Brr2.  
 
Table 3.2: Rate constants and equilibrium dissociation constants of interactions between 
hBrr2 or fragments thereof and nucleotides. 








































We have established the expression of yeast and human Prp8, Snu114 and Brr2 using 
synthetic, expression-optimized genes and the MultiBac system. We could co-express and co-
purify a complex of full-length yPrp8 and ySnu114. Additionally, we were able to 
reproducibly express in large amounts and purify full length Brr2 from both organisms as well 
as truncations thereof. Notably, using limited proteolysis, we have defined a stable 200 kDa 
portion of hBrr2 comprising both helicase cassettes. This fragment yielded crystals that 
diffracted to beyond 2.7 Å resolution. 
We have solved the crystal structure of the entire human Brr2 helicase region, clarifying 
how two helicase cassettes interact and are arranged with respect to each other in a tandem 
SF2 enzyme. We also provide a structure of the RP33-linked S1087L variant of Brr2
HR
 
which, along with the wild type structure, offers possible explanations for the dysfunction of 
this Brr2 mutant as well as other Brr2 variants that have been investigated in the past. 
Furthermore, our work revealed the mode of binding of adenine nucleotides as well as 
nucleotide preferences of both cassettes. 
Guided by these structures, we have interrogated which structural elements and 
organizational aspects are fundamental for the enzyme mechanism using mutational analyses. 
The results allowed speculation about novel regulatory principles underlying Brr2 function. 
We have also performed pre-steady state kinetic studies to understand how ATP binds to the 
two different nucleotide binding pockets of hBrr2. While our work still does not clarify all the 
details of the Brr2 helicase mechanism and of the precise roles of this enzyme during pre-
mRNA splicing, we have provided a solid framework on which to interpret mechanistic 
studies. 
4.1 Brr2 structure as a tandem repeat of two expanded 
Hel308 modules 
Our structural studies show that Brr2 consists of two consecutive Hel308-like modules 
expanded by IG domains. The structures of other Ski2-type helicases, Hjm (a DNA helicase 
that binds fork-related Y-structured DNAs unwinding their double stranded regions) and Mtr4 
(a RNA helicase working as an auxiliary factor of the exosome), as well as of Prp43 (a DEAH 





architecture as Hel308 (Walbott et al., 2010; Weir et al., 2010; Oyama et al., 2009). 
Interestingly, the sequence similarities to Hel308 beyond the RecA domains of Hjm, Mtr4, 
Prp43 and Brr2 were not previously recognized. It seems that the Hel308 domain organization 
is a common architecture used by both Ski2-like and DEAH helicases and raises the 
possibility that these helicases may share structural and potentially mechanistic similarities in 
regions beyond their helicase domains.  
The tandem RecA domains of nucleic acid helicases bear conserved sequence motifs to 
bind and hydrolyze nucleotide triphosphates (Q, I and II in the first RecA domain; VI in the 
second RecA domain), to bind nucleic acids (Ia, Ib and Ic in the first RecA domain; IV, IVa, 
V and Vb in the second RecA domain) and to coordinate nucleic acid and nucleotide binding 
(III in the  first RecA domain; Va in the second RecA domain) (Jankowsky, 2011). 
Corresponding motifs could also be located in both cassettes of hBrr2. Due to the circular 
arrangement of the RecA, WH and HB domains in both hBrr2
HR
 cassettes, the helicase motifs 
of the RecA domains are proximal to each other and form bona fide substrate binding sites 
(Fig. 3.15) unlike in many other helicase apo structures (Jankowsky and Fairman, 2007).  
Apart from the conserved RecA-like catalytic modules, nucleic acid unwindases 
frequently harbor accessory domains that influence catalytic activities or mediate interaction 
with other factors. Upon sequence and structural analysis, it was shown that Brr2 
encompasses helicase-associated Sec63 units. Previous mutagenesis studies suggested that the 
N-terminal RecA-like domains and the HB domain of the N-terminal Sec63 unit form a 
functional entity and that this architecture serves to integrate a ratcheting device on the Sec63 
unit (HB) with the catalytic RecA-like domains (Pena et al., 2009; Zhang et al., 2009), 
thereby coupling the ATPase activity to nucleic acid translocation. The overall similarity to 
Hel308, including the presence of a ratchet in the HB and the WH as a connecting element 
between RecA domains and HB, may suggest that Brr2 can processively plow through 
extended RNA duplexes. This potential processivity is attractive, considering that Brr2 needs 
to unwind U4/U6, which contains long stem regions and is highly stable in yeast (Brow and 
Guthrie, 1988). However, there is presently no direct evidence showing that Brr2 is a 
processive helicase.  
Brr2 additionally contains 60 conserved residues preceding the first RecA domain that 
tightly encircle the N-terminal cassette (Fig. 3.12). The reduction in helicase activity observed 
upon deletion of this N-terminal expansion suggests that it supports a productive domain 
organization or may be involved in substrate binding. Differently structured and positioned N-





Prp43 (Walbott et al., 2010). In Mtr4, a 60-residue extension N-terminal to RecA-1 folds into 
a long β-hairpin loop. This N-terminal β-hairpin packs with its β-strands against the first 
RecA and latches onto the second RecA. Thus, the active conformation of the two RecA 
domains in Mtr4 seems to be stabilized by intramolecular interactions via the N-terminal β-
hairpin on one side and by contacts between the HB and the RecA domains on the opposite 
side. The N-terminal extension of Prp43 consists of 94 residues encompassing three α-helices. 
Helix 1 packs between the WH and HB domains whereas helices 2 and 3 interact with RecA-
1. These helices are separated by an ordered 20 residue linker that braces the helicase ring 
structure, apparently once more supporting a productive domain conformation. Thus, although 
these N-terminal extensions are poorly conserved and may vary considerably in length 
between yeast and human proteins, they seem to serve similar functions. Topologically, the 
N-terminal extension at the N-terminal cassette of Brr2 is equivalent to the inter-cassette 
linker at the C-terminal cassette. The extensive interaction of the linker with the C-terminal 
cassette and its lack of exposed loops explain why it was not cut during limited proteolysis. 
Both cassettes of Brr2 interact through an extensive interface (Fig. 3.16). The N-terminal 
IG domain is fitted squarely between the C-terminal RecA-2 and WH domains. An additional 
inter-cassette contact area ensues between the N-terminal RecA-1 and WH domains and the 
C-terminal RecA-2 domain. This intimate cassette interaction is likely a hallmark of all Brr2 
enzymes and functionally important, considering that the majority of interacting side chains 
are conserved among Brr2 orthologs (Fig 3.13). Additionally, it explains why deletion of the 
C-terminal cassette or RecA and WH domains is detrimental to the overall stability of yBrr2 
in vivo (Zhang et al., 2009). 
4.2 RNA binding by Brr2 
In SF2 helicases, nucleic acid substrates preferentially bind with a 3'-to-5' directionality 
across the first and second RecA like domains, which could explain the 3'-to-5' unwinding 
directionality commonly observed with these enzymes (Hopfner and Michaelis, 2007). 
Particularly, a 3'-to-5' translocation has been experimentally confirmed for Hel308 (Guy and 
Bolt, 2005), Mer3/HFM1 (Nakagawa and Kolodner, 2002) and Mtr4 (Bernstein et al., 2008), 
which are all members of the Ski2-like subfamily to which Brr2 belongs (Bleichert and 
Baserga, 2007; Jankowsky, 2011). Therefore, Brr2 is also expected to translocate in the 3'-to-
5' direction on its nucleic acid substrates. This mode of engaging the RNA fits our current 
model of how Brr2 accommodates its substrate (Fig. 3.19), which is further supported by 





seen in the related Ski2-like helicase Mtr4 (Weir et al., 2010). Second, the entrance and walls 
of the N-terminal tunnel are positively charged, suitable for interaction with the negatively 
charged RNA backbone (Fig. 3.15). Third, defective Hel308-like RNA binding at the N-
terminal cassette can explain the loss of activities in several characterized Brr2 variants (Fig. 
3.12. Fourth, a Hel308-like mode of RNA binding at the N-terminal cassette could also 




In the context of the spliceosome, Brr2 has been suggested to translocate on U4 during 
catalytic activation (Frilander and Steitz, 2001). However, the 3'-end of U4 is occluded by 
secondary structures and/or bound proteins in the U4/U6 di-snRNA (Achsel et al., 1999; 
Leung et al., 2011). In agreement with the general trend for SF2 helicases, the hBrr2
HR
 
structure suggests that the enzyme could possibly load onto an internal single-stranded region 
of U4 downstream of stem I by opening the N-terminal cassette between the RecA-2 and HB 
domains.  
Consistent with our modeling exercise and mutational analyses, recent data demonstrated 
that only the N-terminal cassette of Brr2 form RNA interactions and that Brr2 initiates U4/U6 
disruption by translocating on U4 and unwinding U4/U6 stem I (Hahn et al., 2012). 
Additionally, Brr2 was shown to specifically bind to the single-stranded region of U4 
preceding U4/U6 stem I supporting our structural findings. This same region on U4 is 
recognized by the RNase H domain of Prp8, indicating that the RNase H domain interferes 
with U4/U6 unwinding by blocking Brr2's interaction with U4 snRNA (Mozaffari-Jovin et al., 
2012).   
4.3 The C-terminal cassette as an intramolecular cofactor  
Brr2 is one of the few known helicases (together with Slh1 (Martegani et al., 1997) and 
ASCC3 (Dango et al., 2011)) that contain two helicase-like modules. The function of the 
second helicase-like module has long been elusive and intriguing. The C-terminal cassette 
displays several substantial deviations in the canonical helicase motifs. The glutamate of the 
typical motif II, DExD/H, is replaced with an aspartate (DDAH) in the C-terminal cassette 
yBrr2. This glutamate has been postulated to be the key catalytic residue that activates a water 
molecule to hydrolyze NTP in DExD/H-box proteins and other helicases (Cordin et al., 2006; 
Sengoku et al., 2006; Caruthers and McKay, 2002). Likewise, the Ser-Ala-Thr (SAT) residues 
in motif III are replaced with SNC or SSS in the case of yeast and human sequences, 





the two RecA domains upon ATP and RNA binding and to play a role during unwinding by 
DExD/H-box proteins (Sengoku et al., 2006; Zhang et al., 2009). The C-terminal cassette also 
lacks obvious motifs IVa and V.  
Most enzyme families contain inactive members thought to have arisen by gene 
duplication events followed by subsequent accumulation of inactivating mutations. 
Evolutionary conservation suggests that such pseudoenzymes are functionally important. 
However, in most cases, their functions are unknown (Adrain and Freeman, 2012). During 
this work, we have shown that the C-terminal cassette of Brr2 is a pseudo-helicase that has 
been converted into an intramolecular regulator of a neighboring, similarly structured active 
helicase. This non-enzymatic role of the C-terminal cassette is in agreement with its non-
canonical ATPase and helicase motifs (Noble and Guthrie, 1996; Lauber et al., 1996) and 
with previous genetics analyses showing that mutations in putative active site residues of the 
C-terminal cassette still support splicing (Kim and Rossi, 1999). However, our results 
additionally show that the C-terminal cassette can still bind ATP but specifically lost its 
ability to hydrolyze the nucleotide. Furthermore, we have been able to show that, apart from 
the substantial deviations in the canonical helicase motifs, the C-terminal cassette exhibits an 
increased barrier to adopt a hydrolytic conformation which seems to further consolidate the 
inactivity of this cassette. 
Our modeling studies corroborated by mutational analyses suggest that the C-terminal 
cassette most likely also does not bind RNA during duplex unwinding. Our findings are 
consistent with recent results from (Hahn et al., 2012). In agreement with this finding, the C-
terminal cassette does not seem to rely on specific sequences or structures of its RNA 
substrate to modulate the N-terminal cassette activity since such stimulatory effect due to the 
presence of the C-terminal cassette was not only observed with U4/U6 di-snRNA as a 
substrate but also with a simple model duplex (Fig. 3.17).  
Furthermore, our results identify a number of features that are required for the cofactor 
function of the C-terminal cassette and suggest mechanisms by which it may act. Our 
mutational studies show that direct inter-cassette contacts are essential for cassette 
communication. Due to their large contact area, the cassettes most likely mutually stabilize 
the specific conformational states they adopt in the apo form of hBrr2
HR
. We suggest that 
crystal crosslinking has cemented these conformations considering that we do not observe any 
significant conformational changes in the nucleotide-bound states. Our nucleotide 
preparations obviously contained both ATP (or analog) and ADP. The outcome of our 





conformations in the apo form (ADP at the N-terminal cassette, Mg
2+
-ATP at the C-terminal 
cassette). Bound ADP suggests that we observed the post-ATP hydrolysis and post-phosphate 
release state at the N-terminal cassette in agreement with the enhanced N-terminal ATPase 
activity in the presence of the C-terminal cassette. Thus, the C-terminal cassette may drive 
ATP hydrolysis and/or phosphate release at the N-terminal cassette, thereby facilitating 
associated changes in nucleic acid binding and unwinding. 
Our structural analyses show that the C-terminal cassette preferentially binds Mg
2+
-ATP 
in the presence of the N-terminal cassette, but we did not indicate whether it cycles between 
nucleotide-bound and free states during RNA unwinding. However, our preliminary pre-
steady state kinetic studies on nucleotide binding to hBrr2 indicated that nucleotide release 
from the C-terminal cassette binding pocket is very slow suggesting that ATP is stably bound 
to the C-terminal cassette when Brr2 is not in the presence of RNA. Since the adoption of the 
hydrolytic conformation is hindered at the C-terminal cassette, it seems to be 
conformationally more restricted than the N-terminal cassette and may remain stably 
associated with the nucleotide. The function of the nucleotide at the C-terminal cassette may 
thus be to rigidify its structure and allow it to act as a scaffold on which the N-terminal 
cassette could efficiently undergo conformational changes required for duplex unwinding.  
The C-terminal cassette may also exploit inter-cassette contacts to directly influence the 
positioning of active site domains in the N-terminal cassette. Interactions between the HLH 
and HB domains are important for duplex unwinding in the related Hel308 (Richards et al., 
2008; Woodman et al., 2007). In Brr2, the N-terminal IG domain intervenes between the 
HLH and HB domains and is connected to the upper part of the inter-cassette linker. 
Mutations in the linker affected Brr2
HR
 activity both negatively and positively (Fig. 3.21). It is 
conceivable that different functional states (such as ATP bound, ATP hydrolyzed, ADP 
bound) are associated with different relative orientations of the cassettes and that such 
conformational changes may be transmitted via the linker and the IG domain to the N-
terminal HLH and HB domains, thereby modulating the activity of the N-terminal helicase. 
It has been suggested that Brr2 may acquire processivity by oligomerization of its ATPase 
units in a fashion analogous to ring-forming helicases (Staley and Guthrie, 1998). While our 
data indeed indicate that Brr2's full helicase activity only unfolds given a direct interaction of 
the N- and C-terminal RecA domains, the linear disposition of these four domains in Brr2 is 
decisively different from the ring-like arrangement of the corresponding domains in 
hexameric helicases. Furthermore, our results also suggest that the C-terminal RecA domains 





cassette RecA contacts may be explained by stabilization of the N-terminal RecA and WH 
domains and by their positioning relative to other active site elements. 
4.4 Remote regulation of the N-cassette activity 
Mutations that interfere with ATP binding at the C-terminal cassette, which is remote 
from the N-terminal active site and from the cassette interface, also exhibit strong effects on 
the N-terminal helicase. This observation demonstrates that, in principle, ligand binding at the 
C-terminal cassette can be sensed by the N-terminal helicase, which is consistent with our 
preliminary data showing that the N-terminal cassette binds nucleotides differently in the 
presence of the C-terminal cassette. While we presently cannot trace this long range 
communication on the atomic level, it is likely also conducted through the direct inter-cassette 
RecA or linker contacts discussed above. 
Mutational analyses furthermore support that Brr2 is not simply optimized for helicase 
activity but for versatile regulation on various levels. The inter-cassette communication 
uncovered here suggests novel regulatory functions for at least some of the many 
spliceosomal proteins that interact at the C-terminal cassette of Brr2, which include factors 
essential for different steps of splicing catalysis (Van Nues and Beggs, 2001; Liu et al., 2006). 
The ability of the C-terminal cassette to transmit signals to the N-terminal cassette suggests 
that these proteins may not merely use the C-terminal cassette as a passive landing pad but 
also to influence the N-terminal cassette from a distance, by modulating its nucleotide 
binding, hydrolysis, RNA binding or coupling of ATPase and helicase activities. The 
observation that, while many mutations reduced Brr2 helicase activity, one variant (PPP1296–
8AAA in the linker) exhibited significantly enhanced unwinding activity indicates that 
interacting factors may either down or up-regulate Brr2. Sequentially binding proteins may 
thus switch the enzyme on or off as required during particular phases of the splicing process. 
The above principles also offer one possible solution to the intriguing problem of how a 
large number of factors can influence alternative splicing. Several of these proteins may 
directly or indirectly target the expanded surface provided by the C-terminal cassette to 
modulate Brr2 activity, which would affect splicing kinetics and consequently the choice or 
proofreading of alternative splice sites. Analogous kinetic switches, influencing splice site 
choice via the modulation of U1 snRNP interaction with 5' SS, have recently been uncovered 
(Yu et al., 2008). This study showed that the presence of silencer sequences altered the U1 
snRNP/5' SS complex rendering it less able to engage U2 snRNP. These silencer sequences 





to splicing. These findings demonstrate that minor perturbations of spliceosomal protein-
protein or protein-RNA interactions can alter delicate kinetic balance thereby influencing 
splice site choices.  
We also note that similar regulatory principles as in Brr2 may also be at work in other 
proteins from diverse cellular contexts, which are composed of active and inactive nucleotide 
binding domains, such as the membrane associated guanylate kinase CASK (Mukherjee et al., 
2011) or the cystic fibrosis transmembrane conductance regulator (CFTR) (Aleksandrov et 
al., 2002; Basso et al., 2003). CASK is composed of an N-terminal CaM-kinase domain and a 
C-terminal set of domains typical of membrane-associated guanylate kinases, including a 
guanylate kinase domain that is catalytically inactive and supposed to function as a protein 
interaction platform. Interestingly, the phosphorylation rate of the active CASK CaM-kinase 
domain is dramatically increased in the context of the full-length protein compared to the 
CaM-kinase domain alone. CFTR contains two nucleotide binding domains that share low 
sequence similarity and exhibit functional asymmetry. The N-terminal domain displays 
unorthodox residues in the nucleotide binding site and is catalytically inactive although it 
binds ATP. In contrast, the C-terminal nucleotide binding domain binds and hydrolyses ATP. 
It has been suggested that cooperative interaction between N- and C-terminal domains results 
in functional coupling of nucleotide binding at the two domains and channel gating.  
4.5 Molecular basis for the RP33 form of retinitis 
pigmentosa 
The present structure rationalizes the dysfunction of many previously investigated Brr2 
variants. In particular, effects of mutations that have been recently linked to RP33 (Zhang et 
al., 2009; Benaglio et al., 2011) are seen to interfere with hBrr2 function. 
Mapping RP33-linked Brr2 mutations on the structure suggested that these mutations 
interfere in diverse ways with Brr2 activity as shown directly for the S1087L mutation. 
Leucine 1087 is located in the ratchet helix of the N-terminal HB domain and thus may exert 
its effect through dysfunctional RNA binding or translocation at the N-terminal cassette. 
Since the S1087L mutation has no discernable effect on the folding of Brr2, it is likely that at 
least some of the RP33-linked Brr2 variants are incorporated into spliceosomes in vivo. The 
presence of such RP33-linked variants may result in a slow-down of spliceosome catalytic 
activation due to impairment of hBrr2 activity. This inefficiency of the splicing reaction is 





critical for cell survival in tissues that require particularly elevated splicing activity, as 
observed in the retina (Tanackovic et al., 2011). Alternatively, a retina-specific splicing event 
may no longer be supported by the reduced levels of the splicing machinery (Yin et al., 2011; 










Already before incorporation into the spliceosome, Brr2 is associated with its U4/U6 
substrate in the context of the U4/U6.U5 tri-snRNP. Brr2 unwinds the U4/U6 di-snRNA in 
vitro (Laggerbauer et al., 1998; Raghunathan and Guthrie, 1998) and it is required for 
spliceosome activation in vivo (Kim and Rossi, 1999). However, U4/U6 unwinding has to be 
delayed until splice sites have been reliably located. Brr2 also acts a second time during 
spliceosome disassembly (Small et al., 2006). Therefore, Brr2 apparently has to be turned on 
and off several times during a splicing event. Our crystal structure of hBrr2
HR
 provided 
insights into the mechanism of action whereby the two ring-like helicase domains of Brr2 
cooperate to unwind the U4/U6 snRNA duplex. The C-terminal helicase unit, while inactive 
in ATP hydrolysis and RNA duplex unwinding, strongly stimulates the N-terminal helicase. 
Using structure-guided mutagenesis, we delineated communication lines between the 
cassettes required for this modulation. Using pre-steady state kinetics, we also probed the 
nucleotide binding preferences and worked out possible nucleotide binding mechanisms of 
either cassette. Our results revealed the structural and functional interplay between two 
helicase cassettes in a tandem SF2 enzyme and suggested how Brr2 interactors may exploit 
the C-terminal cassette as a “remote control” to regulate the N-terminal helicase of the 
enzyme (Fig 5.1A and B). 
However, several mechanistic aspects of Brr2 helicase action remain unclear, including 
the molecular mechanisms whereby the helicase may be switched on and off during splicing. 
Brr2 tightly interacts with Prp8 and Snu114 (Achsel et al., 1998) and both of these U5 
proteins have been shown to modulate Brr2 activity (Kuhn and Brow, 2000; Kuhn et al., 
2002; Small et al., 2006). A C-terminal fragment of Prp8, which contains its RNase H-like 
and Jab1/MPN-like domains, has been shown to stimulate Brr2-mediated U4/U6 unwinding 
activity in vitro, but the mechanism whereby this is achieved is presently unknown (Maeder et 
al., 2009; Pena et al., 2009).  
During this thesis, we could also demonstrate, using analytical gel filtration analysis, that 
both yPrp8
RNaseH-Jab1/MPN
 as well as the Jab1/MPN domain of yPrp8 alone (yPrp8
Jab1/MPN
) form 
stable complexes with recombinant yBrr2 (Fig. 5.2, Weber et al., 2011). These initial findings 
paved the way for large scale production of human and yeast Brr2-Prp8
Jab1/MPN
 complexes for 
structural analyses and further elucidation of the role of the Prp8
Jab1/MPN
 domain in the 






Fig 5.1: (A, B) Schematic representations of Brr2
HR
. 2D scheme of Brr2
HR
 summarizing the main findings of this 
thesis: N- and C-terminal cassettes intimately interact and changes in the interaction surface modulate Brr2 
activity (inter-cassette contacts are indicated by semitransparent yellow circles). Both cassettes bind nucleotides, 
although with different affinities. RNA interactions are mainly fostered by the N-terminal cassette. Domains and 
elements are colored as in Fig. 3.12 (B) The C-terminal cassette as an intramolecular power switch in the Brr2 
helicase. RNA duplex unwinding by the active N-terminal cassette (blue) is stimulated by the C-terminal cassette 
(light blue). The RNA duplex is represented in gold and orange colors.   




that can be further 
used as a platform for crystallization trials with RNA and other splicing factors. Indeed, steps 





complex at 3.4 Å resolution (Mozaffari-Jovin et al., 2013). We have 
also further optimized yBrr2
 
fragments based on hBrr2
HR
 that are now successfully used to 
obtain crystals of yBrr2 complexes. By means of rapid kinetic measurements, we have 
demonstrated that N- and C-terminal cassettes bind nucleotides with different affinities. These 
findings can be further complemented by studies investigating the influence of RNA, protein 
interactors (e.g. Prp8
Jab1/MPN
) and mutations (e.g. in the cassette interface and ATP binding 
pocket)
 






Fig. 5.2: (A) Ribbon plot of the crystal structure of yPrp8
RNaseH-Jab1/MPN
. Helices – blue; strands – red; loops – 
gray. A disordered linker is indicated by a dashed lined. The domains and protein termini are labeled. (B) 
Coomassie-stained SDS gels of analytical gel filtration runs (Superdex 200) of a yBrr2/yPrp8
RNaseH-Jab1/MPN
 
mixture (top) and of a yBrr2/yPrp8
Jab1/MPN
 mixture (bottom). Fractions eluting from the column are indicated 









 elute as the 
individual proteins (peak fractions 25-30 on top panel and 29-35 on bottom panel). These results indicate that 
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